Advance

Program
2023 Washington, DC | May 19-24
conference.thoracic.org
ATS 2023 INTERNATIONAL CONFERENCE
MAY 19-24, WASHINGTON, DC

This ATS International Conference Advance Program is published by the ATS as a service to attendees.
This publication contains the programs and speakers for the postgraduate courses, scientific and
educational sessions presented at the conference.

While every effort is made to ensure accuracy, ATS makes no warranties, expressed or implied, related to
the information. Information contained herein is subject to change without notice.

The information contained in this program is up to date as of January 20,2023. Look for W to view more
information about ATS events, assemblies and sections.

1 Friday Postgraduate Courses

6 Saturday Postgraduate Courses
19 Sunday Conference Sessions
37 Monday Conference Sessions
60 Tuesday Conference Sessions
79 Wednesday Conference Sessions

https://conference.thoracic.org/attendees/

The Advance Program is published by the ATS as a service to attendees. While every effort is made to ensure accuracy,
ATS makes no warranties, expressed or implied, related to the information. Information contained herein is subject to change without notice
FRIDAY • MAY 19 REGISTER NOW 1

ATS: COMMITTED TO EXCELLENCE IN CONTINUING

MEDICAL EDUCATION AND SCIENTIFIC EXCHANGE
The American Thoracic Society is committed to providing education and scientific
exchange of the highest quality at our International Conference and other programs.
As an accredited provider of the Accreditation Council for Continuing Medical Education (ACCME), the ATS must ensure
objectivity, scientific rigor, balance, and freedom from commercial bias in Conference presentations.
ATS relies on the assistance of Conference Session organizers, chairs and presenters, Assembly Program Committees, the
ATS Education Committee, and the ATS International Conference Committee to accomplish this. In keeping with ACCME
standards and ATS policies on management of conflict of interest, all moderators and speakers must complete conflict of
interest review and resolution prior to the Conference.
ATS thanks Conference presenters for their cooperation in completing disclosure forms by announced deadlines, and
thanks Conference session organizers and all those involved in this important process.

POSTGRADUATE COURSES
Assembly on Critical Care
8:00 a.m. - 4:00 p.m.
Target Audience
Providers of critical care or emergency medicine
Objectives
At the conclusion of this session, the participant will be able to:
• apply ultrasound at bedside to assess critically ill patients
• apply ultrasound to guide common ICU procedures
• diagnose alternate etiologies of shock in the critically ill patient
This is a 2-day postgraduate course that consists of didactic lectures
and hands-on stations. The focus is primarily bedside transthoracic
echocardiography, with some diagnostic ultrasound. The topics include
basic and intermediate critical care echocardiography (including
Friday, May 19 hemodynamic measures), assessment of fluid status, procedural
guidance for vascular access and thoracentesis, venography. The
w hands-on stations will include both healthy models and laptops that can
Click here to register for demonstrate abnormal pathology.
Friday Sessions and Presentation
Chairing: M.J. Lanspa, MD, MSCR, ATSF, Salt Lake City, UT
X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France
CLINICAL 8:00 Welcome and Introduction to Critical Care Ultrasound:
Training and Competency
POSTGRADUATE COURSE M.J. Lanspa, MD, MSCR, ATSF, Salt Lake City, UT
8:15 Basic Physics, Artifacts, and Knobology
PG1A CRITICAL CARE ULTRASOUND AND Z. Shaman, MD, Cleveland, OH
ECHOCARDIOGRAPHY I
8:45 Transthoracic Windows and Views
R This is part 1 of a two-part course which includes PG1B on Saturday, May
20. Those registering for PG1A will be registered for PG1A and PG1B.
Pre-registration and additional fees required. Attendance is limited.
Member: $1230
LMIC Member: $1165
Non-Member: $1640
In-Training Member: $935
LMIC In-Training Member: $655
In-Training Non-Member: $1060
9:15
J.C. Klick, MD, Burlington, VT
Basic Evaluation of LV Systolic Function, Measurement
of Cardiac Output
C. Bennett, DO, Rochester, MN

ATS 2023 • Washington, DC

2 FRIDAY • MAY 19

9:45 Basic Evaluation of RV Size and Function, Pulmonary Cardiac Output

Embolus J.C. Klick, MD, Burlington, VT
D. Pradhan, MD, ATSF, New York, NY S. Cha, MD, Baltimore, MD
A. Sarwal, MD, Winston-Salem, NC
10:15 Break
Z. Shaman, MD, Cleveland, OH
10:30 Practical Skills Session: Hands-On Station I L. Rapoport, MD, MS, Santa Clara, CA
Apical Window S. Bain, MD, Seattle, WA
Z. Shaman, MD, Cleveland, OH Diastolic Measurements
J.C. Klick, MD, Burlington, VT A. Leibowitz, MD, Boston, MA
C. Bennett, DO, Rochester, MN X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France
D. Pradhan, MD, ATSF, New York, NY C. Bennett, DO, Rochester, MN
S. Sarzynski, MD, MHSc, Bethesda, MD J. Kasal, MD, St. Louis, MO
P.K. Mohabir, MD, Stanford, CA J.E. Pittman, MD, Salt Lake City, UT
Parasternal Window R.E. Burk, MD, Reno, NV
R.E. Burk, MD, Reno, NV
A. Leibowitz, MD, Boston, MA
L. Rapoport, MD, MS, Santa Clara, CA CLINICAL
S. Bain, MD, Seattle, WA
POSTGRADUATE COURSE
D.A. Sweeney, MD, La Jolla, CA
S. Cha, MD, Baltimore, MD
PG2 BRONCH DAY 2023: A COMPREHENSIVE,
Subcostal Window HANDS-ON GUIDE TO BASIC
G.B. Allen, MD, Burlington, VT
BRONCHOSCOPY, EBUS, AND
X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France
A. Sarwal, MD, Winston-Salem, NC
NAVIGATIONAL BRONCHOSCOPY

12:00
V.A. Dinh, MD, Loma Linda, CA
J. Kasal, MD, St. Louis, MO
J.E. Pittman, MD, Salt Lake City, UT
Lunch
R Pre-registration and additional fees required. Attendance is limited.
Member: $600
LMIC Member: $420
Non-Member: $700
In-Training Member: $380
LMIC In-Training Member: $270
In-Training Non-Member: $500
Assemblies on Clinical Problems; Critical Care; Pediatrics;
12:30 Lunch and Clinical Cases Thoracic Oncology
S. Sarzynski, MD, MHSc, Bethesda, MD
8:00 a.m. - 4:00 p.m.
12:45 Chest Ultrasound
P.K. Mohabir, MD, Stanford, CA Target Audience
Adult and pediatric pulmonologists and intensivists, thoracic surgeons,
1:15 Valvulopathy and Endocarditis physicians in training, allied health professionals: anesthesiologists
R.E. Burk, MD, Reno, NV interested in improving their skills in diagnostic and therapeutic flexible
1:45 Basic Assessment of Diastolic Function bronchoscopy and EBUS
A. Leibowitz, MD, Boston, MA Objectives
2:15 Break At the conclusion of this session, the participant will be able to:

2:30 Practical Skills Session: Hands-On Station II : • diagnose and manage adults and children with benign and
malignant respiratory diseases
Lung Ultrasound
• improve knowledge of basic flexible bronchoscopy and strengthen
D.A. Sweeney, MD, La Jolla, CA
D. Pradhan, MD, ATSF, New York, NY procedural skills
V.A. Dinh, MD, Loma Linda, CA • understand the indications for linear and radial endobronchial
G.B. Allen, MD, Burlington, VT ultrasound and the skills necessary to perform these
S. Sarzynski, MD, MHSc, Bethesda, MD
This course is designed to provide a comprehensive introduction to
P.K. Mohabir, MD, Stanford, CA
diagnostic and therapeutic flexible bronchoscopy. Participants will
acquire the knowledge and skills to improve their proficiency in
bronchoscopic techniques and be introduced to linear EBUS, radial
EBUS and navigational bronchoscopy. A series of lectures will be
followed by intensive, hands-on training. Through the use of physical

ATS 2023 • Washington, DC

FRIDAY • MAY 19 REGISTER NOW 3

and virtual reality simulators participants will strengthen their procedural 1:30 Break
skills. This course will be of particular interest to providers seeking to 1:40 Practical Skills Session
refine their bronchoscopy skills and who wish to review the data behind
the various bronchoscopic techniques. Audience response will be used Navigational Bronchoscopy: Radial Endobronchial
during lectures. Ultrasound Electromagnetic Navigation Bronchoscopy
R. Semaan, BS, MD, Pittsburgh, PA
Chairing: C. Argento, MD, Baltimore, MD J. De Cardenas, MD, Ann Arbor, MI
A.V. Gonzalez, MD, MSc, Montreal, Canada
Navigational Bronchoscopy: Robotic Bronchoscopy
D. Dibardino, MD, Philadelphia, PA
A.A. Wagh, MD, MS, Chicago, IL
R. Semaan, BS, MD, Pittsburgh, PA
E. Malsin, MD, Chicago, IL
8:00 Introduction
Endobronchial Ultrasound Anatomy
C. Argento, MD, Baltimore, MD
O. Kalchiem-Dekel, MD, New York, NY
8:05 Optimizing Basic Bronchoscopy Skills V.K. Holden, MD, Baltimore, MD
C.R. Macrosty, DO, Chapel Hill, NC
Endobronchial Ultrasound-Guided Transbronchial
8:30 Maximize Outcomes in High Risk Patients Needle Aspiration
K. Van Nostrand, MD, Atlanta, GA B. Husta, MD, New York, NY
8:55 Role of Flexible Bronchoscopy in Management of Y.B. Gesthalter, MD, San Francisco, CA
Hemoptysis Endobronchial Valves
C.R. Lamb, MD, Burlington, MA A. Demaio, MD, New York, NY
9:20 Pediatric Flexible Bronchoscopy for the Adult and A. Sarkar, PhD, Chicago, IL
Pediatric Bronchoscopist 3:45 Questions and Wrap-Up
C. Spencer Grant, MD, New York, NY C. Argento, MD, Baltimore, MD
9:45 Break
9:55 The Fundamentals of Lineal EBUS BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
A. Demaio, MD, Baltimore, MD
POSTGRADUATE COURSE
10:20 Navigational Bronchoscopy: From Fluoroscopy to
Robotics
L. Frye, MD, Salt Lake City, UT PG3 PEDIATRIC SLEEP-RELATED BREATHING
DISORDERS: STATE OF THE ART AND
10:45 Bronchoscopic Lung Volume Reduction
CURRENT BEST PRACTICES
P. Lee, MD, Singapore
11:10
11:30
12:15
Questions and Answers
Lunch
Practical Skills Session
R Pre-registration and additional fees required. Attendance is limited.
Member: $600
LMIC Member: $420
Non-Member: $700
In-Training Member: $380
LMIC In-Training Member: $270
In-Training Non-Member: $500
Assemblies on Pediatrics; Sleep and Respiratory Neurobiology
Bronchoscopy With Biopsy and Needle Aspiration of
Endobronchial Lesion 8:00 a.m. - 4:00 p.m.
M. Weir, MBChB, Philadelphia, PA Target Audience
C. Kapp, MD, Chicago, IL Clinicians including pediatricians, family practitioners, intensivists,
Bronchoscopic Management of Hemoptysis pulmonologists, sleep medicine physicians, researchers, allied health
C.R. Lamb, MD, Burlington, MA professionals, nurses, nurse practitioners, respiratory therapists, and
G.Z. Cheng, MD, PhD, San Diego, CA trainees (all levels).

Management of the Difficult Airway and Objectives

Trachcostomy Tubes At the conclusion of this session, the participant will be able to:
E. Volker, MD, MSPH, Denver, CO • describe the current and emerging understanding of SRBD in
C.R. Macrosty, DO, Chapel Hill, NC children and apply this knowledge to clinical practice and research
Techniques for Foreign Body Removal Using Flexible • recognize the interplay of pediatric SRBD and chronic pulmonary
Bronchoscopy conditions
D. Dibardino, MD, Philadelphia, PA
A.V. Gonzalez, MD, MSc, Montreal, Canada

ATS 2023 • Washington, DC

4 REGISTER NOW FRIDAY • MAY 19

• integrate new treatment options into the management of pediatric 10:45 Breakout Groups/Case Discussions
SRBD to ensure personalized patient-centered care Group A - Medical Management of OSA/SRBD
This, first of its kind, course will provide a state of the art practical, S. Hawkins, MD, BS, Aurora, CO
evidence-based, and comprehensive approach to the evaluation and Group B - Surgical Management of OSA/SRBD
management of pediatric sleep-related breathing disorders (SRBD). O.M. Vanderveken, MD, PhD, Edegem, Belgium
There will be a mix of interactive didactic sessions (highlighting the
intersection of basic science, translational and clinical aspects of 11:36 Lunch
pediatric SRBD), panel discussions, and hands-on stations. Small 12:36 Overview of Non-Invasive Ventilation in Pediatric SRBD
group, case-based, breakout sessions will give participants the R. Amin, MD, Toronto, Canada
opportunity to interact with national and international experts in the field.
Hands-on stations will provide learners with a unique “real-time” 12:56 Practical Skills Session
experience with advanced diagnostic and therapeutic modalities as they Pediatric PAP Mask Fit and Adherence
relate to pediatric SRBD. D.L. Olmstead, BScN, MN, NP, Edmonton, Canada
T. Cranford, MHPE, RRT, RRT-NPS, RPSGT, CCSH,
Chairing: Z. Ehsan, MD, Kansas City, MO Kansas City, MO
C.M. Cielo, DO, Philadelphia, PA
S.L. Verhulst, MD, PhD, MSc, Edegem, Belgium CPAP and APAP
U.A. Katwa, MD, Boston, MA
8:00 Welcome, Introductions and Overview S.L. Verhulst, MD, PhD, MSc, Edegem, Belgium
Z. Ehsan, MD, Kansas City, MO
Bilevel S, ST and VAPS
8:05 The Future of Pediatric Sleep: Challenges and R. Amin, MD, Toronto, Canada
Opportunities H. Sawnani, MD, Cincinnati, OH
D. Gozal, MD, MBA, ATSF, Columbia, MO
2:16 Break
8:25 Recognizing OSA in Children With and Without
Respiratory Disease 2:45 Practical Skills Session
U.A. Katwa, MD, Boston, MA DISE Directed Surgery and HGNS
8:40 When It’s Not OSA - Understanding Sleep-Related O.M. Vanderveken, MD, Edegem, Belgium
Breathing Disorders in Children CPAP and NIV Download Interpretation and Adherence
I.A. Perez, MD, ATSF, Los Angeles, CA G.R. Nino, MD, Washington, DC
8:55 Polysomnography for the Non-Sleep Doc: Looking M.S. Xanthopoulos, MS, PhD, Philadelphia, PA
Beyond the AHI Heated High Flow Nasal Cannula
J.E. Maclean, BSc(Hons), MD, PhD, Edmonton, Alberta, S. Hawkins, MD, BS, Aurora, CO
Canada
3:50 Closing Remarks
9:10 When Polysomnography Is Not an Option: Alternative Z. Ehsan, MD, Kansas City, MO
Testing and Where They Fit In
R. Bhattacharjee, MD, San Diego, CA
9:25 Break
CLINICAL

9:40 Overview of Non-Surgical Treatment Strategies for POSTGRADUATE COURSE

Sleep-Related Breathing Disorders
R. Ersu, MD, Ottawa, Canada PG4 STATE OF THE ART MANAGEMENT OF
9:55 Overview of Upper Airway Surgery for Sleep-Related NONINVASIVE VENTILATION FROM
Breathing Disorders HOSPITAL TO AMBULATORY CARE
S.L. Ishman, MD, MPH, Cincinnati, OH
10:10 Overview of Skeletal Surgery for Sleep-Related
Breathing Disorders
S. Susarla, DMD, MD, MPH, Seattle, WA
R Pre-registration and additional fees required. Attendance is limited.
Member: $600
LMIC Member: $420
Non-Member: $700
In-Training Member: $380
LMIC In-Training Member: $270
In-Training Non-Member: $500
Assemblies on Sleep and Respiratory Neurobiology, Clinical
10:25 Shared Decision Making in Pediatric SDB
A. Bandyopadhyay, MD, Indianapolis, IN Problems, Critical Care
8:00 a.m. - 4:00 p.m.

ATS 2023 • Washington, DC

FRIDAY • MAY 19 REGISTER NOW 5

Target Audience 11:55 Lunch

Health care providers who care for patients with complex
12:45 Practical Skills Session
pulmonary-sleep disorders and chronic respiratory failure syndromes
including noninvasive ventilation; physicians, advanced practice Respiratory Assist Devices: Differences Between
providers, nurses, respiratory therapists, and fellows. S/ST/PC
Objectives D. Zielinski, MD, Montreal, Canada
At the conclusion of this session, the participant will be able to: M. Kaminska, MD, Montreal, Canada

• define new strategies for inpatient to ambulatory evaluation and

management of complex inpatient pulmonary-sleep disorders Differences Between ASV vs VAPS
• define strategies for evaluation and management of common chronic B. Selim, MD, Rochester, MN
hypercapnic respiratory failure syndromes including neuromuscular A. Sahni, MBBS, Chicago, IL
disease, COPD, obesity hypoventilation syndrome Home Mechanical Ventilators
• develop expertise on management of noninvasive ventilation M. Cao, DO, Stanford, CA
including advanced respiratory assist devices and home mechanical J.M. Coleman, MD, Chicago, IL
ventilators 2:15 Break
This combined didactic and skills-based course aims to highlight 2:30 Practical Skills Session
hospital to ambulatory management of complex pulmonary-sleep
NIV Downloads
disorders and chronic hypercapnic respiratory failure syndromes. The
J.E. Orr, MD, La Jolla, CA
skills-based section will focus on state of the art management of
S.L. Katz, MD, Ottawa, Canada
noninvasive ventilation including home mechanical ventilation.
Attendees will have the opportunity to learn device algorithms, modes, Daytime Ventilation Modes
interpretation of device downloads, and apply these skills towards L.F. Wolfe, MD, Chicago, IL
specific disease states to optimize patient care. B. Lussier, MD, Dallas, TX
Mechanical Airway Clearance
Chairing: M. Cao, DO, Stanford, CA
K.A. Provost, DO, PhD, Buffalo, NY
B. Selim, MD, Rochester, MN
J.P. Brown, MD, PhD, Salt Lake City, UT
S. Sharma, ATSF, Morgantown, WV
J.H. Hansen-Flaschen, MD, ATSF, Wynnewood, PA
8:00 Introductions
M. Cao, DO, Stanford, CA
8:10 Atrial Fibrillation, Arrhythmias, and Transition to
Ambulatory Care
R. Mehra, MD, MSCR, ATSF, Cleveland, OH
8:40 Post Operative Discharge on Opiates
J.E. Orr, MD, La Jolla, CA
9:10 ILD Awaiting Lung Transplant
B. Selim, MD, Rochester, MN
9:40 Acute Heart Failure From Inpatient to Ambulatory Care
S. Sharma MD, ATSF, Morgantown, WV
10:10 Break
10:25 Noninvasive Ventilation in Obesity Hypoventilation
Syndrome
B. Mokhlesi, MD, MS, Chicago, IL
10:55 Advances in Noninvasive Ventilation for ALS
J.H. Hansen-Flaschen, MD, ATSF, Wynnewood, PA
11:25 Updates in Noninvasive Ventilation for Stable
Hypercapnic COPD
J.M. Coleman, MD, Chicago, IL

ATS 2023 • Washington, DC

6 REGISTER NOW SATURDAY • MAY 20

Chairing: M.J. Lanspa, MD, MSCR, ATSF, Salt Lake City, UT

X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France
8:00 Vascular Ultrasound: DVT Evaluation
L. Rapoport, MD, MS, Santa Clara, CA
8:25 Vascular Access
S. Bain, MD, Seattle, United States
8:45 Tamponade
G.B. Allen, MD, Burlington, VT
9:15 Using Ultrasound to Assess Intravascular Volume and
Fluid Responsiveness
X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France
9:45 Ultrasound for Diuresis and Dialysis
D.A. Sweeney, MD, La Jolla, CA
Saturday, May 20 10:15 Break
10:30 Practical Skills Session: Hands-On Station III
w Vascular Ultrasound
Click here to register for Z. Shaman, MD, Cleveland, OH
Saturday Sessions and Presentation J.C. Klick, MD, Burlington, VT
D. Pradhan, MD, ATSF, New York, NY
S. Sarzynski, MD, MHSc, Bethesda, MD
J.E. Pittman, MD, Salt Lake City, UT
CLINICAL L. Rapoport, MD, MS, Santa Clara, CA
Tamponade Evaluation
POSTGRADUATE COURSE
P.K. Mohabir, MD, Stanford, CA
R.E. Burk, MD, Reno, NV
PG1B CRITICAL CARE ULTRASOUND AND A. Leibowitz, MD, Boston, MA
ECHOCARDIOGRAPHY II C. Bennett, DO, Rochester, MN
R This is part 2 of a two-part course which includes PG1A on Friday, May S. Bain, MD, Seattle, WA
19. Pre-registration and additional fees required. Attendance is limited. G.B. Allen, MD, Burlington, VT
See PG1A for course fees.
Volume Status
Assembly on Critical Care X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France
8:00 a.m. - 4:00 p.m. D.A. Sweeney, MD, La Jolla, CA
A. Sarwal, MD, Winston-Salem, NC
Target Audience V.A. Dinh, MD, Loma Linda, CA
Providers of critical care or emergency medicine J. Kasal, MD, St. Louis, MO
Objectives S. Cha, MD, Baltimore, MD
At the conclusion of this session, the participant will be able to: 12:00 Lunch
• apply ultrasound at bedside to assess critically ill patients 12:30 Lunch and Intro to Neuro Ultrasound
• apply ultrasound to guide common ICU procedures A. Sarwal, MD, Winston-Salem, NC
• diagnose alternate etiologies of shock in the critically ill patient 12:45 Abdominal Ultrasound
V.A. Dinh, MD, Loma Linda, CA
This is a 2-day postgraduate course that consists of didactic lectures
and hands-on stations. The focus is primarily bedside transthoracic 1:15 Goal Directed Management of Shock Using
echocardiography, with some diagnostic ultrasound. The topics include Echocardiography
basic and intermediate critical care echocardiography (including J. Kasal, MD, St. Louis, MO
hemodynamic measures), assessment of fluid status, procedural 1:45 Incorporating Echocardiography into CPR
guidance for vascular access and thoracentesis, venography. The S. Cha, MD, Baltimore, MD
hands-on stations will include both healthy models and laptops that can
demonstrate abnormal pathology. 2:15 Break

ATS 2023 • Washington, DC

SATURDAY • MAY 20 REGISTER NOW 7

2:30 Practical Skills Session: Hands-On Station IV incorporated into practice. Course faculty are experts involved the
Abdominal Ultrasound creation of these guidelines. The course will incorporate interactive
D.A. Sweeney, MD, La Jolla, CA case-based review and panel discussion.
Z. Shaman, MD, Cleveland, OH Chairing: P. Akuthota, MD, ATSF, La Jolla, CA
D. Pradhan, MD, ATSF, New York, NY M. Kraft, MD, ATSF, New York, NY
S. Sarzynski, MD, MHSc, Bethesda, MD B.D. Medoff, MD, Boston, MA
G.B. Allen, MD, Burlington, VT F. Holguin, MD, MPH, Aurora, CO
S. Cha, MD, Baltimore, MD
8:00 How Should I Interpret the ERS/ATS Severe Asthma
Echo in Shock and CPR Guidelines?
C. Bennett, DO, Rochester, MN F. Holguin, MD, MPH, Aurora, CO
R.E. Burk, MD, Reno, NV
L. Rapoport, MD, MS, Santa Clara, CA 8:30 Anti-Eosinophil and Anti-IL-4/IL-13 Therapies in Severe
A. Sarwal, MD, Winston-Salem, NC Asthma: What Do the Guidelines Say?
S. Bain, MD, Seattle, WA Speaker to be Announced
J.E. Pittman, MD, Salt Lake City, UT 9:00 Omalizumab in Severe Asthma: Where Does It Fit In Now?
Ask the Expert Speaker to be Announced
A. Leibowitz, MD, Boston, MA 9:30 Case-Based Panel Discussion
X. Monnet, MD, PhD, Le Kremlin-Bicêtre, France M. Kraft, MD, ATSF, New York, NY
V.A. Dinh, MD, Loma Linda, CA
9:50 Break
J. Kasal, MD, St. Louis, MO
J.C. Klick, MD, Burlington, VT 10:05 Long-Acting Muscarinic Antagonists: Good for All with
P.K. Mohabir, MD, Stanford, CA Severe Asthma?
Speaker to be Announced
10:35 Macrolides in Severe Asthma: Underutilized in the Age
CLINICAL
of Biologics?
POSTGRADUATE COURSE Speaker to be Announced
11:05 Frontiers in Clinical Trial Designs in Severe Asthma
PG5 SEVERE ASTHMA 2023: IMPLEMENTING L.C. Denlinger, MD, PhD, Madison, WI
CURRENT GUIDELINES INTO PRACTICE 11:35 Case-Based Panel Discussion
R Pre-registration and additional fees required. Attendance is limited. P. Akuthota, MD, ATSF, La Jolla, CA
Member: $440 In-Training Member: $255 11:55 Lunch
LMIC Member: $310 LMIC In-Training Member: $180
Non-Member: $540 In-Training Non-Member: $380 12:35 GINA and NAEPP Guidelines: Differences, Similarities,
and Implementation Challenges
Assemblies on Allergy, Immunology and Inflammation
J.A. Krishnan, MD, PhD, ATSF, Chicago, IL
8:00 a.m. - 4:00 p.m.
1:05 Break
Target Audience
1:15 Severe Asthma Case Discussion
Pulmonary and allergy physicians, physicians in training, and
advanced practice providers who care for patients with asthma. Speaker to be Announced

Objectives 3:15 Panel Discussion with Guideline Co-Chairs

At the conclusion of this session, the participant will be able to: B.D. Medoff, MD, Boston, MA

• discuss how to interpret clinical guidelines recommendations

• identify adults and children with asthma in whom monoclonal
anti-IL5 antibody, omalizumab, tiotropium, and macrolides are
indicated
• describe a NIH clinical trial testing personalized treatment options
for severe asthma
This session will provide a comprehensive, pragmatic overview of the
latest guidelines for severe asthma management from GINA, the
NAEPP and ATS/ERS, with a particular focus on how they can be

ATS 2023 • Washington, DC

8 REGISTER NOW SATURDAY • MAY 20

9:45 Social Determinants of Health

BEHAVIORAL • CLINICAL
I.L. Riley, MD, MPH, Durham, NC
POSTGRADUATE COURSE 10:15 Centering the Margins
M. George, PhD, RN, New York, NY
PG6 TOWARDS DISMANTLING STRUCTURAL 10:45 Selecting and Applying Quantitative Methods in Equity
INJUSTICE IN PULMONARY AND Research
CRITICAL CARE MEDICINE - A PRIMER S.O. Okelo, MD, PhD, Los Angeles, CA
ON HEALTH EQUITY RESEARCH
11:15 Unique Aspects of Qualitative Methods in Equity
R Pre-registration and additional fees required. Attendance is limited.
Member: $440
LMIC Member: $310
Non-Member: $540
In-Training Member: $255
LMIC In-Training Member: $180
In-Training Non-Member: $380
Assemblies on Behavioral Science and Health Services Research;
11:45
12:45
Research
T. Bryant-Stephens, MD, Philadelphia, PA
Lunch
A Mixed-Methods Evaluation of Disparities in Clinical
Health Equity and Diversity Committee; Section on Medical Communication
Education D.C. Ashana, MD, MBA, MS, Durham, NC

8:00 a.m. - 4:00 p.m. 1:15 Breakout Session #2: Generating a Health Equity
Research Agenda
Target Audience
Clinicians and scientists interested in health equity research and 1:40 Break
examining the relationship between social determinants of health and 2:10 Panel Discussion: Writing About Health Disparities
outcomes in pulmonary, critical care, and sleep medicine.
2:50 Advocacy and Policy
Objectives C. Fuller, ScD, MS, Atlanta, GA
At the conclusion of this session, the participant will be able to:
3:20 Breakout Session #3: Writing a Health Equity Research
• construct a research question grounded in equity theories and Proposal
frameworks
3:45 Review and Wrap-Up
• propose a research agenda using tailored methods that center
marginalized groups
• create a dissemination plan that maximizes reach and policy impact CLINICAL • TRANSLATIONAL
Structural inequities lead to poor health outcomes for marginalized POSTGRADUATE COURSE
patients with pulmonary, critical care, and sleep related illnesses. The
goal of this postgraduate course is to engage non-equity investigators
PG7 UPDATES ON LUNG TRANSPLANTATION;
from all career stages and provide them with a primer on doing health
WHAT PULMONOLOGISTS NEED TO
equity research. This session will leverage case studies and facilitated
small group exercises to introduce principles of health equity research KNOW
and allow participants to apply these principles in real time to practice
developing their own health equity research proposal.

Chairing: J. Odackal, MD, MSc, MA, Westerville, OH

D.C. Ashana, MD, MBA, MS, Durham, NC
R Pre-registration and additional fees required. Attendance is limited.
Member: $440
LMIC Member: $310
Non-Member: $540
In-Training Member: $255
LMIC In-Training Member: $180
In-Training Non-Member: $380
Assemblies on Clinical Problems, Allergy, Immunology and
M. Sharp, MD, MHS, Baltimore, MD
Inflammation, Critical Care
8:00 Introduction to Seminar and Learning Objectives
8:00 a.m. - 4:00 p.m.
8:15 Health Equity Research Theory and Framework Target Audience
C.E. Brown, MD, MA, Seattle, WA Providers caring for patients with end-stage lung diseases, that might
8:45 Breakout Session #1: Generating a Health Equity benefit from lung transplant. Pulmonologists, thoracic surgeons,
Research Question physical therapists, pharmacists, transplant pulmonologists, surgeons,
and trainees interested in lung transplant.
9:15 Break
Objectives
At the conclusion of this session, the participant will be able to:

ATS 2023 • Washington, DC

SATURDAY • MAY 20 REGISTER NOW 9

• better understand the indications and proper timing of referral for 1:10 Antibody Mediated Rejection; What’s New in Risk and
lung transplantation as well as optimization of patients with end Management?
stage lung disease prior to listing R.R. Hachem, MD, Saint Louis, MO
• understand the process of donor selection and optimization, 1:35 Biomarkers and Therapeutic Targets, PFT, BAL, Liquid
peri-operative care of lung transplant including mechanical Biopsy and Biologics
ventilation and ECMO support J.L. Todd, MD, MHS, Durham, NC
• recognize various causes of acute and chronic allograft dysfunction 2:00 Panel Discussion
and how to utilize the current methods to diagnose and treat them 2:15 Break
This session will provide updates and cover important topics of lung 2:30 CLAD; Diagnosis and Management- Anything New or All
transplant that are highly relevant to ATS attendees. The audience will Doom and Gloom?
learn about indications and proper referral, donor selection, operative E.D. Lease, MD, Seattle, WA
care and complication as well as immune mediated rejections and long
term outcomes of lung transplant. 2:55 Quality of Life Post Lung Transplant; How Much Are We
Really Helping Our Patient With End Stage Lung
Chairing: C.A. Hage, MD, ATSF, Pittsburgh, PA Diseases?
C.M. Shaver, MD, PhD, Nashville, TN J.P. Singer, MD, MSci, San Francisco, CA
J.F. Mcdyer, MD, Pittsburgh, PA
3:20 Retransplant for CLAD; Indications, Outcomes and
P.M. Shah, MD, Baltimore, MD
Ethical Implications
8:00 Introduction V.N. Lama, MD, MS, Ann Arbor, MI
C.A. Hage, MD, ATSF, Pittsburgh, PA
3:45 Panel Discussion
8:05 Indications and Timing of Referral for Lung Transplant;
3:58 Concluding Remarks
Who and When?
L.J. Benvenuto, MD, New York, NY
8:30 Optimization of Lung Transplant Recipients; How Can It CLINICAL
Be Achieved?
M.R. Anderson, MD, MS, Philadelphia, PA POSTGRADUATE COURSE
8:55 Is My Patient Ready for Listing, Science or Art and How
Can We Quantify Readiness?
PG8 INTERSTITIAL LUNG DISEASE:
G.S. Dhillon, MPH, MD, Stanford, CA DELIVERING OPTIMAL, PATIENT
CENTERED CARE
9:20 Panel Discussion
9:35
9:50
Break
Donor Management and Selection; Is There a Perfect
Donor for My Recipient?
E. Cantu III, MD, MSCE, Philadelphia, PA
R Pre-registration and additional fees required. Attendance is limited.
Member: $440
LMIC Member: $310
Non-Member: $540
In-Training Member: $255
LMIC In-Training Member: $180
In-Training Non-Member: $380
Assemblies on Clinical Problems; Behavioral Science and Health
10:15 Perioperative Care of Lung Transplant, Mechanical Services Research; Environmental, Occupational and Population
Ventilation, ECMO and Other Critical Care Treatments Health; Nursing; Pulmonary Circulation; Pulmonary Rehabilitation
J.C. Salgado, MD, Miami, FL 8:00 a.m. - 4:00 p.m.
10:40 Primary Graft Dysfunction; Is It Just a Post-Op ALI or Target Audience
Much More and What Can Be Done to Minimize Its Risk? This course should be broadly relevant to those who provide clinical
J.M. Diamond, MD, MSCE, Philadelphia, PA care for patients with ILD. This will include fellows, general
pulmonologists, ILD specialists, and advanced care nurses.
11:05 Panel Discussion
Objectives
11:20 Airway and Vascular Complications Mimicking Acute
At the conclusion of this session, the participant will be able to:
Rejection
M.M. Crespo, MD, Philadelphia, PA • be able to apply a consistent, effective strategy to ILD/IPF diagnosis

11:45 Lunch • understand the range of therapeutics available for ILD and how and
when to prescribe them
12:45 Acute Cellular Rejection; Updates on Diagnosis and
Management
M.E. Snyder, MD, Pittsburgh, PA

ATS 2023 • Washington, DC

10 REGISTER NOW SATURDAY • MAY 20

• be able to integrate a holistic and interdisciplinary approach to ILD 2:40 Tough Cases
patient care M. Kreider, MD, MSCE, ATSF, Philadelphia, PA
R.K. Putman, MD, MPH, Boston, MA
This course will provide a practical approach to the diagnosis and
A.O. Adegunsoye, MD, MS, Chicago, IL
management of patients with ILD. It will bring recommendations and
T.J. Corte, MBBS, BScM, PhD, Sydney, Australia
guidelines into a usable strategy that will facilitate the care of patients
M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands
with ILD. This will occur through didactics, simulated MDD, and panel
S.K. Danoff, MD, PhD, ATSF, Baltimore, MD
discussions of difficult cases with audience engagment through
V. Steen, MD, Washington, DC
audience response which will provide a range of learning strategies to
L.P. Hariri, MD, PhD, ATSF, Boston, MA
help the largest number of learners.
S. Hobbs, MD, Lexington, KY
Chairing: M. Kreider, MD, MSCE, ATSF, Philadelphia, PA A. Calypso, MSN, CRNP, Baltimore, MD
S.K. Danoff, MD, PhD, ATSF, Baltimore, MD 3:50 Wrap-Up
8:00 Introduction S.K. Danoff, MD, PhD, ATSF, Baltimore, MD
M. Kreider, MD, MSCE, ATSF, Philadelphia, PA
8:10 Clinical Evaluation of the New ILD Patient BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
S. Sood, MD, MS, Philadelphia, PA
8:35 New Guidelines for the Diagnosis of ILD POSTGRADUATE COURSE
K.I. Aronson, MD, MSci, New York, NY
PG9 FUND ME: OVERCOMING THE BARRIERS
9:00 Recognizing CT Patterns
S. Hobbs, MD, Lexington, KY
AND CHALLENGES TO SUCCESSFUL
CAREER DEVELOPMENT AWARDS
9:25 Patients at Risk for ILD

9:50
10:20
R.K. Putman, MD, MPH, Boston, MA
Break
Natural History of Disease and Monitoring
A.O. Adegunsoye, MD, MS, Chicago, IL
R Pre-registration and additional fees required. Attendance is limited.
Member: $440
LMIC Member: $310
Non-Member: $540
In-Training Member: $255
LMIC In-Training Member: $180
In-Training Non-Member: $380
Assemblies on Critical Care, Behavioral Science and Health
10:45 Speed MDD Services Research, Clinical Problems, Nursing, Pediatrics,
S.K. Danoff, MD, PhD, ATSF, Baltimore, MD Pulmonary Infections and Tuberculosis, Respiratory Cell and
K.I. Aronson, MD, MSci, New York, NY Molecular Biology; Supported by MITT
S. Sood, MD, MS, Philadelphia, PA 8:00 a.m. - 4:00 p.m.
L.P. Hariri, MD, PhD, ATSF, Boston, MA
Target Audience
S. Hobbs, MD, Lexington, KY Early-stage investigators (fellows, junior faculty, advanced practice
V. Steen, MD, Washington, DC nurses, PhDs) interested in submitting clinical, translational, health
A.O. Adegunsoye, MD, MS, Chicago, IL services, or implementation science F, K, or other career development
11:55 Lunch awards.
12:55 Therapies for Pulmonary Fibrosis Objectives
T.J. Corte, MBBS, BScM, PhD, Sydney, Australia At the conclusion of this session, the participant will be able to:
1:20 Therapies for CTD-ILD • compose a competitive mentored grant award application with an
F. Castelino, MD, Boston, MA emphasis on innovative research and training plans that highlight
1:45 Non-Pharmacologic Care in ILD the candidate’s potential as well as the strength of their mentorship
M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands team and institutional environment

2:10 Break • formulate and articulate integrated training, mentoring, and research
plans that outline a clear path forward for future independent funding
and career development
• gain a better understanding of the grant review process, including
resubmission, through participation in a mock study section
Writing mentored research awards can be paralyzing and stressful. In
this session, participants will learn fundamental skills needed to develop
a competitive mentored grant proposal, including how to write

ATS 2023 • Washington, DC

SATURDAY • MAY 20 REGISTER NOW 11

compelling specific aims and develop integrated research, mentoring, 2:05 Mock Study Section
and training plans that outline a clear trajectory to future awards and S.J. Denstaedt, MD, Ann Arbor, MI
independence. Participants will gain an appreciation of the review 2:45 Break
process through participation in a mock study section and interact
throughout the day with a diverse faculty composed of previous 2:55 Post-Grant Review: What Happens Next
awardees, experienced mentors, grant reviewers and program officers J.W. Christman, MD, ATSF, Columbus, OH
from various funding bodies. This session will be broadly applicable to 3:10 Making the Most of a Career Development Grant and
potential applicants with any clinical, basic, translational, or health Other Nitty-Gritty
services research focus. C.T. Hough, MD, MSc, Portland, OR

Chairing: E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI 3:25 Disparities Across Grantee Populations
S.J. Denstaedt, MD, Ann Arbor, MI N. Kaminski, MD, ATSF, New Haven, CT
H.L. Lindroth, PhD, RN, Rochester, MN 3:40 Panel Discussion and Wrap-Up
M. Long, PhD, Columbus, OH M. Long, PhD, Columbus, OH
8:00 Introductions
E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI
CLINICAL
8:10 Anatomy of a Career Development Award
H.L. Lindroth, PhD, RN, Rochester, MN POSTGRADUATE COURSE
8:25 How Do You Know You Are Ready to Write a Mentored
Grant? PG10 QUITTING IS WINNING: TOBACCO AND
D. Sheppard, MD, San Francisco, CA E-CIGARETTE CESSATION
8:35

8:45
What Are Potential Sources of Funding for Mentored
Grants?
D.K. Costa, PhD, RN, Orange, CT
Panel Discussion: Tips From Successful Grant
R Pre-registration and additional fees required. Attendance is limited.
Member: $440
LMIC Member: $310
Non-Member: $540
In-Training Member: $255
LMIC In-Training Member: $180
In-Training Non-Member: $380
Assemblies on Environmental, Occupational and Population
Recipients
K.O. Lindell, PhD, RN, ATSF, Charleston, SC Health; Behavioral Science and Health Services Research;
Nursing; Pediatrics; Tobacco Action Committee, Pediatric
9:20 Break
Advocacy Subcommittee
9:30 Integrated Career Development and Training Plans
8:00 a.m. - 4:00 p.m.
T.S. Valley, MD, MSc, Ann Arbor, MI
Target Audience
10:00 Small Group Breakout: Career Development/Training
Clinicians, trainees and multidisciplinary allied health personnel.
Plans
S.J. Denstaedt, MD, Ann Arbor, MI Objectives
At the conclusion of this session, the participant will be able to:
10:50 Break
• describe the differences between various types of tobacco, nicotine,
11:00 Writing Compelling Specific Aims
and vaping products and how this affects risk and nicotine
J.A. Bastarache, MD, Nashville, TN
dependence
11:30 Small Group Breakout: Writing Specific Aims
• appropriately evaluate and treat patients of all ages with nicotine
E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI
dependence, utilizing both behavioral and pharmacologic
12:00 Research Plan Basics interventions based on new guideline recommendations and best
T.J. Iwashyna, MD, PhD, Baltimore, MD practices
12:30 Lunch • improve the quality of care provided to those with nicotine
1:00 The Other Sections: Facilities, Budget, Animals, Humans dependence by understanding how to develop inpatient and
and More outpatient treatment services
K.M. Ridge, PhD, Chicago, IL The primary goal of this session is to provide learners with up to date,
1:25 Questions and Answers With NIH Program Officers evidence-based knowledge and skills in the assessment and treatment
M. Craig, PhD, Bethesda, MD of nicotine dependence. The course will provide timely information
about tobacco products, associated risks, and how this knowledge
1:50 NIH Scoring
informs the approach to tobacco cessation. The treatment approach will
E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI
be individualized and evidence-based, and will span all age groups

ATS 2023 • Washington, DC

12 REGISTER NOW SATURDAY • MAY 20

(adolescent to adult) and practice settings (inpatient and outpatient). 2:25 E-Cig/Tobacco Cessation Approaches: Adult Outpatient
Timely updates about regulation/policy, cannabinoid use in e-cigarettes, Clinic
and EVALI will be shared. Course faculty include multidisciplinary T. Fisher, DNP, APN, Philadelphia, PA
clinical, research, and advocacy experts. Participants will attend 2:55 E-Cig/Tobacco Cessation Approaches: Pediatric
breakout sessions to refine new skills. Outpatient Clinic
Chairing: S.C. Sadreameli, MD, MHS, Baltimore, MD A.M.H. Casey, MD, Boston, MA
A.E. Lang, PharmD, Fort Eustis, VA 3:25 Treatment Approaches Panel
M.E. Rebuli, PhD, Chapel Hill, NC H. Kathuria, MD, ATSF, Boston, MA
8:00 Opening Remarks T. Fisher, DNP, APN, Philadelphia, PA
S.C. Sadreameli, MD, MHS, Baltimore, MD A.M.H. Casey, MD, Boston, MA

8:05 Product Overview: From Cigarettes to ENDS and More 3:55 Concluding Remarks and Dismissal
S.C. Sadreameli, MD, MHS, Baltimore, MD A.E. Lang, PharmD, Fort Eustis, VA

8:30 Tobacco Policy and Regulation Updates

G. Ewart, MHS, Washington, DC BASIC • TRANSLATIONAL
8:55 Questions and Answers for Talks 1 and 2
POSTGRADUATE COURSE
S.C. Sadreameli, MD, MHS, Baltimore, MD
G. Ewart, MHS, Washington, DC
PG11 A HANDS-ON INTRODUCTION TO
9:05 How Do We Take an Effective History?
STUDYING THE LUNG MICROBIOME
S.D. Krefft, MD, MPH, Aurora, CO
9:30

9:55
Motivational Interviewing as an Approach to Cessation
M. Eakin, PhD, Baltimore, MD
Questions and Answers for Talks 3 and 4
S.D. Krefft, MD, MPH, Aurora, CO
R Pre-registration and additional fees required. Attendance is limited.
Member: $440
LMIC Member: $310
Non-Member: $540
In-Training Member: $255
LMIC In-Training Member: $180
In-Training Non-Member: $380
R Registrants must bring a laptop to the course to view the course material.
M. Eakin, PhD, Baltimore, MD Assemblies on Pulmonary Infections and Tuberculosis; Allergy,
10:05 Break Immunology and Inflammation
10:15 Treatment of Adult Nicotine Dependence 8:00 a.m. - 4:00 p.m.
A.E. Lang, PharmD, Fort Eustis, VA Target Audience
10:40 Treating Tobacco Dependence in the Pediatric Clinic Research scientists interested in designing, performing, and
H.J. Farber, MD, MSPH, ATSF, Houston, TX understanding the analysis of lung and airway microbiome samples
using sequencing-based techniques.
11:05 Questions and Answers for Talks 5 and 6
A.E. Lang, PharmD, Fort Eustis, VA Objectives
H.J. Farber, MD, MSPH, ATSF, Houston, TX At the conclusion of this session, the participant will be able to:
• apply research design and analytical approaches needed to conduct
11:15 Lunch
culture-independent assessment of microbiome communities in
11:45 Breakout Session respiratory specimens
12:45 EVALI: Diagnosis, Treatment, Prevention • integrate microbiome sequencing results with current culture-based
M.E. Rebuli, PhD, Chapel Hill, NC models of respiratory infection and re-evaluate disease paradigms
1:10 E-Cigarettes and Cannabinoids and apply this knowledge when designing studies of the lung
A.P. Tackett, PhD, Los Angeles, CA microbiome
1:35 Questions and Answers for Talks 7 and 8 • apply a combination of basic science and multi-dimensional
M.E. Rebuli, PhD, Chapel Hill, NC computational approaches for investigating microbial function and
A.P. Tackett, PhD, Los Angeles, CA mechanisms of disease. Audience will be equipped to prioritize
mechanistic approaches to the microbiota
1:45 Break
This course provides an up to date and accessible introduction to
1:55 E-Cig/Tobacco Cessation Approaches: Inpatient Consult microbiome analyses for trainees and investigators. The course will
Service introduce methodologies used to study the lung microbiome using
H. Kathuria, MD, ATSF, Boston, MA culture-independent methods. During the session, participants will learn
how to design, execute, analyze and interpret a lung microbiome study.

ATS 2023 • Washington, DC

SATURDAY • MAY 20 REGISTER NOW 13

Experiences will include didactic sessions, facilitated small-group

BASIC • TRANSLATIONAL
discussions on designing and executing lung microbiome studies, and
demonstrations on the use of statistical software to analyze microbiome POSTGRADUATE COURSE
data. Attendees will be provided with a set of microbiome data as well
as annotated code for hands-on analysis.
PG12 MOLECULAR TARGETING IN COPD -
Chairing: A.A. Pragman, MD, PhD, Minneapolis, MN FROM BASICS THROUGH MULTI-OMIC
R.P. Dickson, MD, Ann Arbor, MI INTEGRATION TO NOVEL
L.N. Segal, MD, New York, NY THERAPEUTICS
8:00

8:45
An Introduction to Thinking About the Microbiome
R.P. Dickson, MD, Ann Arbor, MI
Contaminomics
M.J. Cox, BSc(Hons), PhD, London, United Kingdom
R Pre-registration and additional fees required. Attendance is limited.
Member: $440
LMIC Member: $310
Non-Member: $540
In-Training Member: $255
LMIC In-Training Member: $180
In-Training Non-Member: $380
R Registrants must bring a laptop to the course to view the course material.
9:15 Integrating Microbiota Findings With Our Disease
Assemblies on Respiratory Cell and Molecular Biology;
Models
Environmental, Occupational and Population Health; Respiratory
A.A. Pragman, MD, PhD, Minneapolis, MN
Structure and Function
9:45 Break 8:00 a.m. - 4:00 p.m.
10:15 Longitudinal Microbiome Studies Target Audience
D. Bogaert, MD, PhD, Edinburgh, United Kingdom Basic science researchers looking for novel druggable targets in
10:45 Studying Viruses and Fungi in Lung Microbiome Studies COPD. Clinicians (clinician scientist) interested in novel approaches to
R.G. Collman, MD, Philadelphia, PA treat COPD.
11:15 Hands-On Microbiome Analysis - Part I Objectives
C. Brown, BA, MS, Ann Arbor, MI At the conclusion of this session, the participant will be able to:
12:15 Lunch • understand genetic susceptibililty, disease heterogeneity and
pathological mechanisms underlying COPD
1:15 Hands-On Microbiome Analysis - Part II
C. Brown, BA, MS, Ann Arbor, MI • learn about novel molecular pathways currently being targeted for
future therapeutics
1:45 Microbial-Host Interactions
L.N. Segal, MD, New York, NY • learn and understand how to use current technologies to delineate
novel targets for drug discovery
2:15 Metagenomics and Metatranscriptomics
C. Langelier, MD, PhD, San Francisco, CA COPD is the third leading cause of death worldwide but there are only
limited symptomatic therapeutic options available with no causal
2:45 Break treatment able to reverse or prevent the progression of COPD,
3:15 Introduction to Integrative, Therapeutic and revealing a high unmet medical need for novel therapeutics. To combat
Environmental Applications in Microbiome Studies this problem a thorough understanding of the molecular mechanisms
S.H. Chotirmall, MD, PhD, Singapore behind COPD are crucial for the development of new targets. Here we
present leading avenues of investigation that will enhance the
3:30 An Introduction to Microbiome Analytics for Integrative
participants understanding of COPD patho-mechanisms and how the
Microbiome Studies
integration of cutting-edge technologies can help in our stride towards
J.K. Narayana, BS, MS, Singapore
finding more efficient therapies.
3:45 Consultation Session
Chairing: Y. Tesfaigzi, PhD, Boston, MA
E.R. Neptune, MD, ATSF, Baltimore, MD
I.M. Adcock, PhD, London, United Kingdom
M.P. Goldklang, MD, New York, NY
8:00 The Future of COPD Research - How We Can Model
Susceptibility, Exposures and the Resultant Endotypes?
A.O. Yildirim, PhD, Munich, Germany
COPD Setting the Scene

ATS 2023 • Washington, DC

14 REGISTER NOW SATURDAY • MAY 20

8:16 Air Pollution - The Forgotten Etiology of COPD

CLINICAL
E. Coffman, BS, MPH, Durham, NC
8:36 Genetic Susceptibility POSTGRADUATE COURSE
B.D. Hobbs, MD, MSc, Boston, MA
8:56 The Pathological Mechanisms of COPD PG13 HUFFING AND PUFFING: BEST
P.J. Barnes, MD, DSc, ATSF, London, United Kingdom PRACTICE AND STATE OF THE ART IN
CPET AND PFT
9:16 A Multi Edged Sword - Heterogeneity in COPD

9:36
J.A. Wedzicha, MD, ATSF, London, United Kingdom
Break
Immune Targets in COPD
R Pre-registration and additional fees required. Attendance is limited.
Member: $440
LMIC Member: $310
Non-Member: $540
In-Training Member: $255
LMIC In-Training Member: $180
In-Training Non-Member: $380
Assemblies on Respiratory Structure and Function; Clinical
10:07 Adaptive Immune Cells in COPD
F. Polverino, MD, PhD, Houston, TX Problems; Pulmonary Rehabilitation
10:27 Specialized Pro Resolving Molecules: A New Approach 8:00 a.m. - 4:00 p.m.
to Resolution of Inflammation Target Audience
P.J. Sime, MD, ATSF, Richmond, VA Current and future directors of PFT and CPET labs, attending
10:47 Novel Immune-Therapeutic Targets in COPD physicians, respiratory therapists, clinical physiologists, trainees,
fellows, and other interested health care providers.
T.M. Conlon, PhD, Munich, Germany
Objectives
Metabolic Targets in COPD
At the conclusion of this session, the participant will be able to:
11:08 Mitochondrial Dysfunction in COPD
• integrate/incorporate the principles and practice of pulmonary
C.R. Kliment, MD, PhD, Pittsburgh, PA
function diagnostic tests
11:28 Disease Pathogenesis Stems From Altered
• improve and develop greater confidence interpreting pulmonary
Immunometabolic Processes
function test results in clinical practice
S.M. Cloonan, PhD, New York, NY
• apply and improve the performance and interpretation of
11:48 Lunch and Group Discussions
cardiopulmonary exercise testing
Lets Regenerate the Lung
This course will focus on clinical physiology, combining guidelines from
12:49 Remodeling and Tissue Repair the new technical standards published in the past three years and
C. Kim, PhD, Boston, MA interpretive strategies document published in the last year with
1:09 Silencing Senescence interactive experience in small group settings focusing on the
M. Lehmann, PhD, Munich, Germany performance, interpretation, and reporting of pulmonary function testing
(PFT) and cardiopulmonary exercise testing (CPET). We will combine
1:29 Novel Transcriptomics-Guided Approaches for didactic lectures with case-based instruction, small group discussion,
Druggable Targets and live demonstration of cardiopulmonary exercise testing. We will use
R. Gosens, PhD, Groningen, Netherlands a multidisciplinary team approach to facilitate case discussions
Tricks and Tools including content experts, clinicians, physiologists, and pulmonary
function laboratory medical directors from around the world.
1:50 Ultra-Resolution Biomedical Imaging
T. Hackett, PhD, ATSF, Vancouver, Canada Chairing: T. Decato, MD, Torrance, CA
2:10 Break M.C. Mccormack, MHS, MD, Baltimore, MD
H.B. Rossiter, PhD, Torrance, CA
2:40 Workshop 1 - Translational and Multidisciplinary Lung
Microengineering 8:00 Blows and Flows: State of the Art in Spirometry
K. Hajipouran Benam, PhD, Pittsburgh, PA S. Stanojevic, PhD, Halifax, Canada
3:10 Workshop 2 - High-Throughput Omics Guides 8:30 Pump Up the Volume: Interpretation and Assessment of
Therapeutic Targeting Lung Volumes
M. Sauler, MD, New Haven, CT B. Borg, BSc, Melbourne, Australia
3:40 Closing Discussion 8:55 Insane in the Membrane: Demystifying DLCO
I.M. Adcock, PhD, London, United Kingdom T. Decato, MD, Torrance, CA

ATS 2023 • Washington, DC

SATURDAY • MAY 20 REGISTER NOW 15

9:20 Turbulence Ahead: Updates in Bronchoprovocation • understand recent developments in lung cancer diagnosis
Testing • understand recent advances in the treatment of lung cancer
T.S. Hallstrand, MD, MPH, ATSF, Seattle, WA
This course will provide a comprehensive review of topics in the
10:00 Break evaluation and management of patients with lung cancer. We discuss
10:20 Don’t Forget About the Kids: Essentials in Pediatric recent developments in tobacco control, updated guidelines and
Pulmonary Function Testing practical tips for lung cancer screening, and minimally invasive
C.L. Ren, MD, MBA, ATSF, Philadelphia, PA diagnostic approaches for patients with lung nodules. The treatment of
10:50 Putting It All Together: Small Group PFT Case early stage, locally advanced and metastatic disease, highlighting
Discussions novel/minimally invasive approaches as well as the use, and toxicities of
R. Clay, MD, Clackamas, OR immunotherapy will also be covered. Attention will be given to the
impact of lung cancer on underrepresented populations as well as the
A.S. Niven, MD, Rochester, MN
K. Jakharia, MBBS, MD, Chapel Hill, NC rising incidence of lung cancer in non-smoking females. Interactive
tumor boards will be held to highlight these topics and facilitate
11:40 Lunch audience engagement.
12:10 Start Me Up: CPET Patient Setup and Demonstration
Chairing: D.J. Feller-Kopman, MD, Lebanon, NH
C.D. Mottram, RRT, RPFT, Rochester, MN
N.T. Tanner, MD, MSCR, Charleston, SC
1:10 Dancing in the Dark: CPET Reference Values
8:00 Introduction
H.B. Rossiter, PhD, Torrance, CA
D.J. Feller-Kopman, MD, Lebanon, NH
1:40 Blinded Me With Science: CPET Data Display and
8:05 Engaging the Community in Lung Cancer Screening &
Interpretation
Tobacco Cessation
D.A. Kaminsky, MD, Burlington, VT
P. Galiatsatos, MD, Baltimore, MD
2:10 Break
8:30 Addressing Disparities in Lung Cancer: The Rural
2:30 What I Like About You: Typical CPET Responses Among Population
Disease States R. Hasson, MD, Lebanon, NH
K.E. Sietsema, MD, Torrance, CA
8:55 Lung Cancer Screening: Ensuring High Quality and
3:00 Express Yourself: CPET Small Group Cases Improving Uptake
T. Decato, MD, Torrance, CA R.S. Wiener, MD, MPH, ATSF, Boston, MA
9:20 Getting to the Nodule: Updates in Advanced
CLINICAL • TRANSLATIONAL Bronchoscopy
S. Shojaee, MD, MPH, Nashville, TN
POSTGRADUATE COURSE 9:45 Break
10:05 Interactive Tumor Board
PG14 STATE OF THE ART: LUNG CANCER IN D.A. Arenberg, MD, ATSF, Ann Arbor, MI
2023
10:35 Biomarkers in Lung Cancer: From Early Detection to
R Pre-registration and additional fees required. Attendance is limited.
Member: $440
LMIC Member: $310
Non-Member: $540
In-Training Member: $255
LMIC In-Training Member: $180
In-Training Non-Member: $380
Assemblies on Thoracic Oncology; Clinical Problems
11:00
Prognosis
A. Vachani, MD, MS, Philadelphia, PA
Addressing Disparities: Lung Cancer in Women
N.T. Tanner, MD, MSCR, Charleston, SC
11:25 Updates in the Surgical Treatment of Lung Cancer
8:00 a.m. - 4:00 p.m.
D. Molena, MD, New York, NY
Target Audience
All providers caring for patients with lung nodules/lung cancer 11:50 Lunch
(pulmonologists, thoracic surgeons, radiation oncologists, NP/PAs).Those 12:50 Updates on SBRT for Lung Cancer
interested in the translational research being done in this field. S. Badiyan, MD, St. Louis, MO
Objectives 1:15 The Role of Immunotherapy in Lung Cancer
At the conclusion of this session, the participant will be able to: S. Scott, MD, Baltimore, MD
• understand the racial and gender disparities related to lung cancer 1:40 Interactive Tumor Board
screening, diagnosis and treatment D.J. Feller-Kopman, MD, Lebanon, NH

ATS 2023 • Washington, DC

16 REGISTER NOW SATURDAY • MAY 20

2:10 Break 8:00 Introduction and Overview

J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil
2:30 Minimally Invasive Palliation: A Focus on the Airway and
Pleura 8:15 Utilizing the Science of Learning to Improve Your
U.S. Chaddha, MBBS, New York, NY Teaching
M.M. Hayes, MD, ATSF, Boston, MA
2:55 The Top 5: This Year’s Most Important Articles
J.R. Jett, MD, Denver, CO 8:45 Tips and Tricks for Creating the Perfect PowerPoint
B. Coruh, ATSF, Seattle, WA
3:20 Panel Discussion With the Experts
G.A. Silvestri, MD, Charleston, SC A. Trainor, MD, Boston, MA
K. Montemayor, MD, Baltimore, MD
M.C. Ferrera, MD, Boston, MA
BEHAVIORAL D. Furfaro, MD, Boston, MA
J.B. Richards, MD, MA, ATSF, Cambridge, MA
POSTGRADUATE COURSE M.M. Hayes, MD, ATSF, Boston, MA
9:40 Break
PG15 TEACHING SKILLS FOR BUSY
10:00 Two Tips for Teaching Critical Thinking
CLINICIANS: EFFICIENT AND EFFECTIVE R.M. Schwartzstein, MD, Boston, MA
TEACHING STRATEGIES FOR ALL
CLINICIANS 10:15 Using Advocacy Inquiry to Give Effective Feedback
M. Soffler, MD, New York, NY
R Pre-registration and additional fees required. Attendance is limited.
Member: $440
LMIC Member: $310
Non-Member: $540
Education Committee
In-Training Member: $255
LMIC In-Training Member: $180
In-Training Non-Member: $380
11:00

11:30
Teaching in the ICU: A Team Based Sport
W.G. Carlos, MD, MSCR, ATSF, Indianapolis, IN
Two Tips to be a Great Mentor
T.S. Wang, MD, ATSF, Los Angeles, CA
8:00 a.m. - 4:00 p.m. 11:45 Lunch
Target Audience 12:45 Two Tips for Teaching Physiology
Physicians, Physicians In-Training, Advanced Practice Providers, J.B. Richards, MD, MA, ATSF, Cambridge, MA
Nurses, Pharmacists, Respiratory Therapists, Medical Students,
1:00 Teaching in the Clinic: Tips and Tricks for Optimized
anyone who teaches
Outpatient Education
Objectives E. Kelly, MD, Dublin, Ireland
At the conclusion of this session, the participant will be able to:
1:30 Creating a Wicked White Board: Tips and Tricks to
• identify and define effective strategies for teaching adult medical Enhance Your Chalk Talks
learners in different clinical settings J.B. Richards, MD, MA, ATSF, Cambridge, MA
• describe educational strategies for promoting critical thinking, giving K. Montemayor, MD, Baltimore, MD
feedback, and mentoring effectively A. Trainor, MD, Boston, MA
M.C. Ferrera, MD, Boston, MA
• review and practice strategies to improve your white board teaching D. Furfaro, MD, Boston, MA
and your PowerPoints M.M. Hayes, MD, ATSF, Boston, MA
Teaching is a core component of medical practice, from teaching 2:20 Break
patients about their medical conditions to helping students and trainees
develop their clinical skills. Most physicians, however, have not had 2:30 Pro Tips for Procedural Teaching in a Busy Environment
formal training on best practices in medical education, and are not D. Kelm, MD, ATSF, Rochester, MN
aware of evidence-based strategies for teaching medical learners. In J.I. Mcsparron, MD, ATSF, Ann Arbor, MI
this postgraduate course, medical education experts from the American 3:00 Two Tips to Incorporate Diversity, Equity, and Inclusion
Thoracic Society will review effective and efficient teaching strategies Into Your Teaching
that participants can incorporate into their teaching activities. Through R. Esteitie, MD, Saginaw, MI
an interactive, hands-on approach participants will learn about and have
3:15 Teaching With Technology in 2023
the opportunity to practice the teaching skills covered in this course.
A. Cooper, MD, Columbus, OH
Chairing: M.M. Hayes, MD, ATSF, Boston, MA 3:45 Wrap-Up Questions and Answers
J.B. Richards, MD, MA, ATSF, Cambridge, MA J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil
J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil

ATS 2023 • Washington, DC

SATURDAY • MAY 20 REGISTER NOW 17

NETWORKING SUPER CENTER

w
The Networking Super Center is open to al attendees from 1:30 p.m. Saturday, May 29 2:00 p.m. Wednesday. May 24th.
Stop by one of the Learning Studios for specialized programming where you can participate in studio talks, panel discussions and
networking opportunities.
The Super Center includes, the ATS Center, Center for Career Development, International Participant's Center, Clinician's Center and the
Science and Innovation Center
COLLABORATE, EDUCATE, CONNECT AND LEARN

4:15 p.m. - 5:30 p.m.

OPENING CEREMONY
w
ATS 2023 kicks off with the Opening Ceremony, featuring a keynote address by Stephen K. Klasko, MD, MBA. During his career
he has been dean at two medical colleges (Drexel and University of South Florida), president of a University (Thomas Jefferson
University) and CEO of two academic health systems (USF health and Jefferson Health).
Dr. Klasko was named a distinguished fellow of the World Economic Forum in 2020, the #2 most influential person in healthcare in 2018 by
Modern Healthcare, the #21 most creative person in business by fast company in 2019 and has been a Becker's top 100 healthcare leader
for the last 5 years in a row.
At Thomas Jefferson University, he led a system that in eight years went from a two hospital, one campus university with $1 billion in revenue
to an 18 hospital, two campus university with almost 10,000 students and a Medicaid and Medicare Advantage health insurance plan, making
Jefferson the first "integrated delivery and financial network" in Philadelphia. He led the integration of Jefferson's extensive academic
pulmonary program through a significant donation to create the Korman Respiratory Institute and led the integration of that institute into a
partnership with National Jewish.
He has written six books from 1999 to 2023 each one advocating for transformations in patient centered healthcare and innovative medical
education. His book UnHealthcare: A Manifesto for health assurance has been translated to several languages.
Dr. Klasko has written more than 100 articles for business journals, blogs and podcasts on the need for more equitable healthcare and
"healthcare at any address" and started the Philadelphia Collaborative for health Equity which has been replicated in several other cities.
He was featured in the European Business Review for his exemplary leadership during the COVID crisis in an article called Leadership Plus
penned by the chair of leadership at Wharton Business School, Michael Useem.
Also during the Opening Ceremony:
• ATS President Greg Downey, MD, ATSF, will provide an update of the Society's major accomplishments for the past year and priorities
for the coming one;
• The latest class of ATS Fellows and Research Program awardees will be recognized; and
• The Public Service Award, World Lung Health Award, Jo Rae Wright Award for Outstanding Science and .J. Randall Curtis Humanism
Award will be presented

ATS 2023 • Washington, DC

18 REGISTER NOW SATURDAY • MAY 20

5:30 p.m. - 6:30 p.m.

THE NETWORKING EXCHANGE FOR EARLY CAREER PROFESSIONALS

w
The Network Exchange is a welcome event for all Early Career Professionals (residents, fellows, post docs, IP members, and
other medical professionals) and takes place on Saturday following the Opening Ceremony. This one-hour event allows attendees to
network and mingle with peers as well as provides information at the start of the conference. This event includes cocktails
and appetizers.
What to expect at the one-hour event?
• Come mingle with colleagues, mentors and peers
• Learn about the ATS Road Map for Early Career Professionals
• Learn how you can become an ATS member for FREE and much more
This event is sponsored / organized by the Members in Transition and Training (MITT) committee.
R This event is free to paid conference registrants

ATS 2023 • Washington, DC

SUNDAY • MAY 21 REGISTER NOW 19

MTE7 INTERSTITIAL LUNG DISEASE IN ANCA VASCULITIS

M. Baqir, MBBS, Rochester, MN
R. Krishna, MBBS, Charleston, SC

K1: KEYNOTE SERIES

8:00 a.m. -8:45 a.m.

The ATS Keynote Series focuses on timely topics of

high relevance to the pulmonary, critical care, and
sleep medicine community. Keynote lectures feature
leaders who have made major contributions in the
important themes programmed at the 2023 conference
and are unopposed by any other programming.
Sunday Morning, May 21
The inaugural Fran Comi Keynote Lecture
will focus on: Minority Health Equity and Disparities

Speaker: Eliseo J. Pérez-Stable, M.D

MEET THE EXPERT SEMINARS

R Pre-registration and additional fees required. Attendance is limited.

$100 Member/Non-Members
$70 LMIC Member/LMIC Non-Members
7:00 a.m. - 8:00 a.m.
YEAR IN REVIEW

MTE1 EMERGING PRESENTATIONS OF ILLICIT OR A1 CLINICAL YEAR IN REVIEW 1

SYNTHETIC DRUGS TOXICITY
P. Camus, MD, Dijon, France 9:00 a.m. - 10:30 a.m.
A.H. Limper, MD, Rochester, MN Target Audience
Pulmonary, critical care and sleep providers. The program will discuss
MTE2 IS OBSTRUCTIVE SLEEP APNEA EFFECTING MY
general topics of interest to a broad group of providers, inside and
BRAIN; LESSONS FROM BENCH TO BEDSIDE
outside of these subspecialties. The program is relevant to not only
C. Lal, MD, ATSF, Charleston, SC
clinicians, but also to researchers and administrators
MTE3 CYSTIC FIBROSIS IN THE ICU: BPH, BACTERIA, AND
Objectives
BEYOND
At the conclusion of this session, the participant will be able to.
G.R. Winter, MD, Birmingham, AL
• apply new clinical research knowledge to clinical practice
MTE4 CARING FOR CHILDREN WHO RECEIVE
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR • apply new findings about key conditions in pulmonary, critical care
NON-MALIGNANT INDICATIONS and sleep
C. Towe, MD, Cincinnati, OH • learn new strategies to manage the care of common conditions in
A. Gupta, MBBS, MPH, Minneapolis, MN pulmonary, critical care, and sleep
10:45 a.m. - 11:45 a.m. Pulmonary, critical care and sleep providers. The program will discuss
MTE5 LUNG NODULE: HOW CAN WE INCREASE THE BIOPSY general topics of interest to a broad group of providers, inside and
DIAGNOSTIC YIELD outside of these subspecialties. The program is relevant to not only
W. Hadid, MD, Lexington, KY clinicians, but also to researchers and administrators.
MTE6 QUALITATIVE RESEARCH FOR THE QUANTITATIVE Chairing: R.J. Shah, MD, MSCE, San Francisco, CA
SCIENTIST: INCORPORATING QUALITATIVE METHODS J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil
INTO SCHOLARSHIP AND CLINICAL PRACTICE S. Auld, MD, MSc, Atlanta, GA
M. Eakin, PhD, Baltimore, MD 9:00 ALI/ARDS
C.T. Hough, MD, MSc, Portland, OR D.W. Russell, MD, Birmingham, AL
S.J. Niranjan, PhD, MS, BPharm, Birmingham, AL
K. Hauschildt, PhD, Baltimore, MD

ATS 2023 • Washington, DC

20 REGISTER NOW SUNDAY • MAY21

9:22 Pulmonary Vascular Disease • develop strategies to evaluate patients with common symptoms that
G.A. Heresi, MD, MSci, Cleveland, OH include uncommon/ rare diseases in the differential diagnosis when
9:45 COPD appropriate
S. Christenson, MD, MS, San Francisco, CA In this session, six unknown cases will be presented by fellows to a
10:07 ILD panel of experts in a traditional Clinical Pathology Conference (CPC)
R.K. Putman, MD, MPH, Boston, MA format. The panel of experts includes three clinician experts, an expert
radiologist, and an expert pathologist. The panel of clinician experts will
discuss the key clinical elements of the history and a differential
BASIC CLINICAL diagnosis. The expert radiologist and pathologist will interpret the
imaging and pathology, respectively, which the expert clinician will then
CRITICAL CARE TRACK use to further the discussion and ultimately make a diagnosis.

A2 JAMA AND THE NEW ENGLAND Chairing: M.M. Lee, MD, ATSF, FCCP, FACP, Los Angeles, CA
JOURNAL OF MEDICINE. DISCUSSION ON C.M. Bojanowski, MD, MSCR, New Orleans, LA
THE EDGE: REPORTS OF RECENTLY 9:00 Expert Clinician
PUBLISHED CRITICAL CARE RESEARCH A.E. Dixon, MA, BM BCH, ATSF, Burlington, VT
9:00 a.m. - 10:30 a.m. 9:20 Expert Clinician
M.P. Rivera, MD, ATSF, Rochester, NY
This session will provide a forum for attendees to interact with the
authors and editors about papers published in JAMA and the New 9:40 Expert Clinician
England Journal of Medicine. Papers presented will be recent E. Schmidt, MD, ATSF, Aurora, CO
publications, selected by the editors, to be of significant importance to 10:00 Expert Radiologist
the field of pulmonary medicine. Attendees will have the opportunity to B. Elicker, MD, San Francisco, CA
hear presentations directly from the author and address questions to
both the authors and editors. The discussion is intended to provide a 10:20 Expert Pathologist
unique insight into these papers, the selection process, and how the J.L. Myers, MD, Ann Arbor, MI
research applies directly to the field of pulmonary medicine.
Speakers and Talks to be Announced CLINICAL
CRITICAL CARE TRACK
CLINICAL
CLINICAL TOPICS IN PULMONARY MEDICINE
A4 ACHIEVING HEALTH EQUITY IN GLOBAL
CRITICAL CARE: CHALLENGES AND
INNOVATIONS
A3 FELLOWS CASE CONFERENCE
Assembly on Critical Care; Africa Interest Group
Assemblies on Behavioral Science and Health Services Research;
Training Committee 9:00 a.m. - 10:30 a.m.
9:00 a.m. - 10:30 a.m. Target Audience
All critical care physicians, advance practice providers, nurses and
Target Audience allied health providers with an interest in healthcare equity and
Clinicians, nurses, fellows, residents, and researchers looking to diversity on a global level
broaden their clinical acumen to facilitate clinical and translational
research Objectives
At the conclusion of this session, the participant will be able to:
Objectives
At the conclusion of this session, the participant will be able to: • better understand challenges and nuances of critical care delivery in
diverse practice settings globally
• recognize clinical, radiographic, and pathologic findings of rare
diseases • incorporate innovative solutions to best practices in critical care in
lower-resourced settings around the world
• gain insight into clinical decision-making skills demonstrated by
master clinicians, radiologists, and pathologists which will improve • describe innovations in critical care research, education and practice
the quality of learners’ practice and potentially improve the quality of in lower-resourced settings
care for the learner’s patients

ATS 2023 • Washington, DC

SUNDAY • MAY 21 REGISTER NOW 21

The practice of critical care around the world varies considerably based exposure, but even a one-time or indirect contact with a hazardous
on environment, geography, and human and material resource agent can result in lung diseases with lasting effects.
availability. Consequently, effective critical care delivery often requires Environmental exposures related to fossil fuel and heavy metals and
nuance and adaptation. With an emphasis on global equity and occupational exposures related to silica and coal mining generate
diversity, this session provides perspective on innovations that improve oxidative stress and inflammation in the lungs. Sustained oxidative
outcomes in lower-resourced settings. This multidisciplinary session will stress causes DNA damage, epigenetic instability, mitochondrial
cover a diversity of essential topics relevant to attendees interested in dysfunction, and cell cycle arrest in key progenitor cells in the lung.
critical care delivery in strained settings around the world.
Inhaled environmental exposures accelerate lung aging by injuring the
Chairing: A. Papali, MD,CM, Charlotte, NC lungs and damaging the cells responsible for wound healing. Novel
D.O. Obaseki, MD, ATSF, Ile-Ife, Nigeria exposure assessment methods, including functional imaging and -omics
9:00 Crisis Standard of Care Protocols in Low-Resource studies, together with mathematical models are needed to quantify
Settings: Ensuring Equity Amidst Scarcity environmental exposures. Interventions that minimize exposure to
E.D. Riviello, MD, MPH, Boston, MA noxious antigens are critical to improve lung health, and novel research
is required to expand our knowledge of therapies that may slow or
9:07 Crisis Standards of Care Protocols in Low-Resource prevent premature lung aging.
Settings: Ensuring Equity Amidst Scarcity
Speaker To Be Announced Speakers and Talks to be Announced

9:15 Sepsis Treatment Around the World: Challenges and

Innovations BASIC • CLINICAL • TRANSLATIONAL
J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil
SCIENTIFIC SYMPOSIUM
9:30 Oxygen Delivery: Overcoming Supply Chain Problems
During the COVID-19 Pandemic
E. Vanderwal, PA, Sidvokodvo, Swaziland A6 BEYOND TRANSCRIPTOMICS: THE NEXT
FRONTIER IN COPD/EMPHYSEMA
9:45 Innovations in Critical Care Education: Lessons from
Kenya Assemblies on Respiratory Cell and Molecular Biology; Allergy,
B.W. Lee, MD, Bethesda, MD Immunology and Inflammation; Clinical Problems; Section on
Genetics and Genomics
10:00 Decolonizing Global Critical Care
R. Haniffa, MD, Edinburgh, United Kingdom 9:00 a.m. - 10:30 a.m.
10:15 Essential Emergency and Critical Care Target Audience
Speaker To Be Announced Providers of lung health care, those who provide care to patients with
COPD/emphysema, and basic and translational scientists with an
interest in COPD/emphysema and gene x environment interactions
BASIC • TRANSLATIONAL Objectives
At the conclusion of this session, the participant will be able to:
BASIC SCIENCE CORE
• apply emerging data to identify cell types and lung compartments
A5 QUANTIFICATION OF ENVIRONMENTAL injured in COPD to more accurately discuss disease biology and
likely disease trajectories with patients to improve care quality
EXPOSURES USING STATE-OF-THE-ART
METHODS • understand existing gaps in the knowledge of pathobiology in COPD

9:00 a.m. - 10:30 a.m. • identify emerging resources and data being applied to facilitate
future therapeutic development
This is part 1 of a 2-part symposium.
Therapeutic discoveries have not kept pace with the significant,
Part 1 focuses on quantification of environmental exposures using world-wide burden of disease associated with COPD/emphysema. No
state-of-the-art methods. major class of drugs has introduced for COPD therapy in decades,
Part 2 on Sunday, May 21, 2:15 p.m.-3:45p.m. focuses on the suggesting the urgent need to delineate disease mechanisms that will
physiological and cellular impact of environmental exposures. facilitate drug discovery. Multiple recent publications have detailed at
single-cell resolution the cellular transcriptional response to chronic
Occupational and environmental lung diseases are caused by the
smoke exposure and COPD/emphysema, particularly in the in the distal
inhalation of chemical irritants, allergens or toxins in work or home
airways and alveoli. This session will explore approaches, including the
environments. Most diseases are caused by repeated, long-term
integration of multi-omic datasets and the application of longitudinal

ATS 2023 • Washington, DC

22 REGISTER NOW SUNDAY • MAY21

cohorts and novel model systems that will extend understanding of • describe the current evidence underpinning the new PR clinical
disease mechanisms to facilitate therapeutic discovery. practice guidelines

Chairing: A.A. Wilson, MD, Boston, MA • apply the new clinical practice guidelines into current practice
A.X. Zhou, PhD, Boston, MA • better understanding of the evidence and implementation of clinical
M.C. Basil, MD, PhD, Philadelphia, PA practice guidelines for PR will improve the quality of life/health status
9:00 RASCs, BASCs, or TASCs? ASCing What Cells in the of this patient group
Respiratory Bronchioles Contribute to COPD Attendees will develop an understanding of the new pulmonary
Pathogenesis rehabilitation (PR) clinical practice guidelines, recommendations across
M.C. Basil, MD, PhD, Philadelphia, PA the spectrum of chronic lung disease and the evidence that underpin
9:13 CAPitalizing on Single Cell RNA Sequencing to Identify this guidance. The session will also give practical tips on how to
Dysregulated Alveolar Endothelium in COPD implement this guidance.
M. Sauler, MD, New Haven, CT Chairing: L. Houchen-Wolloff, PhD, Leicester, United Kingdom
9:26 Integrating GWAS Signals with Omics Datasets to S.P. Bhatt, MD, MSPH, Birmingham, AL
Identify Causal Variants in COPD 9:00 Rationale for New ATS Clinical Practice Guidelines in
M.H. Cho, MPH, MD, Boston, MA Pulmonary Rehabilitation
9:39 Application of Human iPSC Model Systems to Illuminate C.L. Rochester, MD, New Haven, CT
the Functional Contribution of COPD GWAS Genes to 9:10 Overview of New Guidelines
Cellular Phenotypes A.E. Holland, PT, PhD, Melbourne, Australia
R. Werder, PhD, Melbourne, Australia
9:35 Spotlight on Post-Hospitalization Rehabilitation
9:52 Novel Signaling Pathways as Potential Therapeutic P. Camp, PT, PhD, Vancouver, Canada
Targets in COPD Pathogenesis
E.R. Neptune, MD, ATSF, Baltimore, MD 9:55 Patient Speaker
Speaker To Be Announced
10:04 Can Insights from the Pediatric Lung Teach Us About
COPD? 10:00 Strategies for Implementation of the New Guidelines
X. Sun, PhD, San Diego, CA N.S. Cox, PT, MSci, PhD, Melbourne, Australia
10:17 Leveraging Multilevel Profiling of Longitudinal Cohort 10:15 Panel and Audience Discussion
Participants to Illuminate COPD Endotypes
M.R. Faner, PhD, BSc, Barcelona, Spain
BASIC • CLINICAL • TRANSLATIONAL

BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM

SCIENTIFIC SYMPOSIUM A8 BRONCHOPULMONARY DYSPLASIA

ACROSS THE LIFESPAN
A7 THE NEW ATS CLINICAL PRACTICE Assembly on Pediatrics
GUIDELINES FOR PULMONARY
REHABILITATION 9:00 a.m. - 10:30 a.m.
Target Audience
Assemblies on Pulmonary Rehabilitation; Behavioral Science and Neonatologists, pediatric pulmonologists, pediatric radiologists,
Health Services Research respiratory therapists, adult pulmonary critical care specialists, and
9:00 a.m. - 10:30 a.m. basic science researchers interested in pulmonary development and
molecular mechanisms of lung injury
Target Audience
Clinicians and researchers working with patients with chronic Objectives
respiratory disease, in particular those involved in PR, as well as At the conclusion of this session, the participant will be able to:
patients, care givers and patient advocacy groups with an interest in
• to describe new findings about pre- and postnatal molecular
PR.
mechanisms of lung injury that may plausibly serve as therapeutic
Objectives targets that mitigate severe respiratory disease trajectories in
At the conclusion of this session, the participant will be able to: preterm at risk for BPD

ATS 2023 • Washington, DC

SUNDAY • MAY 21 REGISTER NOW 23

• to integrate new guidelines into current practice related to the

CLINICAL
multidisciplinary care of children with established BPD with focus on:
multidisciplinary BPD care programs, pulmonary vascular disease, SCIENTIFIC SYMPOSIUM
and the application of advanced imaging
• to improve the quality of life/health status of patients with BPD by A9 USING TECHNOLOGY TO SAVE THE BRAIN
understanding how longitudinal pulmonary function trajectories in AND BODY: NOVEL INTERVENTIONS TO
childhood, adolescence, and adulthood are modified by BPD MANAGE PAIN, ANXIETY, DELIRIUM, AND
Bronchopulmonary dysplasia (BPD), the chronic lung disease of PROMOTE MOBILITY IN ICU
infancy, is the most common morbidity of preterm birth. Despite
Assemblies on Nursing; Critical Care
improvements in the respiratory care of infants born preterm, the
incidence of BPD is increasing, owing to the improved survival of infants 9:00 a.m. - 10:30 a.m.
born extremely preterm. As increasing numbers of preterm infants Target Audience
survive to adulthood, BPD is increasingly recognized as an important Providers at all levels in critical care, as well as patients, caregivers
contributor to morbidity and mortality throughout life even into and administrators
adulthood. This session will situate current information regarding the
Objectives
molecular mechanisms of BPD pathogenesis within the context of
At the conclusion of this session, the participant will be able to:
longitudinal state-of-the-art, evidence-based respiratory care practices
and outcomes research of individuals with established BPD. • describe novel non-pharmacological interventions to manage pain,
anxiety, stress and delirium, and how they can be utilized to improve
Chairing: J.A. Wambach, MD, MS, St. Louis, MO delirium outcomes in critically ill adults
M.J. Kielt, MD, Columbus, OH
• define strategies and pitfalls involving use of technologies to aid
9:00 Introduction patient assessment in the ICU, including machine-learning
M.J. Kielt, MD, Columbus, OH technologies
9:03 Antenatal Determinants of Bronchopulmonary Dysplasia • apply an understanding of the advantages and challenges of novel
S.H. Abman, MD, Aurora, CO technologies, and how to implement these to improve outcomes in
9:15 Lung Injury and Lung Developmental Programming in ICU delirium survivors
BPD Delirium occurs in up to 80% of patients admitted to the Intensive Care
E. Plosa, MD, Nashville, TN Unit (ICU) and is a major risk factor for Post-Intensive Care Syndrome
9:27 Multidisciplinary BPD Care (PICS). In addition to delirium, ICU patients experience pain and anxiety
L.D. Nelin, MD, Columbus, OH secondary to procedures, invasive ventilation, forced immobilization,
and inability to communicate. Our symposium presents innovative
9:39 Evaluation and Management of Pulmonary Vascular clinical care approaches leveraging technology to provide
Disease in BPD non-pharmacological interventions for management of pain, anxiety,
S. Bhombal, MD, Palo Alto, CA and delirium. We will also present machine learning approaches for
9:51 Advanced Imaging in Bronchopulmonary Dysplasia patient assessment, patient communication technology, music
N. Higano, PhD, Cincinnati, OH applications to manage delirium, pain and anxiety, and telehealth-based
cognitive and physical training for ICU delirium survivors.
10:03 BPD Respiratory Trajectories in Childhood,
Adolescence, and Adulthood Chairing: S.H. Khan, DO, Indianapolis, IN
S.A. Mcgrath-Morrow, MD, Philadelphia, PA H.L. Lindroth, PhD, RN, Rochester, MN
10:15 Panel Discussion 9:00 Ready for Prime Time: Novel Technology Applications to
J.A. Wambach, MD, MS, St. Louis, MO Manage Pain, Anxiety, Sleep in ICU Patients
L.L. Chlan, PhD, RN, ATSF, Rochester, MN
9:15 Revitalizing Brain Body After Critical Illness: Lessons
Learned from a Remote, Video-Based Physical and
Cognitive Training Program
B.A. Khan, MD, Zionsville, IN
9:30 Designing and Implementing a Music Listening
Intervention to Manage the Complex Needs of Patients in
the ICU Environment
A. Heiderscheit, PhD, MT-BC, LMFT, Minneapolis, MN

ATS 2023 • Washington, DC

24 REGISTER NOW SUNDAY • MAY21

9:45 Benefits and Challenges in Implementation of a Music Chairing: F. Holguin, MD, MPH, Aurora, CO
Intervention Application in an Academic ICU K. Sumino, MD, MPH, Saint Louis, MO
S.H. Khan, DO, Indianapolis, IN 9:00 Introduction, Current Options for Asthma Reliever and
10:00 Safer Than Skynet: Using Machine Learning to Save the Guidelines
Patients from Delirium K. Sumino, MD, MPH, Saint Louis, MO
H.L. Lindroth, PhD, RN, Rochester, MN 9:07 Use of ICS Plus SABA As-Needed in Asthma
10:15 We Can’t Manage What We Do Not Assess: Supporting J.C. Cardet, MD, MPH, Tampa, FL
Patient Communication and Symptom Assessment in 9:22 Use of ICS Plus Formoterol As-Needed in Asthma
the ICU H. Reddel, MBBS, PhD, Glebe, Australia
J. Guttormson, MS, PhD, RN, Milwaukee, WI
9:39 Pediatric Perspective of Reliever Therapy in Asthma
F.D. Martinez, MD, Tucson, AZ
BEHAVIORAL • CLINICAL 9:55 Challenges and Equity in US and Global Perspective
Surrounding Choice of Relievers in Asthma
SCIENTIFIC SYMPOSIUM F. Holguin, MD, MPH, Aurora, CO
10:11 Panel Discussion/Questions: Panel 1
A10 ASTHMA HOT TOPIC 2023: WHICH “ICS A. Papi, MD, Ferrara, Italy
PLUS BRONCHODILATOR” RELIEVER 10:15 Panel Discussion/Questions: Panel 2
FOR WHICH PATIENT? E. Israel, MD, Boston, MA
Assemblies on Allergy, Immunology and Inflammation; Pediatrics 10:19 Panel Discussion/Questions: Panel 3
9:00 a.m. - 10:30 a.m. H. Reddel, MBBS, PhD, Glebe, Australia

Target Audience 10:23 Panel Discussion/Questions: Panel 4

Clinicians (physicians, nurses, fellows, residents, pharmacists), F.D. Martinez, MD, Tucson, AZ
researchers, administrators, regulators and policymakers,or anyone 10:27 Panel Discussion/Questions: Panel 5
involved in delivery of care and the science of patients with asthma F. Holguin, MD, MPH, Aurora, CO
Objectives 10:29 Panel Discussion/Questions: Panel 6(Moderator)
At the conclusion of this session, the participant will be able to: K. Sumino, MD, MPH, Saint Louis, MO
• understand the evidence behind various options for asthma reliever
inhalers, and their strengths and potential limitations. The audience
CLINICAL
will be able to fill their knowledge gaps about reliever inhalers for
both pediatric and adult patients SCIENTIFIC SYMPOSIUM
• learn about the practical application of each reliever option for
different populations and settings (pediatrics, adults, US, A11 CARING FOR HISTORICALLY
international) and gain knowledge on how to integrate the decision MARGINALIZED PATIENTS: ETHICAL,
on the choice of reliever in asthma patient management LEGAL AND ADVOCACY PRIMER FOR
• improve the understanding of challenges and remaining PROVIDERS
implementation and research gaps in reliever therapy in asthma.
Assemblies on Critical Care; Nursing; Ethics and Conflict of
The audience will be able to identify implementation gaps in care
Interest Committee
and begin to develop methods to address those gaps
9:00 a.m. - 10:30 a.m.
Evidence regarding use of a reliever coupled with inhaled
corticosteroids (ICS) in asthma has been mounting and there have Target Audience
been substantial changes in guideline-based recommendations in ICU clinicians including physicians, nurses, and respiratory
recent years. Currently, three reliever options are available; short-acting therapists, as well as healthcare administrators, health policy makers
beta-agonist (SABA), ICS plus SABA, and ICS plus formoterol. This and patient advocates
symposium will review the current evidence, research gaps, Objectives
controversies, implementation challenges and equity around the clinical At the conclusion of this session, the participant will be able to:
application of each reliever option in asthma in a broad range of
• understand complexity around care and decision making for patients
patients and settings (mild-severe, pediatric-adults, international-US).
who are undocumented or crossing state lines to seek medical therapies
The session will enhance understanding of how to choose and use
not offered in their home state
asthma relievers in clinical practice, and identify future research needs.

ATS 2023 • Washington, DC

SUNDAY • MAY 21 REGISTER NOW 25

• recognize and mitigate issues surrounding care of incarcerated patients

BEHAVIORAL • CLINICAL • TRANSLATIONAL
and clinician interactions with law enforcement
• define new strategies to understand ethical issues surrounding patients SCIENTIFIC SYMPOSIUM
medical decision making for patients limited health literacy or with
non-traditional alternate decision making structure, or no legally A12 PUBLICATION TO EMPOWERMENT-
authorized representative TRANSITIONING SCIENCE INTO
In this symposium, we consider practical ethics involved in the care for a ENVIRONMENTAL JUSTICE ADVOCACY
wide range of patients with vulnerabilities, due to lack of representation, that Assemblies on Environmental, Occupational and Population
may be underappreciated by their providers: internally displaced people and Health; Allergy, Immunology and Inflammation; Behavioral
refugees seeking asylum; individuals along the spectrum of criminalization Science and Health Services Research; Clinical Problems;
from arrest to incarceration; patients without consistent housing; and those Nursing; Pediatrics
without legally-recognized heteronormative relationships. Additionally, we
acknowledge, across all topics, of the effects of systemic racism that 9:00 a.m. - 10:30 a.m.
disproportionately disenfranchise communities of color. This session Target Audience
presents ethical challenges while also proposing a framework for advocacy Providers of lung health, including basic, clinical, and translational
for these patient groups from the bedside to the seats of government. researchers focused on disparities, environmental or occupational
exposures, community engaged research or health policy
Chairing: E.S. Demartino, MD, Rochester, MN
K.M. Akgun, MD, MS, ATSF, West Haven, CT Objectives
S. Beesley, MD, MSc, Salt Lake City, UT At the conclusion of this session, the participant will be able to:
M.F. Griffith, MD, MPH, Aurora, CO • to contrast spatial epidemiology and community participatory-based
9:00 Intro: Practical Ethics: Caring for Underrepresented research approaches to quantifying the health impacts of
Patients in the ICU environmental injustice
S. Beesley, MD, MSc, Salt Lake City, UT • to develop a framework for clinical and community-based
9:08 A Chilling Effect: Immigration Policy and Documentation approaches to reducing environmental injustice and improve
Status-Related Challenges to the Delivery of Critical respiratory health outcomes for individual patients and communities
Care for Immigrant Populations • to examine the impact of policy-based initiatives to reduce
M. Venkataramani, MD, MPH, Baltimore, MD environmental injustice
9:18 Serious Mental Health, Home Insecurity and Family Environmental justice recognizes the disparities in exposure to
Estrangement: Clinical Challenges in Medical Decision environmental hazards borne by communities of color as a result of
Making and Patients Declining Treatment structural racism. These disparities have profound health impacts, from
M.F. Griffith, MD, MPH, Aurora, CO birth into adult life. Improving respiratory health for communities
9:30 Advocating for the Rights of Justice-Involved Patients impacted by environmental injustice requires both high quality research,
E.S. Demartino, MD, Rochester, MN and mechanisms to move from research into action. This jointly
sponsored, multi-disciplinary symposium aims to bridge this gap,
9:45 Decision Making for ICU Patients Without highlighting both advances in research capturing the impact of
Heteronormative Partners/Surrogates environmental injustice, and the role of policy, community advocacy and
K.M. Akgun, MD, MS, ATSF, West Haven, CT clinical care in translating research into meaningful change.
9:55 Navigating Variable Legal Access to Standard Therapies
Chairing: S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN
Across State Lines
N. Thakur, MD, MPH, San Francisco, CA
A.E. Turnbull, DVM, MPH, PhD, Baltimore, MD
A. Lee, MD, MS, New York, NY
10:10 Reducing Stigma During Home Care Transition M.G. Macmurdo, MBChB, MPH, Cleveland, OH
Education Out of the ICU of Low-Literacy Parents of
9:00 The Environmental Injustice of Childhood Asthma
Children with Heart Disease
S. Lovinsky-Desir, MD, MS, New York, NY
S. Staveski, PhD, RN, CPNP-AC, OAKLAND, CA
9:15 Utilizing Community Based Participatory Research in
10:25 Questions and Discussion Environmental Justice Research
S. Beesley, MD, MSc, Salt Lake City, UT N. Thakur, MD, MPH, San Francisco, CA
9:30 Disparities in Heat Exposure: Utilizing Remote Sensing to
Drive Policy Change
T. Insaf, PhD, MBBS, Albany, NY

ATS 2023 • Washington, DC

26 REGISTER NOW SUNDAY • MAY21

9:45 Research in Action: Utilizing Policy Interventions to

Address Environmental Injustice CLINICAL
Speaker To Be Announced
ADULT CLINICAL CORE CURRICULUM
10:00 Confronting Environmental Injustice in the Clinical Care of
Asthma and COPD
D. Belz, MD, MPH, Baltimore, MD CC1 SLEEP CLINICAL CORE CURRICULUM
10:15 Panel Discussion on Addressing Environmental Injustice Education Committee
Through Inter-Professional Collaboration 11:30 a.m. - 1:00 p.m.
S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN
Target Audience
Clinicians who are engaged in maintenance of certification activities
MEDICAL EDUCATION SEMINAR Objectives
At the conclusion of this session, the participant will be able to:
• describe the nuts and bolts of positive airway pressure and when
and how to use it for patients with heart failure and patients with
ME101 BUILDING BLOCKS TO CRAFTING A different types of sleep disordered breathing
SUCCESSFUL CLINICIAN-EDUCATOR
CAREER • identify best practices for diagnosis and management of sleep
disorders in patients with long COVID characterize common
Assembly on Behavioral Science and Health Services Research manifestations of sleep disordered breathing in patients with
10:15 a.m. - 11:15 a.m. neuromuscular disease
Target Audience Chairing: S. Shafazand, MD, Miami, FL
Trainees, junior and mid career faculty pursuing careers as clinician K. Dudley, MD, Boston, MA
educators although all clinician educators are likely to benefit from this
11:30 Wheezing and Snoring: The Intersection of Obstructive
session
Lung Disease and Sleep Disordered Breathing
Objectives M. Lowery, MD, Gainesville, FL
At the conclusion of this session, the participant will be able to: 11:55 Weak Muscles and Restless Sleep: Neuromuscular Disease
• understand how to create an educational portfolio and identify and Sleep Disordered Breathing
mentors early in ones career J. Contreras, MD, Cleveland, OH

• describe opportunities for production of scholarly work as a clinician 12:2 Shallow Breathing into the Night: Obesity Hypoventilation
educator Syndrome
K. Dupuy-McCauley, MD, Rochester, MN
• identify opportunities for leadership in medical education locally, 12:45 Questions and Answers
regionally and nationally
During this interactive session, participants will have the opportunity to
hear from successful, nationally recognized clinician educators in
pulmonary & critical care medicine regarding career advancement as
clinician educators. Topics will include developing an educational
portfolio, fostering successful mentoring relationships, scholarly
productivity, leadership, and networking locally, regionally and nationally
through organizations such as the ATS. Discussants will provide
attendees with practical tips and focused suggestions as well as ample
opportunity for discussion and questions regarding how to best achieve
success in each of the content domains being presented
Faculty
S.M. Kassutto, MD, Philadelphia, PA
L. Santhosh, MD, MEd, San Francisco, CA
B. Coruh, MD,ATSF, FCCP, Seattle, WA
W.G. Carlos, MD, MSCR, ATSF, Indianapolis, IN

ATS 2023 • Washington, DC

SUNDAY • MAY 21 REGISTER NOW 27

11:45 a.m. - 1:15 p.m.

DIVERSITY FORUM
W
The annual ATS Diversity Forum focuses on diversity within the
fields of pulmonary, critical care, and sleep medicine and
research. All ATS Members are invited to attend this event to
find inspiration and valuable career insights.
The Underrepresented Trainee Development Scholarship will
be presented at this forum. The scholarship was created to
increase representation of underrepresented racial and ethnic
groups as defined by the National Institutes of Health (NIH)
(African American, Hispanic or Latinx, American Indian, Alaskan
Native and Pacific Islander) in pulmonary, critical care, and Sunday
Saturday,
Mid-day,
MayMay
20 21
sleep medicine research by providing an opportunity for trainees
in U.S. based programs to attend the ATS International
Conference
NATIONAL INSTITUTE ON MINORITY HEALTH
The 2023 Diversity Fellowship recipients will also be presented
during the forum. These fellowships are designed to support the AND HEALTH DISPARITIES
efforts of senior fellows, post-doctoral students, or junior faculty
with research, clinical and policy endeavors to advance health
OUTSIDE ORGANIZATION SESSION
equity for patients with respiratory disease, critical care illness
or injury, and sleep disordered breathing. L1 OPPORTUNITIES IN SLEEP AND
RESPIRATORY HEALTH DISPARITIES
The Diversity Forum is organized and presented by the ATS
Membership Committee and will be hosted by its Chair Meshell RESEARCH FUNDED BY NIMHD
Johnson, MD and Vice Chair Alexandra Noel, PhD. The 12:00 p.m. - 1:00 p.m.
Underrepresented Trainee Development Scholarship are
Target Audience
supported by the American Thoracic Society. Providers serving patients that experience health disparities, including
R Pre-registration and an additional fee are required.
$30 members/non-members
racial and ethnic minority, low SES, rural, and sex and gender minority
populations; and members engaged in sleep and respiratory health
research
Objectives
At the conclusion of this session, the participant will be able to:
• describe NIH/NIMHD programs and funding opportunities for
research on the causes and consequences of sleep and respiratory
health disparities in the US
• examine how social determinants of health may impact sleep and
respiratory health disparities
• integrate an understanding of the multilevel causes and
consequences of sleep and respiratory health disparities into current
practice
Racial and ethnic minority and socioeconomically disadvantaged
populations in the US face sleep and respiratory health inequalities. The
National Institute on Minority Health and Health Disparities (NIMHD), in
collaboration with other NIH institutes, promotes and funds research to
understand how social, cultural, and environmental factors contribute to
sleep and respiratory health and health disparities. This session will
highlight NIMHD programs and funding opportunities of interest to ATS

ATS 2023 • Washington, DC

28 REGISTER NOW SUNDAY • MAY21

members and showcase the work of NMIHD grantees, including those • Incorporate updated recommendations and describe the current
studying biobehavioral, structural, environmental, and social evidence, operational challenges, and need to address patient
determinants of sleep and respiratory health and health disparities. preferences for the use of directly observed therapy during
Research gaps, future directions, and NIH funding opportunities will be treatment and management of medication adherence.
discussed. New tools from the U.S. Centers for Disease Control presented will help
Chairing: R. Das, PhD, Bethesda, MD clinical providers and researchers to identify local populations among
whom tuberculosis and chronic pulmonary disease risk is highest, to
12:00 Director’s Introduction to NIMHD better understand demographic differences in risk within their local
E. Perez-Stable, MD, Bethesda, MD area, to communicate effectively with patients, and to use an updated
12:05 Programs and Funding Opportunities in Sleep and approach to monitoring medication adherence. These tools and
Respiratory Health Disparities: Community Health and resources will enhance health screenings and patient outcomes.
Population Sciences
Chairing: C. Winston, PhD, Atlanta, GA
N. Jones, PhD, Bethesda, MD
12:00 Data Tools for State and Local Estimates for Chronic
12:15 Programs and Funding Opportunities in Sleep and
Obstructive Pulmonary Disease - part 1
Respiratory Health Disparities: Integrative Biological and
S.A. Carlson, PhD, MPH, Atlanta, GA
Behavioral Sciences
A.S. Gillman, PhD, MPH, Bethesda, MD 12:10 Data Tools for State and Local Estimates for Chronic
Obstructive Pulmonary Disease - part 2
12:25 Programs and Funding Opportunities in Sleep and
K. Watson, PhD, Atlanta, GA
Respiratory Health Disparities: Clinical and Health
Services Research 12:20 Think. Test. Treat TB. Starting the Conversation
L. Aviles-Santa, MD, MPH, Bethesda, MD N. DeLuca, PhD, MA, Atlanta, GA
12:35 Exposure to Violence, Epigenetic Variation, and Asthma 12:35 Directly Observed Therapy Updates and
in Puerto Rican Children Recommendations
J.C. Celedon, MD, DrPH, ATSF, Pittsburgh, PA J.M.C. Mangan, PhD, ATLANTA, GA
12:50 Panel Discussion 12:50 Panel Discussion and Audience Questions
R. Das, PhD, Bethesda, MD C. Winston, PhD, Atlanta, GA

CENTERS FOR DISEASE CONTROL DIVISION OF LUNG DISEASES, NHLBI/NIH

OUTSIDE ORGANIZATION SESSION OUTSIDE ORGANIZATION SESSION

L2 UPDATES FROM THE CENTERS FOR L3 RECENT CLINICAL AND OMICS FINDINGS
DISEASE CONTROL AND PREVENTION: IN PATIENTS WITH PULMONARY
TOOLS FOR CLINICIANS HYPERTENSION FROM THE NHLBI
12:00 p.m. - 1:00 p.m. PVDOMICS PROGRAM
Target Audience 12:00 p.m. - 1:00 p.m.
Clinicians, academics, and public health practitioners interested in Target Audience
chronic and acute lung disease Healthcare providers, researchers, and trainees with an interest in
Objectives pulmonary hypertension
At the conclusion of this session, the participant will be able to: Objectives
• Identify local geographic areas where chronic pulmonary disease At the conclusion of this session, the participant will be able to:
burden is highest and better understand demographic differences • learn about new genomic findings including rare variant analysis and
within their state. mRNA transcriptomic profiles in the peripheral blood of patients with
• improve communication and education with patients at risk for acute pulmonary hypertension
and chronic disease by using evidence-based, culturally- and • learn about metabolic changes that precede a diagnosis of PAH in
linguistically-appropriate resources to explain tuberculosis risk, scleroderma patients.
recommended testing, and treatment options.
• learn about the effect of pollution on pulmonary vascular disease,
right ventricular function and HRQL in the PVDOMICS cohort.

ATS 2023 • Washington, DC

SUNDAY • MAY 21 REGISTER NOW 29

This session will cover new research discoveries stemming from the • inform clinicians and researchers about the PAHO/WHO
NHLBI “Redefining Pulmonary Hypertension through Pulmonary experiences fostering integrative air quality monitoring as well as
Vascular Disease Phenomics (PVDOMICS)” program that seeks to training opportunities in applying satellite data for health and air
better understand clinical and molecular aspects of pulmonary quality topics.
hypertension (PH), a complex disease with high mortality. This national NASA Earth-observing satellites offer real-time data about natural and
observational clinical study co-sponsored by NHLBI and the Pulmonary anthropogenic processes within atmospheric, aquatic, and terrestrial
Hypertension Association is performing extensive phenotyping in a ecosystems. These data, which complement ongoing epidemiological
large cohort of 1200 participants, which includes the prospective surveillance programs, provide health leaders with valuable insight on
collection and analysis of biomarker, genetic, genomic, and phenotypic the spatial and temporal variation of health risks attributed to harmful
clinical data from subjects with PH for the purpose of identifying exposure to poor air quality. In this session, panelists will demonstrate
subpopulations and intermediate outcome measures. how NASA satellite data can strengthen health applications related to
Chairing: L. Xiao, MD, PhD, Bethesda, MD air quality and respiratory health with community decision-makers.
N.S. Hill, MD, Boston, MA Panelists will share ongoing NASA projects that apply satellite data to
quantify health risks associated with exposure to urban ambient
12:00 Rare Variant Analysis in Non-Group 1 Pulmonary pollution to enhance clinical practice and policy decision-making.
Hypertension
M. Aldred, PhD, ATSF, Indianapolis, IN Chairing: H. Chapman, MD, PhD, MPH, Washington, DC
L. Judd, PhD, Hampton, VA
12:15 The Effect of Pollution on Pulmonary Vascular Disease,
Right Ventricular Function and HRQL in the PVDOMICS 12:00 NASA Health and Air Quality Applications: Applying
Cohort Satellite Data to Respiratory Hea
C. Lim, PhD, Tucson, United States J. Haynes, MS, WASHINGTION, DC
12:30 Metabolic Evolution Precedes PAH Diagnosis in 12:15 Advancing Air Quality Monitoring and Health
Scleroderma: Insights from PVDOMICS and the Johns Surveillance in the Americas
Hopkins Scleroderma Centerr J. Castillo, MSc, Washington, DC
C. Simpson, MD, Baltimore, MD 12:30 The Impacts of Drought on Respiratory Health: Using
12:45 Genomics Analysis of mRNA in Peripheral Venous NASA Data Products to Understand these Connections
Blood Leukocytes for Identification of Clusters Across J. Bell, PhD, Omaha, NE
WSPH Groups and Associations with Severe or Mild 12:45 NASA Applied Remote Sensing Training (ARSET) for
G. Grunig, DVM, PhD, New York, NY Health and Air Quality Applications
M. Follette Cook, PhD, Greenbelt, MD
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
OUTSIDE ORGANIZATION SESSION DIVISION OF LUNG DISEASES, NHLBI/NIH
OUTSIDE ORGANIZATION SESSION
L4 ADVANTAGES OF NASA SATELLITE
DATA IN AIR QUALITY AND L5 CUTTING EDGE IN TRANSLATION - NHLBI
RESPIRATORY HEALTH APPLICATIONS CATALYZE PROGRAM
12:00 p.m. - 1:00 p.m. 12:00 p.m. - 1:00 p.m.
Target Audience Target Audience
Physicians; nurses; allied health professionals; public health Providers of lung health, investigators in lung physiology and
practitioners; community health educators; researchers who are pathophysiology, specific patient group or multiple groups
interested in using Earth observation data for environmental and
occupational health research applications Objectives
At the conclusion of this session, the participant will be able to:
Objectives
At the conclusion of this session, the participant will be able to: • to learn about the NHLBI Catalyze Program and Objectives

• provide an overview of the NASA Health and Air Quality Program • improve NHLBI catalyze program pipeline and success rate
activities that are of interest to clinicians and researchers. • learn emerging technologies and therapeutics for the
• analyze at least three cross-cutting applications where NASA treatment/management of respiratory diseases
satellite data can strengthen scientific understanding of the global
health risk of air pollution.

ATS 2023 • Washington, DC

30 REGISTER NOW SUNDAY • MAY21

The NHLBI Catalyze Program provides a comprehensive suite of In 2017, NHLBI funded 4 groups of investigators to conduct multi-level
support and services to facilitate the translation of basic scientific clinical trials to provide comprehensive asthma care within communities
discoveries into viable therapeutics, devices, and diagnostics ready for where children were at high risk for poor asthma outcomes. The trials
human testing. Currently, the Catalyze Program supports five funding were designed with evidence based interventions targeted to address
opportunities with different funding mechanisms, budget limits, cost findings from a formal needs assessment in each community. Key
sharing requirements, application materials, and project periods. The aspects of these trials included the integration of asthma care for the
Catalyze program have funded 14 awards in lung or lung related children and their families as well as efforts to facilitate the sustainability
research areas, ranging from device, imaging technique, small of the programs after the conclusion of the trials. Investigators will
molecules to biologics on a variety of lung diseases, acute or chronic. briefly review the protocols conducted in each community and provide
ATS noon session will be a good opportunity to highlight/showcase the available results as most of these multi-year trials were recently
catalyze program and to advocate the cutting edge translational effort in completed. The assessment of the sustainability of the programs will be
NHLBI/DLD mission space. conducted in the future.

Chairing: G. Zhou, PhD, Bethesda, MD Chairing: M.M. Freemer, MD, MPH, Bethesda, MD
M. Pieck, PHD, Bethesda, MD 12:00 Asthma among Dine children living on the Navajo Nation
12:00 Introduction to the Catalyze Program B.G. Bender, PhD, Denver, CO
M. Pieck, PhD, Bethesda, MD 12:15 Asthma among West Philadelphia Asthma Care
12:10 Optimization of PET Probe for Imaging Lung Collaborative (WePACC) participants
Fibrogenesis T. Bryant-Stephens, MD, Philadelphia, PA
P.D. Caravan, PhD, Charlestown,, MA 12:30 Asthma among RVA Breathes participants
12:20 Bedside Tomosynthesis Imaging for ICU Patients R.S. Everhart, PhD, Richmond, VA
O. Zhou, PhD, Chapel Hill, NC 12:45 Asthma among Rhode Island Asthma Integrated Care (RI
12:30 Therapeutic Targeting a Ubiquitin E3 Ligase to Control AIR) participants
Pulmonary Inflammation D. Koinis-Mitchell, PhD, Providence, RI
R.K. Mallampalli, MD, Columbus, OH
12:40 Panel Discussion
G. Zhou, PhD, Bethesda, MD MEET THE EXPERT SEMINARS

DIVISION OF LUNG DISEASES, NHLBI/NIH

OUTSIDE ORGANIZATION SESSION
R Pre-registration and additional fees required. Attendance is limited.
$100 Member/Non-Members
$70 LMIC Member/LMIC Non-Members
12:15 p.m. - 1:15 p.m.

L6 COMMUNITY RESULTS FROM ASTHMA MTE8 MITIGATING DISPARITIES IN THE LUNG CANCER
SCREENING PIPELINE
EMPOWERMENT COLLABORATIONS TO
F.C. Duncan, MD, MS, Indianapolis, IN
REDUCE CHILDHOOD ASTHMA S.B. Ogake, MD, Plain City, OH
DISPARITIES E.R. Nunez, MD, Boston, MA
12:00 p.m. - 1:00 p.m. MTE9 PEDIATRIC INVASIVE VENTILATION: MANAGEMENT
Target Audience AND RESOURCE CONUNDRUMS
stakeholders engaged with children with asthma (e.g., health care F. Afolabi, MD, Dallas, TX
providers, public health officials, municipal leaders, care givers) C.D. Baker, MD, Aurora, CO
Objectives A.S. Gelfand, MD, Dallas, TX
At the conclusion of this session, the participant will be able to: D. Liptzin, MD, MS, Missoula, MT

• to assess which interventions affected asthma outcomes in

MTE10 ENGAGING PATIENT, COMMUNITY, AND POLICY
communities with children at high risk for poor outcomes. PARTNERS TO BRING EVIDENCE INTO CLINICAL
PRACTICE
• to understand why an evidence based intervention may need to be M. Trivedi, MD, MPH, Worcester, MA
tailored for a specific community. A.A. Lowe, PhD, MSPH, Tucson, AZ
• to consider how asthma care for children can be coordinated among
a variety of providers.

ATS 2023 • Washington, DC

SUNDAY • MAY 21 REGISTER NOW 31

MTE11 SMALL AIRWAYS DISEASE: WHEN IT’S NOT ASTHMA

S.J. Callahan, MD, Salt Lake City, UT
M. Koslow, MD, Denver, CO
R. De Oliveira Duarte Achcar, MD, Denver, CO
E. Kazerooni, MD, Ann Arbor, MI
MTE13 MEDIA & ME: HOW TO COMMUNICATE SCIENCE AND
HEALTH THROUGH DIFFERENT MEDIA SOURCES
S.C. Sadreameli, MD, MHS, Baltimore, MD
P. Galiatsatos, MD, Baltimore, MD
MTE14 PERSONALIZING SELECTION OF INHALER DELIVERY
SYSTEMS IN COPD
D.A. Mahler, MD, Claremont, NH
D.M.G. Halpin, PhD, Exeter, United Kingdom
MTE15 CYSTIC FIBROSIS PULMONARY EXACERBATIONS:
BASICS FOR THE GENERAL PULMONOLOGIST Sunday Afternoon, May 21
G.R. Winter, MD, Birmingham, AL

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL

YEAR IN REVIEW

A81 PEDIATRIC YEAR IN REVIEW

Assemblies on Pediatrics; Allergy, Immunology and
Inflammation; Clinical Problems; Environmental, Occupational
and Population Health
2:15 p.m. - 3:45 p.m.
Target Audience
Any provider of lung health care for children, as well as clinical and
translational researchers who study pediatric respiratory problems
Objectives
At the conclusion of this session, the participant will be able to:
• learn about the latest science and advocacy related to the impact of
climate change on global respiratory health
• determine local environmental factors that influence respiratory
health (exposome) with a focus on health equity
• learn about the long-term impact of viral pandemics on pediatric
health
This session will provide up-to-date and state-of-the-art information on
four topics: (1) global respiratory health during climate change (2)
pediatric exposome, (3) pandemic science (4) well-being and resilience

Chairing: E. Forno, MD, MPH, ATSF, Pittsburgh, PA

B.T. Kopp, MD, MPH, ATSF, Atlanta, GA
2:15 Pediatric Exposome
S. Lovinsky-Desir, MD, MS, New York, NY
2:38 Epidemic and Pandemic Viruses — Long-term Impact on
Respiratory Health
C. Rosas-Salazar, MD, MPH, ATSF, Nashville, TN

ATS 2023 • Washington, DC

32 REGISTER NOW SUNDAY • MAY21

3:00 Wellness and Resilience 2:51 Implications for Care and Impact on Health Disparities
H.H. De Keyser, MD, MSCR, Aurora, CO R. Adamson, MBBS, ATSF, Seattle, WA
3:23 Global Respiratory Health in the Setting of Climate 3:09 Proposed Alternatives to Race-specific Equations:
Change Possibilities, Pros and Cons
D. Vilcins, PhD, Brisbane, Australia M.C. Mccormack, MHS, MD, Baltimore, MD
3:27 Panel Discussion with Q+A
N.R. Bhakta, MD, PhD, San Francisco, CA
CLINICAL
CLINICAL TOPICS IN PULMONARY MEDICINE
CLINICAL
A82 RACE AND PFTs: USE, CONTROVERSIES, CLINICAL TOPICS IN PULMONARY MEDICINE
AND ALTERNATIVES
Assembly on Clinical Problems; Pulmonary Function Testing A83 GREAT CASES: CLINICAL, RADIOLOGIC,
Committee AND PATHOLOGIC CORRELATIONS BY
2:15 p.m. - 3:45 p.m. MASTER CLINICIANS
Target Audience Council of Chapter Representatives
Clinicians that use PFTs to diagnose or assess patients with 2:15 p.m. - 3:45 p.m.
respiratory disease, and/or clinical researchers with an interest in race
or health equity Target Audience
Clinicians in adult and pediatric PCCM
Objectives
At the conclusion of this session, the participant will be able to: Objectives
At the conclusion of this session, the participant will be able to:
• understand the scientific justification for, potential benefits of, and
• describe findings based on observing master clinicians describe
potential harms from the use of race-specific equations
clinical, radiologic, and pathologic findings to challenging patient
• improve interpretation and clinical application of PFT reports via cases
understanding of how race-specific equations impact
• describe clinical reasoning used to reach a differential diagnosis
percent-predicted PFT values
based on a multidisciplinary team model
• describe potential alternatives to current interpretation strategies
• learners will garner knowledge about treatment & management
and race-specific GLI equations, and their impact on patient care
approaches to different pathologies presented at the conference
Currently, ATS/ERS guidelines recommend the use of race-specific
equations for the interpretation of spirometry. However, their use has Junior physicians (trainees) present interesting cases to a
recently been the subject of intense debate due to concerns that the multidisciplinary panel to demonstrate a team approach to diagnosing
equations may inappropriately normalize lower average lung function and managing challenging clinical cases. It will enhance medical
observed in Black and Asian populations. The session will present knowledge, and diagnostic and management skills.
research related to why race-specific equations are used and what the Chairing: M.J. Mammen, FACP, ATSF, Rochester, NY
potential harms and benefits of their use may be. Additionally, the N.-C. Liang, MD, Encinitas, CA
session will highlight proposed alternatives to race-specific equations
from the literature and discuss pros and cons of their use. 2:15 Master Clinician
A.E. O’Donnell, MD, WASHINGTON, DC
Chairing: N. Thakur, MD, MPH, San Francisco, CA
2:25 Master Clinician
J.H. Brems, MD, MBE, Baltimore, MD
M. Kreider, MD, Philadelphia, NY
S. Lovinsky-Desir, MD, MS, New York, NY
2:43 Master Clinician
2:15 Race-Specific Equations: Why We Use Them, What We
P.C. Stillwell, MD, Aurora, CO
Know, and What We Don’t
S. Stanojevic, PhD, Halifax, Canada 2:53 Master Clinician
J.B. Taylor, MD, MSCR, Pittsburgh, PA
2:33 Prediction of Clinical Outcomes with Race-Specific
Versus Race-Neutral Equations 3:11 Pathology Findings
A.D. Baugh, MD, San Francisco, CA J.L. Myers, MD, Ann Arbor, MI
3:27 Radiological Findings
P. Bergquist, Washington, DC

ATS 2023 • Washington, DC

SUNDAY • MAY 21 REGISTER NOW 33

noxious antigens are critical to improve lung health, and novel research
BASIC • CLINICAL
is required to expand our knowledge of therapies that may slow or
CLINICAL TOPICS IN PULMONARY MEDICINE prevent premature lung aging.
Speakers and Talks to be Announced
A84 THE NEW ENGLAND JOURNAL OF
MEDICINE AND JAMA . DISCUSSION ON
THE EDGE: REPORTS OF RECENTLY BASIC • BEHAVIORAL • CLINICAL
PUBLISHED PULMONARY RESEARCH SCIENTIFIC SYMPOSIUM
2:15 p.m. - 3:45 p.m.
This session will provide a forum for attendees to interact with the A86 PHYSICAL FITNESS AND LUNG HEALTH
authors and editors about papers published in JAMA and the New ATS Public Advisory Roundtable
England Journal of Medicine. Papers presented will be recent
2:15 p.m. - 3:45 p.m.
publications, selected by the editors, to be of significant importance to
the field of pulmonary medicine. Attendees will have the opportunity to Target Audience
hear presentations directly from the author and address questions to Providers of lung health and allied services
both the authors and editors. The discussion is intended to provide a Objectives
unique insight into these papers, the selection process, and how the At the conclusion of this session, the participant will be able to:
research applies directly to the field of pulmonary medicine.
• Describe current ‘state of the art’ evidence supporting the role of
Speakers and Talks to be Announced physical activity in maintaining lung health
• Improve the quality of life/health status of patients by assessing
BASIC • TRANSLATIONAL technologies that may encourage patient engagement in physical
fitness initiatives.
BASIC SCIENCE CORE • Describe new findings related to the role of pulmonary rehabilitation
in preserving lung function and improving quality of life for
A85 PHYSIOLOGICAL AND CELLULAR IMPACT individuals with lung disease
OF ENVIRONMENTAL EXPOSURES
This session will focus on the critical role of physical activity and
2:15-3:45pm conditioning in supporting respiratory health and improving patient
This is part 2 of a 2-part symposium. quality of life. It will explore the current science on exercise and
cardiorespiratory health, technologies to engage patients in physical
Part 1 on Sunday, May 21, 9:00 a.m. -10:30 a.m. focuses on activity, and the critical role of pulmonary rehabilitation in preserving
quantification of environmental exposures using state-of-the-art respiratory health.
methods.
Chairing: M. Manion, BS, Minneapolis, MN
Part 2 focuses on the physiological and cellular impact of
L.M. Schnapp, MD, ATSF, Madison, WI
environmental exposures.
2:15 Session Introduction
Occupational and environmental lung diseases are caused by the
L.M. Schnapp, MD, ATSF, Madison, WI
inhalation of chemical irritants, allergens or toxins in work or home
environments. Most diseases are caused by repeated, long-term 2:30 Every Mile Changes You
exposure, but even a one-time or indirect contact with a hazardous E. Schaller, Patient Speaker, Detroit, MI
agent can result in lung diseases with lasting effects. 2:45 The Role of Physical Conditioning in Respiratory Health
Environmental exposures related to fossil fuel and heavy metals and D.M. Mannino, MD, Lexington, KY
occupational exposures related to silica and coal mining generate 3:00 Pulmonary Rehab to Support Physical Conditioning
oxidative stress and inflammation in the lungs. Sustained oxidative C.L. Rochester, MD, New Haven, CT
stress causes DNA damage, epigenetic instability, mitochondrial 3:15 Monitoring and Tracking Physical Activity: The Role of
dysfunction, and cell cycle arrest in key progenitor cells in the lung. Wearable Tech
Inhaled environmental exposures accelerate lung aging by injuring the Speaker To Be Announced
lungs and damaging the cells responsible for wound healing. Novel 3:30 Exercise for Chronic Lung Conditions: What is the
exposure assessment methods, including functional imaging and -omics Evidence?
studies, together with mathematical models are needed to quantify M.B. Brown, PT, PhD, Seattle, WA
environmental exposures. Interventions that minimize exposure to

ATS 2023 • Washington, DC

34 REGISTER NOW SUNDAY • MAY21

CLINICAL • TRANSLATIONAL BASIC • TRANSLATIONAL

SCIENTIFIC SYMPOSIUM SCIENTIFIC SYMPOSIUM

A87 NEW TREATMENT APPROACHES FOR A88 NEURO-IMMUNE INTERACTIONS IN LUNG

BRONCHIECTASIS DEVELOPMENT AND DISEASE
Assemblies on Pulmonary Infections and Tuberculosis; Allergy, Assemblies on Respiratory Structure and Function; Respiratory
Immunology and Inflammation; Clinical Problems Cell and Molecular Biology; Sleep and Respiratory Neurobiology
2:15 p.m. - 3:45 p.m. 2:15 p.m. - 3:45 p.m.
Target Audience Target Audience
Clinicians and scientists engaged in clinical care and research for Those with clinical and/or research responsibilities
bronchiectasis and related conditions
Objectives
Objectives At the conclusion of this session, the participant will be able to:
At the conclusion of this session, the participant will be able to:
• understand the anatomy and function of the airwayneural network in
• describe new findings about the epidemiology and unmet need in development and physiology
patients with bronchiectasis
• understand how the airway neuralnetwork is altered in chronic lung
• improve the treatment of bronchiectasis patients by better applying disease
the evidence for long term inhaled and oral antibiotics in clinical
• integrate this knowledge to better understand how current and
practice
prospective pharmacological and nonpharmacologicaltreatments
• improve the treatment of bronchiectasis patients by better applying modifying the airway neural network, improve symptoms in patients
the evidence for mucus clearance treatments including airway with chronic lung disease
clearance/physiotherapy and mucus targeting treatments
The vagal nerve integrates afferent and efferent peripheral nerve fibers
This symposium will review the emerging evidence in the field of that control the functions of a large number of internal organs including
bronchiectasis including new data from randomized controlled trials of the respiratory tract. Chronic inflammation drives plasticity of those
inhaled antibiotics, cutting edge science around endotyping, and the neurons, contributing to increased neuronal density in a variety of
application of personalized medicine as well as evidence for emerging pathological conditions including asthma and chronic cough. In addition,
therapies targeting inflammation. evidence is building for a role of the nervous system in guiding
immunological responses. In fact, neuro-immune interactions are
Chairing: S.H. Kasperbauer, MD, Denver, CO recognized to play key roles in inflammation and remodeling in a variety
A.E. O’Donnell, MD, WASHINGTON, DC of chronic lung diseases. As a consequence, there is a need to review
2:15 Patient Speaker current concepts surrounding neuronal development, neuroplasticity
Speaker To Be Announced and neuro-immune interactions in chronic lung disease.
2:20 Epidemiological Approaches to Investigating Treatment Chairing: N. Jendzjowsky, PhD, Torrance, CA
Effects and Unmet Need R. Gosens, PhD, Groningen, Netherlands
E. Henkle, PhD, MPH, Portland, OR
2:15 In Utero Development of the Pulmonary Nervous System
2:40 New Data for Airway Clearance and Mucoactive X. Ai, PhD, Boston, MA
Approaches in Bronchiectasis
A. Basavaraj, MD, FCCP, ATSF, New York, NY 2:33 Dissection of Neuroimmune Control of Lung Function in
Animal Models of Disease
3:00 The Role of Long Term Antibiotic Treatments in X. Sun, PhD, San Diego, CA
Bronchiectasis
T.R. Aksamit, MD, Rochester, MN 2:51 Airway Neuroplasticity in Asthma
M.G. Drake, MD, Portland, OR
3:20 Neutrophils, Eosinophils and Endotyping Bronchiectasis
J.D. Chalmers, MD, PhD, Dundee, United Kingdom 3:09 Macrophage Derived Netrin in Fibrosis
E. Herzog, MD, PhD, New Haven, CT
3:40 Wrap Up and Panel Discussion
S.H. Kasperbauer, MD, Denver, CO 3:27 Targeted Lung Denervation for COPD
D.-J. Slebos, MD, PhD, Groningen, Netherlands

ATS 2023 • Washington, DC

SUNDAY • MAY 21 REGISTER NOW 35

3:30 Can a Household Energy Intervention Change the Social

BEHAVIORAL • CLINICAL
Determinants of Health? Solar Lighting in Rural Uganda
SCIENTIFIC SYMPOSIUM P.S. Lai, MPH, MD, ATSF, Boston, MA

A89 CAN ENVIRONMENTAL INTERVENTIONS BASIC • CLINICAL • TRANSLATIONAL

CHANGE THE SOCIAL DETERMINANTS
OF HEALTH? SCIENTIFIC SYMPOSIUM
Assemblies on Environmental, Occupational and Population
Health; Behavioral Science and Health Services Research; A90 MYTHS OR TRUTHS: CONTROVERSIES IN
International Health Committee RESPIRATORY MEDICINE, THE NEW
2:15 p.m. - 3:45 p.m.
FRONTIER
Target Audience Assemblies on Sleep and Respiratory Neurobiology; Allergy,
Trainees, clinicians, researchers, allied health personnel Immunology and Inflammation; Critical Care; Respiratory Cell and
Molecular Biology
Objectives
At the conclusion of this session, the participant will be able to: 2:15 p.m. - 3:45 p.m.

• describe approaches to quantifying SDOH in the context of high Target Audience

income and low income settings Clinicians and researchers working in the fields of critical care, fibrotic
and inflammatory lung disease, asthma, allergy and sleep medicine
• define how global factors such as climate change influences the
Objectives
relationship between household energy insecurity and SDOH
At the conclusion of this session, the participant will be able to:
• define new strategies for changing the SDOH through environmental
• inform the clinicians and researchers about specific areas of debate
interventions
in management of common and burdensome respiratory conditions:
Social determinants of health (SDOH) are the conditions where people 1) Asthma; 2) OSA; 3) Fibrotic lung disease and 4) ARDS
live, learn, work, and play. SDOH drive disparities in health outcomes,
• apply state of the science to help the audience decide on
but most studies have focused on documenting the role of the SDOH
appropriate 1) management of severe Asthma with biologics; 2) use
rather than on identifying interventions that directly influence the SDOH.
of the AHI in OSA patients; 3) therapeutics in lung fibrosis and 4)
Environmental factors are both a component of and also a potential
treatment of ARDS for their patients
target for intervention on the SDOH. This session, which will include
examples from both high income and low and middle income countries, • identify key gaps for conditions mentioned in objectives 1 and 2 that
will discuss how environmental factors are a core component of the should inform future research
SDOH and show that environmental interventions can change the The pulmonary, critical care, and sleep communities have made
SDOH and address health disparities. progress toward evidence-based care and developing novel therapies
Chairing: P.S. Lai, MPH, MD, ATSF, Boston, MA for “incurable” diseases. However, recent data challenge current
R. Bascom, MD, MPH, Hershey, PA approaches and create uncertainty about the research and
O.B. Ozoh, MBBS, ATSF, MSc, Lagos, Nigeria management approaches to highly burdensome respiratory conditions.
These controversies include 1) management of severe asthma, 2)
2:15 How Do We Quantify the Social Determinants of Health?
apnea-hypopnea index as a prognostic marker in OSA, 3) correcting
J.R. Balmes, MD, ATSF, San Francisco, CA
cellular aging in fibrotic and inflammatory diseases, and 4) targeting
2:30 Environmental Context and Barriers to Asthma Inhaler Use oxygenation during ventilation of acute respiratory distress syndrome.
in High Income vs. Low and Middle Income Countries This session will address the state of the science and evidence for
I.L. Riley, MD, MPH, Durham, NC aspects of managing these conditions to inform clinical decision-making
2:45 Household Energy Use in Low and Middle Income and future research.
Countries Affects Lung Health and Perpetuates Poverty
O.B. Ozoh, MBBS, ATSF, MSc, Lagos, Nigeria Chairing: A. Zinchuk, MD, MHS, BS, New Haven, CT
A.M. Esper, MD, MS, ATSF, Atlanta, GA
3:00 Climate Change Exacerbates Health Inequalities Due to
M. Rojas, MD, Columbus, OH
Household Energy Insecurity
Speaker To Be Announced M. Wechsler, MD, Denver, CO
N.A. Shah, MD, MPH, MSci, New York, NY
3:15 Should I Pay for Food, Rent, or Inhalers? Community
Linkage Resource Programs and Pediatric Asthma
Exacerbations in the United States
N. Thakur, MD, MPH, San Francisco, CA

ATS 2023 • Washington, DC

36 REGISTER NOW SUNDAY • MAY21

2:15 Introduction to Debate 1: Biologics Overlap in Asthma

M. Wechsler, MD, Denver, CO
2:18 Truth: Biologics Can Be Combined and Overlapped in Severe
Asthma
M. Kraft, MD, ATSF, New York, NY
2:27 Myth: Biologics Can Be Combined and Overlapped in Severe
Asthma
P. Akuthota, MD, ATSF, La Jolla, CA
2:36 Summary and Audience Response Results (Debate 1)
M. Wechsler, MD, Denver, CO
2:38 Introduction to Debate 2: Utility of the AHI
N.A. Shah, MD, MPH, MSci, New York, NY
2:40 Truth: The AHI Should Be Used in Prognostication and
Treatment of OSA
A. Malhotra, MD, ATSF, La Jolla, CA
2:49 Myth: The AHI Should Be Used in Prognostication and
Treatment of OSA
S.S. Redline, MD, MPH, Boston, MA
2:58 Summary and Audience Response Results (Debate 2)
A. Zinchuk, MD, MHS, BS, New Haven, CT
3:00 Introduction to Debate 3: Senolytics in Respiratory Diseases
M. Rojas, MD, Columbus, OH
3:02 Truth: Senolytics Can Be Effective in Fibroproliferative and
Other Respiratory Diseases
A.M. Nambiar, MD, MSCR, San Antonio, TX
3:11 Myth: Senolytics Can Be Effective in Fibroproliferative and
Other Respiratory Diseases
B. Crestani, MD, PhD, Paris, France
3:20 Summary and Audience Response Results (Debate 3)
M. Rojas, MD, Columbus, OH
3:22 Introduction to Debate 4: PEEP and Oxygenation in ARDS
A.M. Esper, MD, MS, ATSF, Atlanta, GA
3:24 Truth: PEEP Titration in ARDS Should Prioritize Arterial
Oxygenation
S. Sahetya, MD, MHS, Baltimore, MD
3:33 Myth: PEEP Titration in ARDS Should Prioritize Arterial
Oxygenation
E.C. Goligher, MD, PhD, FRCP(C), Toronto, Canada
3:42 Summary and Audience Response Results (Debate 4 and
Overall Session)
A.M. Esper, MD, MS, ATSF, Atlanta, GA

2:15 p.m. - 4:15 p.m.

Oral And Poster Presentations Of Scientific
Research And Case Reports. Abstract Sessions
Will Be Published In The Final Program.

ATS 2023 • Washington, DC

MONDAY • MAY 22 REGISTER NOW 37

MTE23 BRONCHIECTASIS: CASE-BASED UPDATE ON

GUIDELINES AND NEW TREATMENT OPTIONS
G. Tino, MD, ATSF, Philadelphia, PA
A.E. O’Donnell, MD, WASHINGTON, DC

K2: KEYNOTE SERIES

8:00 a.m. -8:45 a.m.

The ATS Keynote Series focuses on timely topics of

high relevance to the pulmonary, critical care, and
sleep medicine community. Keynote lectures feature
leaders who have made major contributions in the
important themes programmed at the 2023 conference
Monday Morning, May 22 and are unopposed by any other programming.
Monday's Keynote Lecture will focus on: Climate
Effects on Health, and Environmental Policies that
Support and Contribute to Mitigating Existing and
MEET THE EXPERT SEMINARS Future Effects

Speaker To Be Announced
R Pre-registration and additional fees required. Attendance is limited.
$100 Member/Non-Members
$70 LMIC Member/LMIC Non-Members
7:00 a.m. - 8:00 a.m.
MTE16 IT TAKES A VILLAGE: INTEGRATING ILD SUPPORT
GROUPS INTO COMMUNITY MEDICAL CENTERS YEAR IN REVIEW
J. Wescoe, EdM, Coopersburg, PA
D. Corwin, MD, Fountain Hill, PA B1 CLINICAL YEAR IN REVIEW 2
MTE17 SEVERE CHILDHOOD ASTHMA: WHEN TO USE 9:00 a.m. - 10:30 a.m.
BIOLOGICS AND WHAT TO DO IF THEY FAIL
Target Audience
C. Rosas-Salazar, MD, MPH, ATSF, Nashville, TN
Pulmonary, critical care and sleep providers. The program will discuss
L.B. Bacharier, MD, Nashville, TN general topics of interest to a broad group of providers, inside and
MTE18 BIOLOGICS AND BEYOND: UNDERSTANDING AND outside of these subspecialties. The program is relevant to not only
MANAGING SEVERE ASTHMA clinicians, but also to researchers and admini
G.S. Skloot, MD, ATSF, Cary, NC Objectives
M.G. Drake, MD, Portland, OR At the conclusion of this session, the participant will be able to:
10:45 a.m. - 11:45 a.m. • apply new clinical research knowledge to clinical practice.
MTE19 DECENTRALIZED CLINICAL TRIALS IN INTERSTITIAL • apply new findings about key conditions in pulmonary, critical care
LUNG DISEASE and sleep.
R. Aggarwal, MD, Pittsburgh, PA
D.I. Sullivan, MD, Pittsburgh, PA • learn new strategies to manage the care of common conditions in
pulmonary, critical care, and sleep.
MTE20 DYSPNEA DURING MECHANICAL VENTILATION
R.M. Schwartzstein, MD, Boston, MA Pulmonary, critical care and sleep providers. The program will discuss
general topics of interest to a broad group of providers, inside and
MTE21 NEW APPROACHES FOR NON-INVASIVE ACCESS TO outside of these subspecialties. The program is relevant to not only
THE LUNG clinicians, but also to researchers and administrators.
S.D. Spivack, MD, MPH, Bronx, NY
MTE22 COMMUNICATING SCIENCE TO THE PRESS Chairing: R.J. Shah, MD, MSCE, San Francisco, CA
V. Gupta, MD, Seattle, WA J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil
P. Silveyra, PhD, MSc, ATSF, Bloomington, IN S. Auld, MD, MSc, Atlanta, GA

ATS 2023 • Washington, DC

38 REGISTER NOW MONDAY • MAY 22

9:00 Palliative Care 9:00 Safety First: Primary Spontaneous Pneumothorax

A.L. Jennerich, MD, MS, ATSF, Seattle, WA Should Be Drained - the Pros
N. Rahman, BM BCH, MSc, MRCP(UK), Oxford, United
9:23 COVID-19
Kingdom
S.E. Jolley, MD, MSc, Aurora, CO
9:15 Safety First: Primary Spontaneous Pneumothorax Should
9:45 Lung Cancer Be Drained - the Cons
A.C. Melzer, MD, MS, Minneapolis, MN Y.C.G. Lee, MBChB, PhD, Perth, Australia
10:08 Critical Care 9:30 Surgical Decortication Should Be Default First Choice for
Pleural Infection, Not Intrapleural tPA/DNase Therapy - the
Tiffanie Jones, MD, MPH, MSCE, Philadelphia, PA Pros
N. Maskell, DM, Bristol, United Kingdom
9:45 Surgical Decortication Should Be Default First Choice
CLINICAL for Pleural Infection, Not Intrapleural tPA/DNase Therapy
CLINICAL TOPICS IN PULMONARY MEDICINE - the Cons
K. Yasufuku, MD, Toronto, Canada

B2 PRO CON DEBATES ON PLEURAL 10:00 Video-Assisted Thoracoscopic Talc Poudrage Is

CONTROVERSIES: WHAT Preferred Over Indwelling Pleural Catheter for Malignant
Effusion Management - the Pros
PULMONOLOGISTS NEED TO KNOW
E. Gillaspie, MD, MPH, FACS, Nashville, TN
Assemblies on Clinical Problems; Thoracic Oncology
10:15 Video-Assisted Thoracoscopic Talc Poudrage Is
9:00 a.m. - 10:30 a.m. Preferred Over Indwelling Pleural Catheter for Malignant
Target Audience Effusion Management - the Cons
Clinicians, nurses, allied health staff and researchers in respiratory D. Fitzgerald, MBBCH, Tallaght, Ireland
diseases, including chest physicians, interventional pulmonologists,
thoracic/general surgeons, oncologists, general/emergency physicians,
junior staff and scientists BASIC • CLINICAL • TRANSLATIONAL
Objectives CLINICAL TOPICS IN PULMONARY MEDICINE
At the conclusion of this session, the participant will be able to:
• learn about advances in spontaneous pneumothorax care. B3 TARGETING MUCUS ACROSS LUNG
Understand the pros and cons of conservative management versus DISEASES: FROM PATHOGENESIS AND
traditional drainage approach, and new ambulatory drainage devices IMAGING TO THERAPY
• learn about advances in pleural infection care. Understand the pros Assemblies on Clinical Problems; Pediatrics; Respiratory Cell
and cons of intrapleural tPA/DNase therapy versus traditional and Molecular Biology
surgical drainage, and areas of knowledge gaps
9:00 a.m. - 10:30 a.m.
• learn about advances in malignant pleural effusion management.
Understand the pros and cons of indwelling pleural catheter (with Target Audience
Fellows, junior professionals, clinicians, researchers
talc instillation) versus video assisted thoracoscopic surgery
Objectives
The past decade saw an unprecedented number of randomized trials
At the conclusion of this session, the participant will be able to:
published on pleural medicine. These advances bring new questions
and controversies confronting pulmonologists on clinical care. This • describe new findings on the pathogenesis of mucus dysfunction
session highlights topical issues on which opinions are polarized and • recognize imaging features of mucus dysfunction readily to be
management heterogeneous worldwide. Leaders in the field debate the applicable
evidence that support (or not) common practice. In particular, [1]
conservative (non-drainage) approach for spontaneous pneumothorax • describe the new therapies targeting mucus dysfunction
challenges conventional drainage algorithm (PSP trial NEJM 2020); [2] Mucus dysfunction plays a significant role in COPD, asthma, and cystic
intrapleural tPA/DNase therapy questions need for surgical drainage of fibrosis. It has been stimulating progress in understanding the
empyema; and [3] indwelling pleural catheter pleurodesis presents an pathogenesis and imaging of mucus dysfunction. This progress includes
alternative to VAT surgical pleurodesis for malignant pleural effusions. the role of mucus mucins in disease pathogenesis and the use of
imaging modalities, such as computed tomography, to evaluate this
Chairing: D.J. Feller-Kopman, MD, Lebanon, NH
process. This significant progress has been combined with developing
C.R. Lamb, MD, Burlington, MA
targeted therapeutics for mucus dysfunction in cystic fibrosis, furthering

ATS 2023 • Washington, DC

MONDAY • MAY 22 REGISTER NOW 39

studies for therapies for other airway diseases. This session will present • develop a deeper understanding of the challenges of implementing
the advances in mucus dysfunction from pathogenesis and imaging to policies, the unforeseen issues, and how to overcome the
therapy. challenges

Chairing: A.A. Diaz, MD, MPH, Boston, MA Significant attention has focused on identifying strategies to retain and
A.M. Jaramillo, PhD, Aurora, CO recruit women and underrepresented minorities in pulmonary and
J.V. Fahy, MD, San Francisco, CA critical care medicine. Despite this, the COVID-19 pandemic resulted in
J.A. Wedzicha, MD, ATSF, London, United Kingdom women and underrepresented in medicine (URiM) clinicians leaving
pulmonary and critical care medicine not only because of the continued
9:00 Patient’s Perspective racism and sexism that exist but because of the additional challenges
J. Conroy, MSc, Baltimore, United States imposed by the pandemic. New solutions beyond bystander trainings
9:10 Mucus, Mucins, and Mucociliary Dysfunction: A Sticky and implicit bias tests are needed to address the challenges of the past
Problem two years. This session will highlight current system solutions that are
R.C. Boucher, MD, Chapel Hill, NC being implemented and disseminated in academia at a systems level.
9:26 Mucus Dysfunction in Cystic Fibrosis Chairing: E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI
S.E. Birket, PharmD, PhD, Birmingham, AL D. Colon Hidalgo, MD, MPH, aurora, CO
9:42 Seeing Is Believing: Imaging of Mucus Plugs in Asthma J.C. Celedon, MD, DrPH, ATSF, Pittsburgh, PA
and COPD 1 9:00 The Diversity Bonus: Not Just a URiM Issue
E. Dunican, BM BCH, Dublin, Ireland J. Reede, MD, MS, MPH, MBA, Boston, MA
9:50 Seeing Is Believing: Imaging of Mucus Plugs in Asthma 9:15 You Want Us to Stay in Academics? Here Is How You
and COPD 2 Keep Us
A.A. Diaz, MD, Boston, MA D. Montoya-Williams, MD, Philadelphia, PA
9:58 The Dawn of a New Era: Therapies Targeting Mucus 9:25 “Passing the Harasser”: How to Stop the Game and
R. Jain, MD, MSci, ATSF, Dallas, TX Change the Culture
10:14 Panel Discussion and Q & A K. Spear, MPH, Washington, DC
9:40 Actions Speak Out Louder Than Policies: Institutional
Variation in Holding Patients Accountable for
BEHAVIORAL Inappropriate Behaviors
E.M. Viglianti, MD, MPH, MSc, Ann Arbor, MI
CRITICAL CARE TRACK
9:50 Pay to Stay: How Do Funding Agencies Support DEI
B4 FAIL SMARTER AND LEARN FASTER: Faculty?
MOVING BEYOND BYSTANDER TRAINING .A. Bernard, MD, Washington, DC
TO ORGANIZATIONAL STRATEGIES TO 10:05 When Color Blindness Is Not an Option - What
REINFORCE THE DEI PIPELINE IN Institutions Can Do to Recruit, Promote and Retain URiM
PULMONARY AND CRITICAL CARE V. Asare, MD, New Haven, CT

Assemblies on Critical Care; Behavioral Science and Health 10:15 Panel Discussion
Services Research; Clinical Problems; Nursing; Pediatrics J.C. Celedon, MD, DrPH, ATSF, Pittsburgh, PA

9:00 a.m. - 10:30 a.m.

Target Audience BASIC • TRANSLATIONAL
All levels, all practicing healthcare providers
BASIC SCIENCE CORE
Objectives
At the conclusion of this session, the participant will be able to:
B5 BACK TO BASICS: HARNESSING THE
• describe successfully implemented institutional and organizational POWER OF MOUSE MODELS TO
system solutions which can be applied to the participants respective UNDERSTAND HUMAN SEPSIS
institutions and organizations
Assemblies on Allergy, Immunology and Inflammation; Critical
• highlight new NIH strategies to support the pipeline of women and Care; Pulmonary Circulation; Respiratory Cell and Molecular
URiM into pulmonary and critical care Biology
9:00 a.m. - 10:30 a.m.

ATS 2023 • Washington, DC

40 REGISTER NOW MONDAY • MAY 22

Target Audience Target Audience

Basic, translational, and clinical scientists Clinicians and researchers interested in Obstructive Sleep Apnea
(OSA) therapies
Objectives
At the conclusion of this session, the participant will be able to: Objectives
At the conclusion of this session, the participant will be able to:
• describe new mechanistic insights into human sepsis derived from
pre-clinical mouse models • understand better current and future approaches to optimal patient
selection for available OSA therapies
• understand and identify perceived and actual barriers to translating
pre-clinical findings to the clinic • describe recent progress and challenges in the (pre)clinical
development of new drug/device therapies
• identify new strategies to limit infection-induced inflammation
• describe regulatory requirements to translate interventions into
Sepsis, the dysregulated host response to infection, is a life-threatening
FDA-approved clinical therapies
clinical syndrome affecting all cells, tissues, and organs. While no
pre-clinical model can recapitulate the myriad complexities of organ While CPAP can have transformative effects for some patients with
dysfunction and tissue injury in human sepsis, animal models are obstructive sleep apnea (OSA), many patients are unable to tolerate
essential to developing a mechanistic understanding of sepsis and PAP therapy long-term and due to limited alternatives remain untreated.
identifying novel targets for intervention. This symposium will provide Based on recent publications and conference sessions, there is a clear
attendees with a basic overview of commonly used mouse models of need for novel, personalized treatment options.
sepsis, with an emphasis on how these models provided new insights Through state-of-the-art reviews and an in-depth panel discussion, we
directly relevant to human sepsis. will provide the audience with current best practices for more
Chairing: J.A. Bastarache, MD, Nashville, TN established therapies (e.g. oral appliances, hypoglossal nerve
N.S. Mangalmurti, MD, Philadelphia, PA stimulation) and speak to critical issues including regulatory
E.P. Schmidt, MD, ATSF, Boston, MA considerations for the development of novel, personalized alternative
therapies (e.g. ansa cervicale stimulation, endotype-targeted drug
9:00 Utilizing Complementary Murine Models of Experimental therapy, DREADD).
Sepsis to Determine How Age Increases the Virulence of
Gut-Derived Pathogens Chairing: N. Ayas, MPH, MD, Vancouver, Canada
J. Colbert, MD, Aurora, CO F.R. Almeida, PhD, DDSc, Vancouver, Canada
V.Y. Polotsky, MD, PhD, Baltimore, MD
9:20 Preserved Alternative Complement Function is
A. Parekh, PhD, New York, NY
Associated with Improved Survival During ARDS: A
S.S. Redline, MD, MPH, Boston, MA
Translational Perspective
W. Bain, MD, Pittsburgh, PA 9:00 Introduction
N. Ayas, MPH, MD, Vancouver, Canada
9:40 A Clinically Relevant Mouse Model of Sepsis-Induced
Delirium 9:02 Patient Perspective
J.A. Bastarache, MD, Nashville, TN Speaker To Be Announced
10:00 Red Cell-DNA Delivery Contributes to the 9:07 What’s New with Weight Loss, Oral Appliances, and
Heterogeneous Host Response in Sepsis Upper Airway Surgery?
N.S. Mangalmurti, MD, Philadelphia, PA B.A. Edwards, PhD, Melbourne, Australia
10:20 Cytokine Networks That Limit Infection-Induced 9:21 Electrical Stimulation: Hypoglossal Nerve Stimulation,
Inflamation Ansa Cervicale Stimulation, and Transoral Daytime
C. Hunter, PhD, Philadelphia, PA Neurostimulation
D. Kent, MD, Nashville, TN
9:35 Clinical Drug Discovery Based on Endotypes
CLINICAL • TRANSLATIONAL
C.N. Schmickl, MD, PhD, San Diego, CA
SCIENTIFIC SYMPOSIUM 9:49 Preclinical Drug Discovery: Cannabimimetics, Intranasal
Leptin, DREADD, and Beyond
B6 NON-PAP ALTERNATIVES FOR OSA: B. Prasad, MD, ATSF, Chicago, IL
FROM ACCEPTED TO REVOLUTIONARY 10:03 FDA Perspective: Regulatory Considerations for the
Assembly on Sleep and Respiratory Neurobiology Development of New OSA Therapies 1
L. Kim, MD, Silver Spring, MD
9:00 a.m. - 10:30 a.m.

ATS 2023 • Washington, DC

MONDAY • MAY 22 REGISTER NOW 41

10:10 FDA Perspective: Regulatory Considerations for the 9:00 Introduction

Development of New OSA Therapies 2 R.T. Cohen, MD, MPH, Boston, MA
N.A. Weir, MD, Silver Spring, MD 9:03 Patient Speaker
10:17 Panel Discussion Plus Q&A Speaker To Be Announced
S.S. Redline, MD, MPH, Boston, MA 9:08 A Pulmonary Perspective of Sickle Cell Disease and
Disease-Modifying Therapies
A. Campbell, MD, Washington, DC
CLINICAL • TRANSLATIONAL
9:21 Airway Function in SCD: Impact on Morbidity and
SCIENTIFIC SYMPOSIUM Mortality Across the Lifespan
S.M. Willen, MD, Sacramento, CA
B7 SICKLE CELL LUNG DISEASE ACROSS 9:34 Sleep Disordered Breathing in SCD - What Have We
THE LIFESPAN: WHERE ARE WE NOW? Learned?
Assemblies on Pediatrics; Behavioral Science and Health O. Afolabi-Brown, MD, Philadelphia, PA
Services Research; Clinical Problems; Critical Care; Nursing; 9:47 Pulmonary Hypertension Beyond the ATS Guidelines:
Pulmonary Circulation; Sleep and Respiratory Neurobiology New Concepts in Pathophysiology, Diagnosis and
9:00 a.m. - 10:30 a.m. Treatment
R.F. Machado, MD, Indianapolis, IN
Target Audience
Pediatric and adult pulmonary, critical care, and sleep trainees, and 10:00 Acute Chest Syndrome and Venous Thromboembolism
clinicians and researchers interested in the pulmonary complications of in SCD: When the Acute Becomes Chronic
sickle cell disease (SCD) across the lifespan E.S. Klings, MD, Boston, MA
Objectives 10:13 Curative Therapies for Sickle Cell Disease: Potential
At the conclusion of this session, the participant will be able to: Cures for SCD but What About the Lung?
C. Fitzhugh, MD, Bethesda, MD
• define the current state-of-the-art management of the acute and
chronic pulmonary complications of sickle cell disease and identify 10:26 Conclusion
knowledge gaps that exist A.P. Ruhl, MD, MHS, Bethesda, MD
• understand the impact of abnormalities throughout the pulmonary
system (airway, gas exchange/sleep, and vascular) as disease
BASIC • CLINICAL • TRANSLATIONAL
modifiers on SCD outcomes throughout the lifespan
• gain an understanding of the mechanisms of new SCD SCIENTIFIC SYMPOSIUM
disease-modifying therapies including hematopoietic stem cell
transplantation and gene therapy on overall disease progression B8 BEYOND THE LUNGS:
and potential impacts on cardiopulmonary dysfunction EXTRAPULMONARY MANIFESTATIONS
SCD affects approximately 100,000 US individuals, and 300,000 births OF PULMONARY VASCULAR DISEASE
annually worldwide, largely on the African continent. While it is a genetic Assembly on Pulmonary Circulation
hemoglobinopathy, SCD is a systemic disorder. In the lungs, nearly
every cell type and structure are affected, and cardiopulmonary 9:00 a.m. - 10:30 a.m.
complications are a leading cause of morbidity and accelerated Target Audience
mortality. The goal of this scientific symposium is to present recent Providers caring for those with pulmonary vascular disease, and those
findings and evidence-based interventions for acute and chronic with clinical or research responsibilities related to pulmonary vascular
pulmonary complications of SCD across the lifespan. We will actively disease or lung diseases with similar extrapulmonary manifestations
engage pediatric and adult clinicians and researchers to promote Objectives
collaborative investigation and implementation of evidence-based At the conclusion of this session, the participant will be able to:
clinical care for patients living with SCD.
• describe new findings about extrapulmonary manifestations in PAH
Chairing: R.T. Cohen, MD, MPH, Boston, MA within the CNS, skeletal musculature, gut microbiome and changes
A.P. Ruhl, MD, MHS, Bethesda, MD in systemic inflammation, endocrine and metabolic function
E.S. Klings, MD, Boston, MA
• define new strategies to manage the care of PAH including the role
S.C. Sadreameli, MD, MHS, Baltimore, MD
that pulmonary rehabilitation may play and how novel therapeutic

ATS 2023 • Washington, DC

42 REGISTER NOW MONDAY • MAY 22

targets addressing inflammation and metabolism may prove to

BASIC • TRANSLATIONAL
improve clinical outcomes
• apply new findings toward novel research questions and continue SCIENTIFIC SYMPOSIUM
investigation of how these systemic effects of PAH may play a role
in disease development and outcomes B9 SEX-SPECIFIC MECHANISMS OF LUNG
This session will provide a comprehensive review of extrapulmonary DISEASE PATHOGENESIS THROUGH THE
manifestations of pulmonary arterial hypertension (PAH). Several LENS OF SINGLE CELL RNA
systems will be reviewed including the central nervous system, skeletal SEQUENCING
musculature, endocrinological manifestations and the immune system.
Assemblies on Respiratory Cell and Molecular Biology; Allergy,
Presenters will provide a review of the literature from bench to bedside
Immunology and Inflammation; Respiratory Structure and
observations and proposed pathophysiological mechanisms.
Function
Therapeutic implications and knowledge gaps will also be highlighted.
By the conclusion of this session, learners will understand how PAH 9:00 a.m. - 10:30 a.m.
may affect multiple extrapulmonary systems and how the multi-system Target Audience
interplay in the development of this complex disease may contribute to Health professionals and life scientists interested in lung disease
clinical outcomes. pathogenesis, and trainees in biomedical research interested in single
cell profiling studies, bioinformatics, and the role of sex on lung
Chairing: S. Umar, MD, PhD, Los Angeles, CA disease pathogenesis
A. Hemnes, MD, ATSF, Nashville, TN
N. Singh, MD, MBA, Providence, RI Objectives
At the conclusion of this session, the participant will be able to:
9:00 Welcome and Introductions
• describe recent findings from scRNAseq analyses that improved our
9:05 Patient Speaker understanding of sex-based lung disease pathogenesis
Speaker To Be Announced
• understand the role and limitations of single cell profiling in the
9:10 Spinal Cord Neuroinflammation in PAH future of clinical pulmonary medicine with an emphasis on sexually
S. Umar, MD, PhD, Los Angeles, CA dimorphic clinical features
9:22 Questions/Discussion • define emerging single-cell technologies and analytic techniques for
9:26 Retinal Involvement in PAH the study of lung disease and outline a pathway to properly sample,
T. Lahm, MD, ATSF, Denver, CO process, and analyze samples for sex-specific studies
9:38 Questions/Discussion There are well-documented examples of sex-specific clinical features of
many lung diseases. Yet, our understanding of how a patient’s sex
9:42 Gut Microbiome and Systemic Inflammation in PAH
influences lung disease pathogenesis remains limited. This symposium
T. Thenappan, MD, Minneapolis, MN
will cover recent breakthroughs in our understanding of lung disease
9:54 Questions/Discussion enabled by the application of single-cell profiling technologies. This
9:58 Obesity and Metabolic Dysfunction in PAH session reviews the current landscape of ARDS, cystic fibrosis, asthma,
N. Al-Naamani, MD, MS, Philadelphia, PA and COPD pathophysiology discoveries through the lens of single-cell
profiling and the role of sex-specific contributions. As we review these
10:10 Questions/Discussion recent breakthroughs, we will highlight the strengths and limitations of
10:14 Skeletal Muscle and Exercise in PAH this approach and discuss emerging technologies that will shape the
E. Brittain, MD, Nashville, TN future of this field.
10:26 Questions/Discussion Chairing: C.J. Britto-Leon, MD, ATSF, New Haven, CT
R.L. Zemans, MD, Ann Arbor, MI
9:00 Sex-Based Differences in Macrophage Transcriptional
Heterogeneity in Acute Lung Injury
Speaker To Be Announced
9:15 Using Transcriptome Metanalysis to Uncover
Sex-Specific Mechanisms of Asthma Pathogenesis
S. Kay, MD, MS, New Haven, CT

ATS 2023 • Washington, DC

MONDAY • MAY 22 REGISTER NOW 43

9:30 The Sex-Specific Connectome of Airway Immune Cells in 9:00 Introduction to the 2022 Reignition of the Cancer
Cystic Fibrosis as a Determinant of Its Dimorphic Moonshot
Clinical Course S. Elnahal, MD, MBA, Washington, DC
C.J. Britto-Leon, MD, ATSF, New Haven, CT 9:15 Reducing Disparities Across the Lung Cancer
9:45 Sex-Specific Pathogenic Cell Populations in the Fibrotic Continuum: Expanding Use of Proven Early Detection
Lung Strategies
Speaker To Be Announced M.C. Aldrich, MPH, PhD, Nashville, TN
10:00 Lung Spatial Profiling Reveals a Sex-Specific T Cell 9:33 Lung Cancer Screening: Harnessing the VA Enterprise
Signature in COPD Patients with Fatal SARS-CoV-2 to Expand Proven Early Detection Strategies
Infection C.G. Slatore, MD, Portland, OR
F. Polverino, MD, PhD, Houston, TX 9:52 Tobacco Control and Treatment: A Major Key to Cancer
10:15 Using the Human Cell Atlas’ discovAIR Project to Prevention
Uncover Sex-Based Differences That Drive Lung Disease A.C. Melzer, MD, MS, Minneapolis, MN
on a Large-Scale 10:11 Precision Oncology for Lung Cancer: Developing New
Speaker To Be Announced Enabling Cancer Technologies
P. Nana-Sinkam, MD, Richmond, VA

CLINICAL • TRANSLATIONAL
CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
SCIENTIFIC SYMPOSIUM
B10 REIGNITING THE CANCER MOONSHOT:
ATS = MISSION CONTROL FOR LUNG B11 GLOBAL INSIGHTS ON THE LONG-TERM
CANCER SEQUELAE OF INFECTIONS: BEYOND
Assembly on Thoracic Oncology; Tobacco Action Committee COVID
9:00 a.m. - 10:30 a.m. Assemblies on Pulmonary Infections and Tuberculosis; Allergy,
Immunology and Inflammation
Target Audience
Providers of lung health, clinicians and researchers 9:00 a.m. - 10:30 a.m.
Objectives Target Audience
At the conclusion of this session, the participant will be able to: Providers caring for patients with current and/or prior lung infections,
and researchers interested in lung immunology, pneumonia, HIV,
• identify the critical role the NCI Moonshot will play in cancer and/or cognitive impairment
detection and treatment research for years to come
Objectives
• Recognize research gaps in detecting and treating lung cancer At the conclusion of this session, the participant will be able to:
• identify ongoing efforts in tobacco control and early detection • gain understanding of the range and frequency of long-term pulmonary
including screening and biomarkers to improve outcomes from lung and extra-pulmonary sequelae of bacterial and viral infections
cancer
• describe commonalities of mechanisms of impairment from pulmonary
The ATS is a vital partner in NCI’s Cancer Moonshot. Lung cancer care infections
and research will focus on efforts to reduce deaths from this deadliest of
cancers through early detection and new molecularly driven diagnoses • apply knowledge of mechanisms of impairment to improve research into
and targeted treatment. Taken directly from Moonshot version 2.0 the the long-term sequelae of pulmonary infections
overarching themes of this symposium will focus on Expanding Use of Acute pneumonia has long been known to be a significant and persistent
Proven Cancer Prevention and Early Detection Strategies and etiology of mortality worldwide. Acute bacterial and viral pulmonary
Developing new enabling cancer technologies. Each speaker will infections can also lead to persistent morbidity and long-term pulmonary
discuss LC specific topics related to these themes including reducing and extrapulmonary complications. This has recently been highlighted by
disparities, increasing early detection and primary prevention, and the the emergence of post-acute sequelae of SARS-CoV-2 infection (PASC). In
role of biomarkers along the continuum of care. this seminar, we aim to explore the long-term complications of other viral
and bacterial pulmonary infections, highlighting the mechanisms of disease,
Chairing: N.T. Tanner, MD, MSCR, Charleston, SC and allowing the audience to understand differences and commonalities
R.S. Wiener, MD, MPH, ATSF, Boston, MA among these sequelae.
M.P. Rivera, MD, ATSF, Rochester, NY

ATS 2023 • Washington, DC

44 REGISTER NOW MONDAY • MAY 22

Chairing: K. Traber, MD, PhD, ATSF, Boston, MA Chairing: D.J. Feller-Kopman, MD, Lebanon, NH
J.S. Zifodya, MD, MPH, New Orleans, LA M.L. Metersky, MD, Farmington, CT
N. Navuluri, MD, MPH, Durham, NC J.M. Liebler, MD, ATSF, Los Angeles, CA
9:00 Post Infectious Lung Disease: A Global Perspective 9:00 Welcome
A. Ddungu, MBChB, MMed, Kampala, Uganda J. Feller-Kopman, MD, Lebanon, NH
9:20 HIV’s Pulmonary Long Game 9:02 Clinical Practice Guideline Methodology
E.F. Attia, MD, MPH, Seattle, WA K.C. Wilson, MD, ATSF, Boston, MA
9:40 Long Term Cognitive Impact of Pneumonia: Burden and 9:12 Idiopathic Pulmonary Fibrosis (an Update) and
Mechanisms Progressive Pulmonary Fibrosis in Adults: An Official
B.H. Singer, MD, PhD, Ann Arbor, MI ATS/ERS/JRS/ALAT Clinical Practice Guideline
G. Raghu, MD, Seattle, WA
10:00 Mechanisms of Post-Acute Infection Syndromes
J. Sun, PhD, Charlottesville, VA 9:27 Pulmonary Rehabilitation
A.E. Holland, PT, PhD, Melbourne, Australia
10:20 Moderated Q&A
N. Navuluri, MD, MPH, Durham, NC 9:42 ATS Statement on Race and Ethnicity in Pulmonary
Function Test Interpretation
N. Bhakta, MD, San Francisco, CA
CLINICAL
9:57 ATS Statement on Priorities for Interventions to Address
SCIENTIFIC SYMPOSIUM Health Disparities in Lung Nodule Management
K. Steiling, MD, MSc, Boston, MA
B12 ATS CLINICAL PRACTICE GUIDELINES: 10:12 Guideline Implementation
CLINICAL PRACTICE ON THE CUTTING J. Ruminjo, MD, New York, NY
EDGE 10:20 Panel discussion
Assemblies on Behavioral Science and Health Services Research;
Clinical Problems; Pulmonary Infections and Tuberculosis; Sleep
MEDICAL EDUCATION SEMINAR
and Respiratory Neurobiology; This is jointly sponsored by the
PRS and QIIC chairs; Documents Development and
Implementation Committee
9:00 a.m. - 10:30 a.m. ME102 DISCUSSING AND TEACHING ABOUT
Target Audience HEALTHCARE DISPARITIES
Physicians, nurses, respiratory therapists and trainees who care for
Assembly on Behavioral Science and Health Services Research
adults with idiopathic pulmonary fibrosis, post-prematurity respiratory
lung disease, asthma, pneumonia and COPD and sarcoidosis 10:15 a.m. - 11:15 a.m.
Objectives Target Audience
At the conclusion of this session, the participant will be able to: Clinicians and providers interested in learning more about health-care
disparities in pulmonary medicine and how to discuss and teach this
• understand how evidence is used to inform diagnostic and treatment topic to learners in different clinical environments
recommendations
Objectives
• apply clinical recommendations from recently published guidelines in At the conclusion of this session, the participant will be able to:
clinical practice, improving patient outcomes
• participants will be more comfortable incorporating discussions
• obtain new strategies to approach: pulmonary fibrosis, pulmonary about health disparities, race, and racism into their teaching.
rehabilitation and measurements of lung volumes as well as
late-breaking guidelines • participants will be able to define key terms for discussions about
health disparities, such as equality and equity, social determinants
This session is proposed as the 8th annual scientific symposium of health, disparity, and race.
highlighting ATS Clinical Practice Guidelines (CPGs) as requested by
the ATS Executive Committee. We will highlight CPGs published over • participants will be able to describe at least one example of a health
the last year, including: the updated IPF guidelines, the workshop report disparity in pulmonary and critical care medicine.
defining pulmonary rehabilitation, the technical statement on Many medical educators want to teach about health disparities, race,
measurement of lung volumes as well as late approved guidelines. and racism but often find it difficult due to either a lack of familiarity with
the subject or a lack of strategy for how to address these issues after

ATS 2023 • Washington, DC

MONDAY • MAY 22 REGISTER NOW 45

raising them. In this workshop, we seek to allay some of the fears and
empower attendees to feel comfortable discussing and teaching about
health disparities, race, and racism. We will provide an overview of
important terminology used in the field of healthcare disparities and
strategies to encourage and stimulate discussions among medical
teams with learners in different clinical environments.

Faculty: A. Kannappan, MD, Denver, CO

G.B. Tatem, MD, Detroit, MI
E.K. Batchelor, MD, MEd, Phoenix, AZ
R. Adamson, MBBS, ATSF, Seattle, WA

Monday Mid-day, May 22

CLINICAL
ADULT CLINICAL CORE CURRICULUM

CC2 CRITICAL CARE CLINICAL CORE

CURRICULUM
Education Committee
11:30 a.m. - 1:00 p.m.
Target Audience
Clinicians who are engaged in maintenance of certification activities
Objectives
At the conclusion of this session, the participant will be able to:
• describe updates in the diagnosis and management of bacterial and
viral respiratory infections
• identify best practices for treating infections in critically ill
immunosuppressed patients
• describe diagnosis and management of hospital acquired infections
in the intensive care unit

Chairing: S. Ahmed, MD, Albuquerque, NM

D. Kelm, MD, Rochester, MN
E. Kilb, MD, Charleston, SC
11:30. Bacterial Pneumonia in the ICU: From Guidelines to
Practice
Y. Odeyemi, MD, MSc, Rochester, MN
11:55 Reviving the "Other" Respiratory Viruses: Moving Beyond
COVID-19
C. Sriaroon, MD, Tampa, FL
12:20 CAUTI and CLABSI and HAPI Oh MY!: Prevention and
Management of Hospital-Acquired Infections
S. Giovanni, MD, MSCE, Portland, OR
12:45 Questions and Answers

ATS 2023 • Washington, DC

46 REGISTER NOW MONDAY • MAY 22

11:45 a.m. - 1:15 p.m.

ATS WOMEN’S FORUM

w
The annual ATS Women's Forum recognizes the achievements and supports the advancement of women in pulmonary, critical care, and
sleep medicine and research. The forum provides a valuable opportunity for women to find value in the inspirational messages and career
insights the speakers share.
We will also recognize and hear remarks from the 2023 recipient of the Elizabeth A. Rich Award. The Elizbeth Rich Award is presented to an
outstanding woman in ATS who has made significant contributions in the fields of pulmonary, critical car and sleep medicine.
The forum is organized and presented by the ATS Membership Committee and will be hosted by its Chair Meshell Johnson, MD and Vice
Chair Alexandra Noel, PhD. The Minority Trainee Development Scholarships are supported by the American Thoracic Society.
R Pre-registration and an additional fee are required. $30 members/non-members

CLINICAL
ATS ADVANCING ADULT IMMUNIZATION INITIATIVE:
IMMUNE BOOST! ADDRESSING VACCINE PEDIATRIC CLINICAL CORE CURRICULUM
HESITANCY AND THE LANDSCAPE OF
VACCINE-PREVENTABLE DISEASES PCC1 PEDIATRIC CLINICAL CORE CURRICULUM
12:00 p.m-1:00 p.m. Education Committee
TARGET AUDIENCE: Clinicians, Interprofessionals, 12:00 p.m. - 1:00 p.m.
Interventional Pulmonologists, Medical Educators, Nurses,
Respiratory Therapists, Sleep Technologists, Researchers in Target Audience
infectious diseases and vaccines and vaccine hesitancy, and Clinicians who are engaged in maintenance of certification activities
those interested in scientific communication Objectives
Objectives At the conclusion of this session, the participant will be able to:
At the conclusion of this session, the participant will be able to:
• learn new strategies used by clinicians to improve adult • describe diagnosis and management of central and obstructive
vaccination in their own communities sleep disorders in infants
• gain an understanding of emerging strategies to support • identify best practices for management and treatment of pulmonary
vaccine uptake and knowledge about new respiratory hypertension in infants
infectious disease prevention products.
• apply strategies to enhance patient uptake of vaccines in • describe best practices and standards of care for management of
one's home institution or practice environment bronchopulmonary dysplasia in the neonatal intensive care unit and
The COVID-19 pandemic has highlighted the multiple different the post NICU period
challenges that limit adult vaccination rates, and there is an
evolving literature documenting this issue. In 2021 ATS was Chairing: J. Gross, MD, PhD, Denver, CO
awarded a CDC/CMSS grant specifically to work with a number C. Okorie, MD, Paulo Alto, CA
of diversely populated health systems to study immunization M. McCown, MD, Bethesda, MD
practices, identify best practices, and share key learnings. This
session will build upon the existing literature and learnings from 12:00 Bronchopulmonary Dysplasia in the NICU
the CDC/CMSS grant to provide real-world examples about D. Chhabra, MD, Rochester, NY
how clinicians and patients from diverse communities approach
vaccine confidence, hesitancy, and misinformation. Session 12:25 Post NICU Management of BPD
attendees will have access to this new information and hear M. Bansal, MD, Los Angeles, CA
hands-on strategies that they may be able to apply to their 12:50 Questions and Answers
home institutions and practices. This novel session will provide
conceptual and real-world recommendations about addressing
vaccine hesitancy and misinformation to meet the needs of
clinicians seeking tools to help their patients feel more confident
about vaccines and provide cutting edge information on
emerging vaccines for chronic lung disease.

ATS 2023 • Washington, DC

MONDAY • MAY 22 REGISTER NOW 47

DIVISION OF LUNG DISEASES, NHLBI/NIH VARIOUS ORGANIZATIONS

OUTSIDE ORGANIZATION SESSION OUTSIDE ORGANIZATION SESSION

L7 CIRCADIAN RHYTHMS IN PULMONARY L8 PURSUING THE RIGHT FUNDING

AND CRITICAL CARE: IMPLICATIONS FOR SOURCE: INSTITUTES, ORGANIZATIONS
HEALTH AND DISEASE AND FOUNDATIONS SHARE THEIR
12:00 p.m. - 1:00 p.m. FUNDING PRIORITIES
Target Audience 12:00 p.m. - 1:00 p.m.
providers of lung health, pulmonologist, sleep medicine and critical Target Audience
care physicians and clinician-scientist, nurses, basic, translational, and Researchers whose work focuses on pulmonary, critical care, and
clinical lung researchers sleep health as well as health services and quality. Information
Objectives provided could also enhance career development strategies for
At the conclusion of this session, the participant will be able to: students and early career professionals.

• to educate the audience about the connections between circadian Objectives

rhythms and lung health and disease. At the conclusion of this session, the participant will be able to:

• to better understand how the consideration of circadian rhythms is • describe the research priorities and mechanisms of each funding
relevant to critical care clinical practice. agency represented on the panel.

• to identify research opportunities in chronomedicine. • identify specific criteria required for various mechanisms presented
by each agency on the panel
Circadian rhythms help regulate many biological processes, including
metabolism, immunity, and sleep. A growing body of evidence has • identify a funding agency whose priorities and mechanisms are most
linked circadian misalignment to several disease states, including closely aligned with the attendee’s interest and program of research.
clock-gene-related lung diseases (i.e., asthma, COPD, pulmonary This session will introduce programs and research funding opportunities
fibrosis), renewing scientific interest in this space. In the ICU, where offered through various government and non-government agencies.
continuous patient monitoring, constant light exposure, and 24-hour Speakers will present current research priorities and mechanisms of
feeding schedules are standard practice, circadian disruption may funding available within their respective agencies. Time will be provided
impact patient outcomes and even exacerbate disease. During this for audience members to ask questions of the panel of speakers.
session, speakers will highlight recent findings, and describe the
scientific gaps and opportunities for circadian research in the context of Chairing: S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN
ICU management, and overall lung health and disease. J.B. Seaman, PhD, RN, CHPN, Pittsburgh, PA
12:00 Introductions
Chairing: R. Mehra, MD, MSCR, ATSF, Cleveland, United States
J.B. Seaman, PhD, RN, CHPN, Pittsburgh, PA
M.K. Brown, PhD, Bethesda, United States
A.D. Laposky, PhD, Bethesda, United States 12:05 National Institute of Nursing Research
K. Huss, PhD, Bethesda, MD
12:00 ATS-SRN Perspective
R. Mehra, MD, MSCR, ATSF, Cleveland, United States 12:13 National Heart Lung Blood Institute
S. Shenoy, PhD, Bethesda, MD
12:02 Circadian Rhythms in Health and Disease
J. Hogenesch, PhD, Cincinnati, United States 12:21 ATS Research Program
E.M. Nebel, MS, New York, NY
12:12 Circadian Rhythms in Development and Pediatric
Pulmonary function 12:29 Agency for Healthcare Research and Quality
S. Sengupta, MPH, Philadelphia, PA M.A. Miller, MD, MS, Rockville, MD
12:24 Circadian Rhythms and Immune Function in the Lung 12:37 American Lung Association
J.A. Haspel, MD, PhD, St. Louis, MO A.E. Dixon, MA, BM BCH, ATSF, Burlington, VT
12:36 Sleep and Circadian Rhythms in the ICU Environment 12:45 Questions and Answers
M.P. Knauert, PhD, MD, New Haven, CT S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN
12:48 Circadian Disruption in Pediatric OSA
D.F. Smith, MD, PhD, Cincinnati, OH

ATS 2023 • Washington, DC

48 REGISTER NOW MONDAY • MAY 22

U.S. FOOD AND DRUG ADMINISTRATION/FDA/CENTER NATIONAL INSTITUTE OF ALLERGY

FOR DRUG EVALUATION & RESEARCH (FDA/CDER) AND INFECTIOUS DISEASES, NIH
OUTSIDE ORGANIZATION SESSION OUTSIDE ORGANIZATION SESSION

L9 GENERIC DRUG DEVELOPMENT FOR L10 NEW FINDINGS ON ASTHMA AND

RESPIRATORY PRODUCTS, US FOOD ALLERGIC DISEASE IN URBAN
AND DRUG ADMINISTRATION UPDATE ENVIRONMENTS
12:00 p.m. - 1:00 p.m. 12:00 p.m. - 1:00 p.m.
Target Audience Target Audience
Clinicians in practice, researchers, pharmaceutical industry Healthcare providers, clinical researchers, individuals working with
representatives, international drug regulators disadvantaged populations
Objectives Objectives
At the conclusion of this session, the participant will be able to: At the conclusion of this session, the participant will be able to:
• recognize key aspects of the generic drug regulatory approval process, • be able to describe early life lung function interacts with allergic
and how the Office of Generic Drugs (OGD) evaluates comparative sensitization to influence the risk for recurrent wheezing episodes in
clinical information to support bioequivalence for complex inhaled children and be able to apply this knowledge to improve his/her
generic drug products. practice
• describe product-specific guidances for generic drug products recently • describe the utility of airway transcriptome profiling in defining
posted by the Office of Generic Drugs (OGD), with a focus on how these inflammatory pathways driving alterations in lung function at
can inform complex orally inhaled and nasal generic drug development baseline and during respiratory illnesses in exacerbation-prone
urban children
• articulate how emerging technologies and innovative approaches are
being utilized for FDA-funded research, FDA guidance development, • understand the role of DNA methylation in mediating environmental
and regulatory decision-making effects of risk for asthma and allergic sensitization in children
This session will describe respiratory product development of generic drugs This session will provide the listener insights into mechanisms of lung
within the US, focusing on paths forward to bring safe and effective generic function development, lung function trajectories over childhood, and
respiratory products to the American public. A general overview will responses to respiratory infections among urban inner-city children and
summarize the generic drug approval process, including demonstration of adolescents. The first talk will utilize the repeated pulmonary function
bioequivalence and therapeutic equivalence utilizing comparative clinical measurements taken during the longitudinal follow-up of the URECA
information. Discussion of recent generic product approvals and posted birth cohort to demonstrate how atopy and environmental factors
regulatory guidance will provide the audience a greater understanding of the influence lung function trajectories and the development of asthma. The
generic approval process, and how the use of emerging technologies and second talk with elucidate transcriptomic pathways which are activate or
outcomes of research projects contribute to scientific understanding for suppressed during a viral respiratory infection and the impact on lung
these complex orally inhaled and nasal drug products to inform regulatory function. The third talk will present data on epigenetics role in asthma
actions. and allergic sensitizations.

Chairing: K. Witzmann, MD, Silver Spring, MD Chairing: A. Coleman, MD, Bethesda, MD

12:00 Update for Generic Orally Inhaled and Nasal Drug Products 12:00 Interactions Between Allergic Sensitization and Lung
K. Witzmann, MD, Silver Spring, MD Function on Wheezing Illnesses in Urban Children
J.E. Gern, MD, Madison, WI
12:20 Comparative Clinical Considerations in the
Determination of Bioequivalence 12:20 Airway Transcriptome Patterns Relate to Lung Function
D. Santos Conti, PhD, Silver Spring, MD in Urban Children with Exacerbation-Prone Asthma
12:37 Emerging Concepts and New Technologies for M.C. Altman, MD, MPhil, Seattle, WA
Bioequivalence of Orally Inhaled and Nasal Drug Products 12:40 Epigenetic Contributions to Understanding Asthma and
E. Bielski, PhD, Silver Spring, MD Allergic Sensitization in Urban Children
12:54 Question and Answer C. Ober, PhD, Chicago, IL
K. Witzmann, MD, Silver Spring, MD

ATS 2023 • Washington, DC

MONDAY • MAY 22 REGISTER NOW 49

NATIONAL INSTITUTE FOR DIVISION OF LUNG DISEASES, NHLBI/NIH

OCCUPATIONAL SAFETY AND HEALTH OUTSIDE ORGANIZATION SESSION
OUTSIDE ORGANIZATION SESSION
L12 THE MOLECULAR ATLAS OF LUNG
L11 DISPARITIES IN WORK-RELATED DEVELOPMENT (LUNGMAP), PHASE 2
RESPIRATORY DISEASE 12:00 p.m. - 1:00 p.m.
12:00 p.m. - 1:00 p.m. Target Audience
Target Audience Providers of lung health, medical fellows in training, and basic and
Providers of lung health; those interested in prevention of occupational clinical researchers interested in lung biology, developmental biology,
respiratory disease. pediatric lung disease pathogenesis, bioinformatics, and systems biology

Objectives Objectives
At the conclusion of this session, the participant will be able to: At the conclusion of this session, the participant will be able to:
• learn the newest datasets of LungMAP that could inform lung research
• better identify common pitfalls in race and ethnicity reporting in the
occupational respiratory health literature and describe approaches to • learn the innovative technologies for molecular profiling, imaging, and
race and ethnicity data collection and analysis that can improve data analysis of the developing lung.
understanding of health disparities.
• learn how to access and use the LungMAP resources
• learn updated findings about work-related disparities in COVID-19.
Molecular Atlas of Lung Development (LungMAP) is an NHLBI-sponsored
• understand considerations in selecting the appropriate sex to use in program. The overall goal of this program is to establish an open-access
spirometry reference equations for interpreting results from transgender reference resource by creating a comprehensive molecular atlas of the
and gender-diverse people. late-stage developing human lung with data and reagents available to the
The session will provide an update on current issues in work-related research community. Speakers will demonstrate how systems biology and
respiratory disease disparities. It will address the status of race and ethnicity bioinformatic approaches can be used to inform processes in
reporting in occupational respiratory health and considerations for development that are recapitulated in disease and repair. The session will
approaches to data collection and reporting to improve our understanding of illustrate the LungMAP data pipeline which integrates high resolution
racial or ethnic disparities and to better contextualize findings. It will also multi-omics and imaging data.
address disparities in occupations at risk for work-related COVID-19 and Chairing: S. Lin, PhD, Bethesda, MD
considerations in selecting appropriate spirometry test reference sex for N. Salomonis, PhD, Cincinnati, United States
transgender and gender-diverse people.
12:00 Post-Natal Development of Human Lung Cell Niches
Chairing: D.N. Weissman, MD, ATSF, Morgantown, WV M.C. Basil, MD, PhD, Philadelphia, PA
12:00 Introduction to Session 12:12 Applying Single Nuclear Transcriptomics for Study of
D.N. Weissman, MD, ATSF, Morgantown, WV Rare Pulmonary Disorders in Infants and Children
12:03 Status of Race and Ethnicity Reporting in Occupational K.A. Wikenheiser-Brokamp, MD, PhD, Cincinnati, OH
Respiratory Healt 12:24 Single Cell Profiling of Human Bronchopulmonary
A.M. Foreman, PhD, Morgantown, WV Dysplasia
12:22 Work-Related COVID-19 Disparities X. Sun, PhD, San Diego, CA
J.M. Cox-Ganser, PhD, Morgantown, WV 12:36 Multi-Omics Spatial Molecular Profiling of the Human Lung
12:41 Selecting Appropriate Spirometry Reference Sex for G.C.D. Clair, PhD, Richland, WA
Gender-Diverse People 12:48 LungMAP Consortium Assay Breadth in Coordinated
E. Fechter-Leggett, DVM, MPVM, Morgantown, WV Use of Human Tissue Core Biorepository Samples
R. Misra, PhD, Rochester, NY

ATS 2023 • Washington, DC

50 REGISTER NOW MONDAY • MAY 22

VETERANS HEALTH ADMINISTRATION (VA) DIVISION OF LUNG DISEASES, NHLBI/NIH

OUTSIDE ORGANIZATION SESSION OUTSIDE ORGANIZATION SESSION

L13 GENOMICS ANALYSES FROM MILLION L14 UPDATE ON PRECLINICAL MODELS OF

VETERAN PROGRAM IMPROVE LUNG IPF - AN NHLBI CONSORTIUM
CANCER DETECTION AND CARE 12:00 p.m. - 1:00 p.m.
12:00 p.m. - 1:00 p.m. Target Audience
Target Audience Those with research interests involving the study of idiopathic
Those interested in lung cancer research and care, in VA’s Million pulmonary fibrosis and other fibrotic lung diseases.
Veteran Program, in lung cancer screening, or in treatment of those Objectives
with advanced stage lung cancer with immune checkpoint inhibitors. At the conclusion of this session, the participant will be able to:
Objectives • learn new findings regarding the pathogenesis of IPF from its onset
At the conclusion of this session, the participant will be able to: through disease progression.
• describe new findings from the Million Veteran Program and the • increase awareness among the broader IPF research community of
ways that research in this large cohort could benefit the quality of life the availability of new and improved model systems to study IPF.
for patients with, or at risk for, lung cancer.
• to inform the design of research studies involving IPF by leveraging
• describe new findings about how the generation of new knowledge model systems uniquely suited to uncover specific types of disease
at the population level may be used to benefit individual patients. mechanisms, as well as improve model selection for screening and
• describe new findings about how patients can be selected more testing new drugs/biologics that target IPF
efficiently for lung cancer screening through integrating genomics, This session highlights the recent scientific advances and collaborative
clinical, and imaging data from individual patients. research achievements of an NHLBI-sponsored U01 consortium funded
In its Million Veteran Program (MVP), VA has collected blood for through RFA-HL-20-007: Advancing Novel Research Models to Study
genomic analysis from over 900,000 Veterans integrated with Idiopathic Pulmonary Fibrosis. The goal of this initiative is to establish a
associated longitudinal clinical data. Within MVP, VA now also has set of complementary model systems that reproduce essential
conducted the largest genome-wide association study of lung cancer, disease-defining features of human idiopathic pulmonary fibrosis (IPF)
identifying novel risk loci, tumor-specific signals previously masked by in order to develop more effective therapies.
smoking, and polygenic risk scores for risk stratification. This work will
be described along with two related applications: (1) a multiomics Chairing: M. Craig, PhD, Bethesda, MD
dashboard integrating clinical, genetic, and imaging data to improve the 12:00 From Mice to iPS-AT2 and Back
efficiency of selecting high-risk Veterans for screening; (2) use of M.F. Beers, MD, Philadelphia, PA
genomic and phenotypic characterization to stratify those with advanced
12:20 Team Mesenchyme: Integrating iPSC, Matrix Biology,
lung cancer for immunotherapy.
PCLS, and Organoids
Chairing: J.K. Brown, MD, San Francisco, CA B. Gomperts, MD, Los Angeles, CA

12:00 Update on the Million Veteran Program 12:40 A Novel Ferret Model of Idiopathic Pulmonary Fibrosis
S. Muralidhar, PhD, Washington, DC S.M. Rowe, MD, Birmingham, AL

12:15 Genome-Wide Association Study of Lung Cancer in MV

S. Pyarajan, PhD, Jamaica Plains, MA
12:30 Multiomic Predictive Model of Lung Cancer Risk
S. Aguayo, MD, Phoenix, AZ
12:45 Predictive Model for Lung Cancer Treatment with
Immune Checkpoint Inhibitors
M. Green, MD, PhD, Ann Arbor, MI

ATS 2023 • Washington, DC

MONDAY • MAY 22 REGISTER NOW 51

MEET THE EXPERT SEMINARS

R Pre-registration and additional fees required. Attendance is limited.

$100 Member/Non-Members
$70 LMIC Member/LMIC Non-Members.
12:15 p.m. - 1:15 p.m.
MTE24 LOCAL THERAPEUTICS APPROACHES IN MALIGNANT
PLEURAL MESOTHELIOMA: RATIONALE, CLINICAL
DEVELOPMENT AND FUTURE STRATEGIES
G. Stella, MD, PhD, Pavia, Italy
MTE25 MISINFORMATION AND DISINFORMATION ON
COVID-19: HOW TO IMPROVE DISPARITIES AND
INEQUITIES?
M. Mirsaeidi, MD, MPH, Jacksonville, FL Monday Afternoon, May 22
MTE26 HOW TO ASSESS THE OUTCOME OF A PULMONARY
REHABILITATION PROGRAMME?
M.A. Spruit, PT, PhD, Horn, Netherlands CLINICAL
MTE27 SMART THERAPY AND ALLERGIC IMMUNOTHERAPY IN ADULT CLINICAL CORE CURRICULUM
NEW ASTHMA GUIDELINES: PROS AND CONS
M. Cataletto, MD, Brookville, NY CC3 SLEEP CLINICAL CORE CURRICULUM
R. Ramonell, MD, Pittsburgh, PA
Education Committee
MTE28 PROGRESS IN PROGRESSIVE PULMONARY FIBROSIS:
AN UPDATE IN DEFINITION AND MANAGEMENT 2:15 p.m. - 3:45 p.m.
J.V. Pugashetti, MD, Ann Arbor, MI Target Audience
T. Kulkarni, MD, MPH, Birmingham, AL Clinicians who are engaged in maintenance of certification activities
MTE29 BEYOND THE LUNG: TAKING A MULTI-DISCIPLINARY Objectives
APPROACH TO SARCOIDOSIS At the conclusion of this session, the participant will be able to:
M. Sharp, MD, MHS, Baltimore, MD
• describe the nuts and bolts of positive airway pressure and when
N. Gilotra, MD, Baltimore, MD
and how to use it for patients with heart failure and patients with
B. Stern, MD, Baltimore, MD
different types of sleep disordered breathing
MTE30 OBESITY HYPOVENTILATION SYNDROME: CLINICAL
• identify best practices for diagnosis and management of sleep
APPROACH
disorders in patients with long COVID
B.Y. Sunwoo, MBBS, San Diego, CA
• characterize common manifestations of sleep disordered breathing
in patients with neuromuscular disease

Chairing: S. Shafazand, MD, Miami, FL

K. Dudley, MD, Boston, MA
2:15 The Nuts and Bolts of Non-Invasive Ventilation: An
Update for Providers in 2023
M. Soffler, MD, Valhalla, NY
2:40 To PAP or not to PAP: Heart Failure and Sleep
Disordered Breathing
V. Kundel, NYC, NY
3:05 Long Haul COVID and Sleep Disorders
O. Rojanapairat, MD, Los Angeles, CA
3:30 Questions and Answers

ATS 2023 • Washington, DC

52 REGISTER NOW MONDAY • MAY 22

3:10 Panel Discussion

CLINICAL
D.K. Costa, PhD, RN, Orange, CT
YEAR IN REVIEW 3:13 Panel Discussion
T.L. Eaton, PhD, MSc, RN, FNP-BC, ACHPN, Ann Arbor, MI
B81 NURSING YEAR IN REVIEW - WE CAN’T 3:16 Panel Discussion
WAIT: ASSURING A PULMONARY, CRITICAL E.G. Collins, PhD, ATSF, Chicago, IL
CARE, AND SLEEP NURSING WORKFORCE
3:19 Panel Discussion
Assembly on Nursing L.L. Chlan, PhD, RN, ATSF, Rochester, MN
2:15 p.m. - 3:45 p.m. 3:22 Panel Discussion
Target Audience K.O. Lindell, PhD, RN, ATSF, Charleston, SC
Conference participants with concerns about the availability of 3:25 Panel Discussion
pulmonary, critical care, and sleep clinicians, faculty, and researchers M.M. Lyons, PhD, MSN, ACNP-BC, Columbus, OH
Objectives 3:28 Q&A
At the conclusion of this session, the participant will be able to: S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN
• apply new clinical research knowledge to clinical practice and nursing
workforce
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
• gain new findings about strategies to address nursing staffing through
health policies; use of innovative models for well-being, burnout, CLINICAL TOPICS IN PULMONARY MEDICINE
safety; and recruitment and retention of nurses
• identify effective approaches to recruit and retain nurses at various B82 THE GENETICS OF INTERSTITIAL LUNG
stages of the career including early, mid, and senior stages DISEASE: CURRENT STATE AND FUTURE
The current nursing shortage influences the availability of healthcare and PROMISE
research conducted in ATS specialties of pulmonary, clinical care, and Assembly on Clinical Problems
sleep. To increase audience awareness of the current status, speakers
will provide overviews and review the literature about policies related to 2:15 p.m. - 3:45 p.m.
nurse staffing, interprofessional models for nurses’ well-being and safety, Target Audience
and recruitment and retention of the nursing workforce at various stages ILD clinicians, geneticists, physician-scientists
of careers. The audience will benefit from a panel discussion of staffing Objectives
policies, innovative models to address professional role issues, and At the conclusion of this session, the participant will be able to:
approaches that positively influence the recruitment and retention of
nurses. The panel will focus on these issues through the lens of the early, • understand how rare genetic variants and telomere length relate to
mid, and senior career nursing workforce. interstitial lung disease risk, progression, and survival
• describe the current approaches to genetic testing and telomere
Chairing: S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN length testing in ILD and how to counsel patients
J.B. Seaman, PhD, RN, CHPN, Pittsburgh, PA
• define future strategies for applying clinical genetics in the diagnosis
2:15 Introduction and management of ILD
J.B. Seaman, PhD, RN, CHPN, Pittsburgh, PA
Significant progress has been made in our understanding of the genetic
2:20 Supporting Nurse Staffing Through Policy Initiatives susceptibility underlying pulmonary fibrosis, including elucidating the
D.K. Costa, PhD, RN, Orange, CT associations of rare variants in more than 12 genes including genes
2:35 Well-Being, Safety, and Burnout: Interprofessional involved with surfactant metabolism and telomere maintenance.
Teams and the Roles They Play Researchers are beginning to understand how the presence of such
T.L. Eaton, PhD, RN, FNP-BC, ACHPN, Ann Arbor, MI variants informs clinical management and are incorporating genetic
testing into their practice. This includes informing prognosis and
2:50 Models and Strategies for the Recruitment and Retention
treatment strategies for patients affected with ILD and characterizing
of Nurses
risk for unaffected relatives. This session will review the state of
E.G. Collins, PhD, ATSF, Chicago, IL
research related to genetic variants and telomere length in ILD and
3:05 Brief Applicable Highlights from the Future of Nursing provide a roadmap for how future clinical genetics will advance us
2020-2030 Report towards precision medicine in ILD.
S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN

ATS 2023 • Washington, DC

MONDAY • MAY 22 REGISTER NOW 53

Chairing: E.D. Farrand, MD, San Francisco, CA camping). Review of environment specific needs/adaptations for
P.J. Wolters, MD, San Francisco, CA effective device function
L.V. Wain, PhD, Leicester, United Kingdom Session will provide state of the art, evidence based guidance on the
2:15 Overview optimal management of patients with ventilator dependent respiratory
P.J. Wolters, MD, San Francisco, CA disorders. Objectives are to ensure understanding of the evidence
based use of NIV, IMV, cough augmentation and sputum mobilization
2:20 Genetic Variants and ILD
options in advanced lung disease to maintain quality of life, with a focus
B. Crestani, MD, PhD, Paris, France
on maintaining community participation. Optimizing evidence based
2:30 Question and Answer respiratory assistive device adaptations to continue appropriate
2:35 Telomere Length and ILD ventilation and airway clearance while out of the home. Specific
C. Newton, MD, Dallas, TX situations that will be addressed will be sports participation (skiing,
hockey), camping and day and multi-day travel. Patient and family
2:45 Question and Answer panelists will provide expert experiential guidance.
2:50 The Here and Now of ILD Genetics
Speaker To Be Announced Chairing: K.A. Provost, DO, PhD, FCCP, Buffalo, NY
M. Cao, DO, STANFORD, CA
3:00 Question and Answer J.H. Hansen-Flaschen, MD, ATSF, Wynnewood, PA
3:05 The Future of Genetics in ILD: Diagnostic Applications 2:15 Why Am I Carrying All of This STUFF?
C.K. Garcia, MD, PhD, New York, NY K.A. Provost, DO, PhD, FCCP, Buffalo, NY
3:20 Question and Answer 2:30 You Are Going to School Today!
3:25 The Future of Genetics in ILD: Therapeutic Applications R. Amin, MD, Toronto, Canada
J. Morisset, MD, Montreal, Canada 2:45 Ventilators in the Wild! Skiing, Camping and Other Sports
3:40 Question and Answer J.P. Brown, MD, PhD, Salt Lake City, UT
3:00 London/Disneyworld/Laguna Beach Here We Come!
L.F. Wolfe, MD, Chicago, IL
CLINICAL
3:15 No Really, You Really Can Do All This!
CLINICAL TOPICS IN PULMONARY MEDICINE 3:25 Speaker Panel

B83 WHY YES, YOU CAN SKI WITH YOUR

VENTILATOR! USING TECHNOLOGY TO CLINICAL
KEEP NIV/IMV VENTILATOR DEPENDENT
PATIENTS ACTIVE AND ENGAGED IN CRITICAL CARE TRACK
THEIR COMMUNITIES
B84 NEXT GENERATION CRITICAL CARE
Assemblies on Clinical Problems; Pediatrics; Sleep and TRIALS: FROM PRAGMATIC TRIALS TO
Respiratory Neurobiology
PRECISION MEDICINE
2:15 p.m. - 3:45 p.m.
Assemblies on Critical Care; Behavioral Science and Health
Target Audience Services Research; Nursing
Adult pulmonologists, pediatric pulmonologists, respiratory therapists,
mid-level providers, and nurses who care for patients with ventilator 2:15 p.m. - 3:45 p.m.
(NIV or invasive) dependent respiratory failure Target Audience
Clinicians of any discipline who care for critically ill adults or children,
Objectives
and clinical and translational critical care researchers
At the conclusion of this session, the participant will be able to:
Objectives
• develop competency in guideline based implementation of assisted
At the conclusion of this session, the participant will be able to:
NIV and IMV in advanced lung disease
• researchers who attend the session will be able to apply knowledge
• develop competency in airway clearance modalities in advanced
acquired about novel trial designs to interpret and critique the results of
lung disease
future platform, adaptive, pragmatic, and personalized clinical trials
• adapt above competencies to multiple different community
engagement models (school participation, sports, travel and

ATS 2023 • Washington, DC

54 REGISTER NOW MONDAY • MAY 22

• clinicians will be able to assess the strengths and limitations of novel trial Objectives
designs in order to facilitate the implementation of results from future At the conclusion of this session, the participant will be able to:
trials into clinical practice to improve patient outcomes
• to learn new findings on lymphatics structure and function in the lung
• learners will be able to apply an understanding of “individual treatment and how this is related to disease
effect” and “personalized medicine” to the manner in which they • to be able to apply knowledge on lymphatics and follicles in
implement the results of clinical trials into clinical practice management of patients treated with steroids and other immune
Critical care has historically relied on explanatory, parallel-group modulators
randomized trials to generate evidence to inform practice. Such designs can • to be able to apply knowledge on lymphatics and follicles in
be inefficient and expensive. COVID-19 has changed the landscape of management of patients who had undergone lung transplantation
critical care trials by advancing alternative, innovative, and efficient
approaches to trial design, conduct, and analysis. This session will review Lymphatics and lymphoid follicles are integral to the lung immune
these new methods, including platform trials, adaptive trials, Bayesian response and for processing antigens from the environment. This
methods, pragmatic trials, and trials informing personalized treatment sessions will review the biology of the lymphatic and associated
choices. Clinicians will learn how to interpret and apply results of these trials lymphoid follicle and immune responses in the lung, discuss how
to practice. Researchers will learn how to use these methods to generate changes in these structures are associated with different disease
real-world, personalized evidence, improving care for critically ill patients. phenotypes. The learner will better understand how lymphatics are
linked to the immune response and appreciate these understudied
Chairing: M.W. Semler, MD, MSc, Nashville, TN structures in the lung.
C.S. Calfee, MD, MSCR, San Francisco, CA
M.M. Churpek, MD, MPH, PhD, ATSF, Madison, WI Chairing: J.E. Mcdonough, PhD, New Haven, CT
H. Outtz Reed, MD, PhD, New York,, NY
2:15 Introduction: ABCs of Next-Gen RCTs
M.W. Semler, MD, MSc, Nashville, TN 2:15 The Role of Lymphatic Function in the Pathogenesis of
Lung Disease
2:20 Platform Trials
H. Outtz Reed, MD, PhD, New York,, NY
M.N. Gong, MS, MD, Bronx, NY
2:30 Lymphoid Follicles: A Good Intention Turned Bad
2:35 Adaptive Trials and Bayesian Methods
Ali Oender Yildirim, PhD, Neuherberg, Germany
E. Goligher, MD, PhD, Toronto, Canada
2:50 Pragmatic Trials 2:45 Lymphoid Follicles in COPD: An Unanswered Question
J.D. Casey, MD, MSCR, Nashville, TN F. Polverino, MD, PhD, Houston, TX

3:05 Using Biomarkers for Precision Medicine in Clinical Trials 3:00 Pulmonary Lymphatic Diseases: Novel Imaging and
C.S. Calfee, MD, MSCR, San Francisco, CA Interventional Treatment
Speaker To Be Announced
3:20 Using Machine Learning for Precision Medicine in
Clinical Trials 3:15 Multiomics Approaches to Understand Lung Lymphatics
M.M. Churpek, MD, MPH, PhD, ATSF, Madison, WI and Its Role in Lymphangioleiomyomatosis
M. Guo, PhD, Cincinnati, OH
3:35 Roundtable Discussion
M.W. Semler, MD, MSc, Nashville, TN 3:30 Harnessing Lymphatic Transport for Drug Delivery
K. Maisel, PhD, Maryland, MD

BASIC • TRANSLATIONAL
CLINICAL • TRANSLATIONAL
BASIC SCIENCE CORE
SCIENTIFIC SYMPOSIUM
B85 PROCESSING THE ENVIRONMENT: LUNG
LYMPHATICS AND FOLLICLES IN DISEASE B86 PRECISION MEDICINE IN PNEUMONIA

Assemblies on Respiratory Structure and Function; Allergy, Assemblies on Pulmonary Infections and Tuberculosis; Critical
Immunology and Inflammation; Respiratory Cell and Molecular Care
Biology 2:15 p.m. - 3:45 p.m.
2:15 p.m. - 3:45 p.m. Target Audience
Pulmonary, critical care or infectious disease physicians/providers who
Target Audience
see patients hospitalized with pneumonia, and all basic, translational or
Lung health providers, trainees, and those involved in research or
clinical care related to lung disease and immune response

ATS 2023 • Washington, DC

MONDAY • MAY 22 REGISTER NOW 55

clinical researchers with an interest in pneumonia, critical care,

CLINICAL
phenotypes and endotypes
Objectives SCIENTIFIC SYMPOSIUM
At the conclusion of this session, the participant will be able to:
• improve precision in the diagnosis and management of patients with B87 CONTROVERSIES IN PEDIATRIC
pneumonia utilizing clinically available resources like guidelines and OBSTRUCTIVE SLEEP APNEA: A
culture-independent diagnostic tools PRO/CON DEBATE
• understand the existing phenotypes and endotypes in pneumonia Assemblies on Pediatrics; Sleep and Respiratory Neurobiology
and methods to evaluate their trajectory over time 2:15 p.m. - 3:45 p.m.
• define and implement research strategies to characterize patients Target Audience
with pneumonia Clinicians and researchers who care for and study children with
Pneumonia is a leading cause of death globally. With the current obstructive sleep apnea, including sleep medicine physicians, pediatric
approach to pneumonia, which includes diagnosis by symptoms and pulmonologists, and allied health professionals
chest radiograph and management with antibiotics, morbidity and Objectives
mortality remain high. Precision medicine calls for multidimensional At the conclusion of this session, the participant will be able to:
characterization of a patient to identify factors that may indicate
• inform the clinicians and researchers about specific areas of debate
favorable responses to an intervention. The identification of phenotypes
and endotypes are crucial for the development of targeted therapies in in the evaluation and management of obstructive sleep apnea in
pneumonia. In this session, experts will introduce the audience to children
emerging research that supports the presence of phenotypes in • apply state of the science to help the audience decide on
pneumonia and discuss clinical tools that can enhance precision appropriate uses of diagnostic and treatment modalities related to
medicine in pneumonia. pediatric obstructive sleep apnea

Chairing: C. Pickens, MD, Chicago, IL • identify key gaps for conditions mentioned in objectives 1 and 2 that
B.G. Wu, MD, MSc, New York, NY should inform future research
R.P. Dickson, MD, Ann Arbor, MI There has been substantial new clinical research related to the
2:15 Matching Solutions to Complexity: The Role for evaluation and management of obstructive sleep apnea in children
Pneumonia Guidelines in Precision Medicine since clinical practice guidelines were most recently published. As a
B.E. Jones, MD, MSc, Salt Lake City, UT result, a number of controversies exist in this area, including 1) home
sleep apnea testing for the evaluation of OSA in children, 2)
2:33 Multiplex PCR to Enhance Precision in Diagnosing adenotonsillectomy for treatment of mild sleep-disordered breathing in
Pneumonia 2 children, and 3 the use of drug-induced sleep endoscopy for etiology of
D. Stolz, MD, Basel, Switzerland residual OSA following adenotonsillectomy. In this session, a panel of
2:51 Multi-Omics Approaches to Endotyping Pneumonia 3 experts will review the state of the science and evidence for these
C. Dela Cruz, MD, PhD, ATSF, New Haven, CT topics in a pro/con format.
3:09 Immunologic Phenotypes in Community Acquired Chairing: C.M. Cielo, DO, Philadelphia, PA
Pneumonia 4 R. Amin, MD, Toronto, Canada
M.R. Menendez Villanueva, MD, Valencia, Spain
2:15 Introduction
3:27 Mapping the Trajectory of Pneumonia Phenotypes Using R. Amin, MD, Toronto, Canada
Novel Clinical Endpoints 5
R.G. Wunderink, MD, Chicago, IL 2:20 PRO: Home Sleep Apnea Testing Should Be Expanded
to Include Children
I. Tapia, MD, MS, Philadelphia, PA
2:30 CON: Home Sleep Apnea Testing Should Be Expanded
to Include Children
R. Bhattacharjee, MD, San Diego, CA
2:40 Discussion: Home Sleep Apnea Testing for the
Evaluation of OSA in Children
C.M. Cielo, DO, Philadelphia, PA

ATS 2023 • Washington, DC

56 REGISTER NOW MONDAY • MAY 22

2:45 PRO: Adenotonsillectomy Should Be Used for the • describe approaches and participate in effective advocacy to reduce
Treatment of Mild Sleep-Disordered Breathing in the carbon footprint of healthcare both at a provider and system
Children level
S.S. Redline, MD, MPH, Boston, MA Climate change threatens human health with a disproportionate burden
2:55 CON: Adenotonsillectomy Should Be Used for the on vulnerable populations. Human activities contributing to climate
Treatment of Mild Sleep-Disordered Breathing in change include burning of biomass fuels and resultant emission of
Children greenhouse gasses. A ‘carbon footprint’ reflects the effect that a
S.L. Verhulst, MD, PhD, MSc, Edegem, Belgium person, group of people, or industry has on emissions. Healthcare
3:05 Discussion: Adenotonsillectomy for the Treatment of providers and systems directly contribute to and treat climate change’s
Mild Sleep-Disordered Breathing in Children negative effects on health. Thus we are both responsible for and
R. Amin, MD, Toronto, Canada uniquely poised to take a leadership role in individual and industry
response to the climate crisis. Presented are multiple potential points of
3:10 PRO: Drug-Induced Sleep Endoscopy Should be Used healthcare system intervention to reduce the pace of global warming.
for Etiology of Residual OSA Following
Adenotonsillectomy Chairing: E. Brigham, MD, MHS, Vancouver, Canada
C. Heubi, MD, Cincinnati, OH J.M. Radbel, MD, New Brunswick, NJ
J.P. Castner, PhD, RN, Grand Island, NY
3:20 CON: Drug-Induced Sleep Endoscopy Should Be Used
M.B. Rice, MD, MPH, Boston, MA
for Etiology of Residual OSA Following
Adenotonsillectomy 2:15 Scope of the Problem: Healthcare Sector Pollution and
Z. Ehsan, MD, Kansas City, MO Climate Change
J. Sherman, MD, New Haven, CT
3:30 Discussion: Drug-Induced Sleep Endoscopy for
Evaluation of the Etiology of Residual OSA Following 2:35 Changing How We Work: Hospital Operations
Adenotonsillectomy. H. Shankar, MD, Philadelphia, PA
C.M. Cielo, DO, Philadelphia, PA 2:50 Treatment Choices: A Case Study in Inhalers
3:35 Future Directions A. Rabin, MD, Ann Arbor, MI
R. Amin, MD, Toronto, Canada 3:05 The Commute: Implementing Climate Action Plans for
Transportation
R.J. Laumbach, MD, MPH, Piscataway, NJ
TRANSLATIONAL
3:20 We Have an Important Voice: Care Providers as Climate
SCIENTIFIC SYMPOSIUM Advocates
Speaker To Be Announced
B88 LEAPS AND BOUNDS: REDUCING 3:35 Group Discussion
HEALTHCARE’S CARBON FOOTPRINT
Assemblies on Environmental, Occupational and Population
BASIC • TRANSLATIONAL
Health; Critical Care; Nursing; Health Policy Committee
2:15 p.m. - 3:45 p.m. SCIENTIFIC SYMPOSIUM
Target Audience
Researchers focused on healthcare delivery and/or B89 TRANSCRIPTOMIC PROFILING OF
environmental/occupational exposures, those with clinical, research or PULMONARY VASCULAR LESIONS
administrative responsibilities, and policy makers who focus on UNRAVEL MECHANISMS OF PULMONARY
environmental regulations and healthcare delivery ARTERIAL HYPERTENSION
Objectives Assemblies on Pulmonary Circulation; Respiratory Cell and
At the conclusion of this session, the participant will be able to: Molecular Biology; Respiratory Structure and Function
• define the healthcare industry’s contribution to emissions and
2:15 p.m. - 3:45 p.m.
climate change
Target Audience
• understand and apply interventions at the individual and system Investigators and physician scientists interested in advanced
levels to reduce, eliminate, or reverse healthcare’s environmental techniques used to explore molecular mechanisms of pulmonary
impact and emissions vascular remodeling, as well as clinicians, pharmacists and other
caregivers engaged in treating patients with pulmonary hypertensio

ATS 2023 • Washington, DC

MONDAY • MAY 22 REGISTER NOW 57

Objectives
CLINICAL
At the conclusion of this session, the participant will be able to:
• describe new technologies that allow assessment of gene SCIENTIFIC SYMPOSIUM
expression at the cellular and lesional level from animals and
patients with pulmonary vascular disease B90 IMPROVING THE DIAGNOSIS AND
• apply new technologies for assessing cell specific gene expression MANAGEMENT OF PEDIATRIC ACUTE
to advance basic science research in pulmonary vascular biology RESPIRATORY DISTRESS SYNDROME
• apply new knowledge competence to better understand the Assemblies on Critical Care; Pediatrics
pathophysiology of pulmonary vascular disease to help guide the 2:15 p.m. - 3:45 p.m.
diagnosis and treatment of pulmonary arterial hypertension
Target Audience
New techniques in RNA sequencing, spatial tanscriptomics and Clinicians and researchers who care for patients with ARDS
proteomics have rapidly developed and allow for assessment of near
complete gene expression at a microscopic lesional, and cellular level, Objectives
focused on a precise area of interest making it possible to compare At the conclusion of this session, the participant will be able to:
gene expression between different types of pulmonary vascular cells • improve the diagnosis of pediatric ARDS
under baseline and disease conditions. This symposium will present
• integrate new guidelines for the management of PARDS into current
novel findings from multiple laboratories demonstrating how these
practice
techniques are moving the field of pulmonary vascular biology forward,
with a focus on methodology development, the required expertise to • use informatics and data science techniques appropriately in the
carry out such an analyses, bioinformatics, and interpretation of the care of children with PARDS
data. Acute Respiratory Distress Syndrome (ARDS) occurs in both children
and adults, but the management and diagnosis of Pediatric Acute
Chairing: J.R. Klinger, MD, ATSF, Providence, RI
Respiratory Distress Syndrome (PARDS) must consider factors which
J. Leopold, MD, Boston, MA
are unique to children and pediatric ICU practice. In 2015, the Pediatric
M.W. Geraci, MD, Pittsburgh, PA
Acute Lung Injury Consensus Conference (PALICC) published a
2:15 Integrated Analysis of scRNAseq Data Sets to Develop a definition of PARDS, along with clinical practice guidelines. Since then,
Comprehensive Atlas of Endothelial Gene Expression in there has been a wealth of new research focused on PARDS, which
the Normal Lung has prompted an update to PALICC, termed PALICC-2. This session
N. Kaminski, MD, ATSF, New Haven, CT focuses on important concepts and themes from PALICC-2 which are
2:35 Reactivation of Transcriptional Programs That crucial for the clinical care of children with PARDS.
Orchestrate Fetal Lung Development in Human
Chairing: R.G. Khemani, MD, MSCR, Los Angeles, CA
Pulmonary Hypertension
Y. Lopez-Ferandez, MD, PhD, Bizkaia, Spain
S.S. Pullamsetti, PhD, Bad Nauheim, Germany
2:15 Introduction and Overview of PALICC-2
2:50 The Use of Single-Cell Transcriptomics in Animal
G. Emeriaud, MD, PhD, Montreal, Canada
Models of Pulmonary Hypertension to Identify Genetic
Changes Relevant to Human Pulmonary Hypertension 2:20 Patient Speaker
J. Hong, MD, PhD, Los Angeles, CA Speaker To Be Announced
3:10 Combining Spatial Transcriptomics and Single Cell 2:25 How Do We Account for Changing Practice with HFNC
RNAseq to Examine Gene Expression in Pulmonary and NIV in Defining PARDS?
Vasculature Endothelial Cells S. Shein, MD, Cleveland, OH
A. Brodsky, PhD, Providence, RI 2:40 Lung Protective Bundles and Monitoring in PARDS
3:30 Use of Spatial Transcriptomics to Examine Lesion- A. Bhalla, MD, MSc, Los Angeles, CA
Specific Gene Expression in Human Pulmonary Arterial 2:55 What Are the Most Important Outcomes to Follow in
Hypertension PARDS Patients, and Can We Modulate Them with our
K.R. Stenmark, MD, Aurora, CO Therapies?
E. Killien, MD, Seattle, WA
3:10 Understanding Phenotypic Heterogeneity: Can We Get
to Precision-Based Care in PARDS?
J.R. Grunwell, MD, PhD, Atlanta, GA

ATS 2023 • Washington, DC

58 REGISTER NOW MONDAY • MAY 22

3:25 PARDS in the Digital Era: Leveraging Informatics and 2:40 Signalling and Senescence in Lung Aging
Data Science A.L. Mora, MD, Columbus, OH
N. Sanchez-Pinto, MD, MCI, Chicago, IL 2:50 Mutation and Epimutation Changes with Age
3:40 Question and Answer S.D. Spivack, MD, MPH, Bronx, NY
R.G. Khemani, MD, MSCR, Los Angeles, CA 3:00 Extracellular Matrix and Aging in the Lung
J.K. Burgess, BSc, PhD, ATSF, Groningen, Netherlands
BASIC • CLINICAL • TRANSLATIONAL 3:10 Distal Bronchoalveolar Region Changes in Aging and
COPD
SCIENTIFIC SYMPOSIUM R. Shaykhiev, MD, PhD, NEW YORK, NY
3:20 Immunologic Signaling and Exhaustion in the Aging
B91 LUNG AGING: WHY YOUR FEV1 IS Lung
FALLING AND PNEUMONIA IS YOUR B. Ural, PhD, New York, NY
FINAL FRIEND
3:30 Multiomic Revelations in Lung Aging and IPF
Assemblies on Respiratory Cell and Molecular Biology; N. Kaminski, MD, ATSF, New Haven, CT
Respiratory Structure and Function
3:40 Panel Discussion
2:15 p.m. - 3:45 p.m. S.D. Spivack, MD, MPH, Bronx, NY
Target Audience
Clinicians, physiologists, molecular biologists, epidemiologists, and all
points in between BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
Objectives SCIENTIFIC SYMPOSIUM
At the conclusion of this session, the participant will be able to:
• describe new findings about the major pathophysiologic elements of B92 INNOVATIVE APPROACHES TO
the aging lung PERSONALIZED SEVERE ASTHMA
• apply the pathophysiology of lung aging to better manage the MANAGEMENT
common clinical scenarios of ILD, COPD, Th1 asthma, lung Assemblies on Allergy, Immunology and Inflammation;
carcinogenesis Behavioral Science and Health Services Research; Clinical
• improve the healthspan of individuals at risk for age-related lung Problems; Pediatrics; Respiratory Cell and Molecular Biology
disorders, including the consideration of “senolytic” prevention 2:15 p.m. - 3:45 p.m.
maneuvers
Target Audience
We are all aging. Yet the machinery of aging is not well understood. Adult and pediatric asthma providers, including pulmonologists,
Many disorders with which clinicians struggle are strongly allergists and APPs, as well as basic scientists interested in airway
age-associated (UIP/IPF, COPD, Th1 ASTHMA, Lung Cancer, others). immunology, epithelial and airway smooth muscle biology and new
Some central dysfunctions of aging include stochastic deterioration of companies in the severe asthma space
biologic programs; senescence programming, oxidative damage, Objectives
telomeric maintenance failure, immunologic exhaustion, and other At the conclusion of this session, the participant will be able to:
processes. This symposium will review some of the known processes of
aging as they relate to the lung, review some of the most salient • apply home assessments to longitudinal asthma management
studies, and reach for a unified theme for normal as well as accelerated • describe new findings regarding androgens and other sex steroids in
lung aging that may be addressable with preventatives and asthma
therapeutics.
• describe new insights regarding the use of imaging in asthma
Chairing: S.D. Spivack, MD, MPH, Bronx, NY Biologic treatments have been beneficial for many severe asthma
J.L. Schneider, BA, Chicago, IL patients, but many others continue to have debilitating chronic dyspnea,
I. Rahman, PhD, ATSF, Rochester, NY exacerbations and/or medication side effects. Recent advances in
2:15 Overview of Lung Aging asthma biology and in technology have provided exciting opportunities
J.L. Schneider, MD, PhD, Boston, MA to improve personalized severe asthma management. Leveraging
insights from the NHLBI Precise network and ICAN meeting, we will
2:30 Oxidative Shifts in the Aging Lung provide an update on the latest insights in this field.
I. Rahman, PhD, ATSF, Rochester, NY

ATS 2023 • Washington, DC

MONDAY • MAY 22 REGISTER NOW 59

Chairing: H. Durrington, PhD, MA, MBChB, Manchester, United

Kingdom
A.A. Zeki, MD, Davis, CA
B. Gaston, MD, Indianapolis, IN
2:15 Application of an Adaptive Trial Design to Severe
Asthma Research
A. Ivanova, PhD, Chapel Hill, NC
2:28 Questions and Answers

2:33 Androgens and Other Sex Hormones in Severe Asthma

D.C. Newcomb, PhD, Nashville, TN
3:46 Questions and Answers

2:51 Potential Use of Genetics and Biomarkers to Personalize

Severe Asthma Management
V.E. Ortega, MD, PhD, ATSF, Scottsdale, AZ
3:04 Questions and Answers

3:09 Asthma Imaging: Novel Insights

E. Dunican, BM BCH, Dublin, Ireland
3:22 Questions and Answers
3:27 Recent Advances in At-Home Assessments of Asthma
Control
P. Akuthota, MD, ATSF, La Jolla, CA
3:46 Questions and Answers

2:15 p.m. - 4:15 p.m.

Oral And Poster Presentations Of Scientific
Research And Case Reports. Abstract Sessions
Will Be Published In The Final Program.

ATS 2023 • Washington, DC

60 REGISTER NOW TUESDAY • MAY 23

K3: KEYNOTE SERIES

8:00 a.m. -8:45 a.m.

The ATS Keynote Series focuses on timely topics of

high relevance to the pulmonary, critical care, and
sleep medicine community. Keynote lectures feature
leaders who have made major contributions in the
important themes programmed at the 2023 conference
and are unopposed by any other programming.
Tuesday's Keynote Lecture will focus on:
Reducing Gun Violence through Advocacy and
Action by Physicians and Policymakers
Tuesday Morning, May 23 Speakers: Emmy Betz, MD, MPH
Joseph Victor Sakran, MD, MPA, MP

MEET THE EXPERT SEMINARS

R Pre-registration and additional fees required. Attendance is limited.

$100 Member/Non-Members
$70 LMIC Member/LMIC Non-Members
10:15 a.m. - 11:15 a.m C1
YEAR IN REVIEW

CLINICAL YEAR IN REVIEW 3

MTE31 DETECTION OF ALPHA-1 ANTITRYPSIN DEFICIENCY - 9:00 a.m. - 10:30 a.m.
AN UNDERRECOGNIZED POPULATION Target Audience
J. Lascano, MD, Gainesville, FL Pulmonary, critical care and sleep providers. The program will discuss
L. Riley, MD, Kansas City, MO general topics of interest to a broad group of providers, inside and
MTE32 MANAGEMENT OF IMMUNE MEDIATED MYOSITIS outside of these subspecialties. The program is relevant to not only
RELATED LUNG DISEASE IN 2023 clinicians, but also to researchers and administrators
S.K. Danoff, MD, PhD, ATSF, Baltimore, MD Objectives
S. Sehgal, MBBS, CLEVELAND, OH At the conclusion of this session, the participant will be able to:
MTE33 LUNG MOLECULAR ATLAS PROGRAM HUMAN TISSUE • apply new clinical research knowledge to clinical practice.
CORE (LUNGMAP HTC)
• apply new findings about key conditions in pulmonary, critical care
G.S. Pryhuber, MD, Rochester, NY
and sleep.
MTE34 EEG FOR THE GENERAL INTENSIVIST
• learn new strategies to manage the care of common conditions in
D. Anderson, PhD, MD, Edmonton, Canada
pulmonary, critical care, and sleep.
K. Rosenblatt, MD, MHS, Baltimore, MD
Pulmonary, critical care and sleep providers. The program will discuss
MTE35 ENGAGING PARTNERS TO PROMOTE ADHERENCE TO
general topics of interest to a broad group of providers, inside and
CPAP TREATMENT
outside of these subspecialties. The program is relevant to not only
L. Ye, PhD, RN, Boston, MA
clinicians, but also to researchers and administrators.
MTE36 REMOTE PHYSICAL ACTIVITY MONITORING IN
PULMONARY VASCULAR DISEASE Chairing: R.J. Shah, MD, MSCE, San Francisco, CA
R.T. Zamanian, MD, FCCP, Stanford, CA J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil
J. Minhas, MD, MS, MBBS, Philadelphia, PA S. Auld, MD, MSc, Atlanta, GA
9:00 Asthma
V.M. McDonald, PhD, New Lambton Heights, Australia
9:23 Sarcoid
M. Sharp, MD, MHS, Baltimore, MD

ATS 2023 • Washington, DC

TUESDAY • MAY 23 REGISTER NOW 61

9:45 Sepsis
CLINICAL
S. Bhavani, MD, Atlanta, GA
10:08 Sleep CLINICAL TOPICS IN PULMONARY MEDICINE
C. Goldstein, MD, MS, Ann Arbor, MI
C3 PEDIATRIC CLINICAL CHEST ROUNDS

BEHAVIORAL • CLINICAL Assembly on Pediatrics

9:00 a.m. - 10:30 a.m.
CLINICAL TOPICS IN PULMONARY MEDICINE
Target Audience
Pediatric pulmonary clinicians and trainees (including students,
C2 ENDPOINTS FOR THERAPEUTIC TRIALS physicians, advanced practice providers, nurses, therapists) interested
IN ILD in the diagnosis and management of challenging cases
Assemblies on Clinical Problems; Behavioral Science and Health Objectives
Services Research At the conclusion of this session, the participant will be able to:
9:00 a.m. - 10:30 a.m. • generate a broad differential diagnosis for challenging cases in
Target Audience pediatric pulmonary medicine;
Providers of lung health; those with clinical and/or research • apply current diagnostic testing to the management of challenging
responsibilities; those designing or conducting trials of therapies for cases in pediatric pulmonary medicine;
patients with ILD; approval agency representatives; pharmaceutical
company representatives • discuss state of the art management of challenging pediatric
pulmonary cases
Objectives
At the conclusion of this session, the participant will be able to: Pediatric Clinical Chest Rounds is an annual symposium that focuses
on the diagnosis and management of 4 challenging cases selected from
• more fully appreciate the need for patient-centric outcomes in trials case reports submitted to the Pediatric Assembly. Each case is
of therapies for patients with ILD. presented by a trainee (typically Ped Pulm fellow) and a discussion of
• consider the use of specific, supplemental oxygen-related outcomes the main points of the case follows (typically an expert in the field).
in their studies and trials.
Chairing: T.J. Moraes, MD, PhD, BSc, Toronto, Canada
• implement patient-centric outcomes that assess how patients with S.C. Sadreameli, MD, MHS, Baltimore, MD
ILD feel and function in their daily lives. C.E. Loughlin, MD, Chapel Hill, NC
Identifying endpoints that meet requirements for patient centricity, Speakers And Talks To Be Announced
applicability given the known or likely mechanisms of the therapeutic
intervention and achievability within the constraints of therapeutic trials
is key to the design of therapeutic trials for patients with ILD. CLINICAL
Chairing: J. Swigris, DO, MS, Denver, CO CRITICAL CARE TRACK
M. Kalluri, MD, Edmonton, Canada
9:00 Introduction C4 FLUID AND VASOPRESSOR
J.J. Swigris, DO, MS, Denver, CO
RESUSCITATION FOR EARLY SEPSIS:
M. Kalluri, MD, Edmonton, Canada
WHEN, WHICH, AND HOW MUCH?
9:10 Patient reported outcomes as endpoints in trial
J.J. Swigris, DO, MS, Denver, CO Assemblies on Critical Care; Behavioral Science and Health
Services Research; Clinical Problems; Nursing
9:30 Supplemental Oxygen Needs as a Trial Endpoint
K.I. Aronson, MD, MSci, New York, NY 9:00 a.m. - 10:30 a.m.
9:50 Improving Home Spirometry to Make It a Viable Trial Target Audience
Endpoint Clinicians, researchers, trainees, and other team members, including
A.O. Adegunsoye, MD, MS, Chicago, IL nurses and pharmacists, who care for patients with early sepsis.
10:10 Data from Wearables as Trial Endpoints Objectives
K. A. M. Johannson, MD, MPH, ATSF, Calgary, Canada At the conclusion of this session, the participant will be able to:
• understand best practices for early sepsis resuscitation that are
informed by high-quality evidence

ATS 2023 • Washington, DC

62 REGISTER NOW TUESDAY • MAY 23

• identify areas of early sepsis management for which high-quality Target Audience
evidence is lacking Practicing clinicians and other health care providers, health disparities
researchers, quality improvement specialists or policy makers
• learn about trials currently in the field that will bring more data to
inform practice for resuscitation and early sepsis management Objectives
At the conclusion of this session, the participant will be able to:
Hemodynamic resuscitation is a core element of sepsis management
and a focus of guidelines and care bundles, yet the optimal approach to • describe new findings about current biases in care delivery relevant
IV fluid administration and vasopressor use remains controversial. With to pulmonary/critical care medicine
growing concern about the harms of fluid overload, long-standing • identify the limitations of current approaches to clinical
dogma is being challenged and practice is evolving towards decision-making tools and treatment recommendations and
fluid-sparing, early vasopressor strategies. This symposium will provide evidence derived from machine learning approaches
a comprehensive update on current controversies in hemodynamic
resuscitation for sepsis, including discussion of brand new evidence • apply expert-consensus mitigation strategies for bias to improve the
addressing the timing and selection of fluids and vasopressors and quality of clinical care
strategies for real-world implementation. Risk and disease prediction tools are common in clinical practice. They
are vital to high-quality care—simplifying complexity in evidence-based
Chairing: E. Munroe, MD, Ann Arbor, MI fashion. Yet, despite being used everyday use, many tools are now
I.D. Peltan, MD, MSc, Murray, UT recognized to be racially biased, skewing clinical judgments, to
I.S. Douglas, MD, FRCP, Denver, CO contribute to worse outcomes for minoritized populations. This session
9:00 Too Much of a Bad Thing? Pathophysiology of Harm brings together experts in health equity and clinical/prediction testing to
from IV Fluids and Vasopressors in Sepsis discuss this manifestation of structural racism in pulmonary and critical
I.S. Douglas, MD, FRCP, Denver, CO care medicine. Attendees will learn about real world examples of biased
tools used every day in our field, build a framework for understanding
9:13 A World of New Evidence: Fluid Volume, Choice, Timing,
how biased tools emerge, and review mitigation strategies.
and Reversal in Sepsis Resuscitation
T. Meyhoff, MD, Copenhagen, Denmark Chairing: A.D. Baugh, MD, San Francisco, CA
9:26 Selecting and Adding Vasopressors in Septic Shock D.C. Ashana, MD, MBA, MS, Durham, NC
E. Munroe, MD, Ann Arbor, MI T.S. Valley, MD, MSc, Ann Arbor, MI
9:39 Making it Personal: Individualizing Resuscitation Targets 9:00 Introduction
P. Bhatraju, MD, Seattle, WA A.D. Baugh, MD, San Francisco, CA
9:52 Unintended Consequences: Understanding Effects of 9:05 Color-Blind or Context Blind? Understanding Race in
New Resuscitation Strategies on Patient Care Processes Pulmonary Function Testing
C. Permpikul, MD, Bangkok, Thailand A.D. Baugh, MD, San Francisco, CA
10:05 Evidence to Practice: Teamwork Makes Resuscitation 9:16 Hold Your Breath: The Journey to an Equitable Pulse
Work Oximeter
T. Hiller, BSN, RN, Denver, CO T.S. Valley, MD, MSc, Ann Arbor, MI
10:18 Panel Discussion and Questions: What’s Next for Sepsis 9:27 When Technology Imitates Life: How Bias Manifests in
Resuscitation? Risk Prediction and Artificial Intelligence
D.C. Ashana, MD, MBA, MS, Durham, NC
9:38 Shortcomings of Standard Cystic Fibrosis Screening
CLINICAL Tests Among Individuals of African Ancestry
SCIENTIFIC SYMPOSIUM J.L. Taylor-Cousar, MD, MSc, ATSF, Denver, CO
9:49 Unequal Risk: Modifying Lung Cancer Screening
C5 DISMANTLING STRUCTURAL RACISM Guidelines
FROM RISK AND DISEASE PREDICTION IN 10:00 The Bias of Machines
PULMONARY AND CRITICAL CARE L.A. Perine, MBA, College Park, MD
MEDICINE 10:11 Summary
Assemblies on Behavioral Science and Health Services Research; D.C. Ashana, MD, MBA, MS, Durham, NC
Critical Care 10:16 Discussion
9:00 a.m. - 10:30 a.m. T.S. Valley, MD, MSc, Ann Arbor, MI

ATS 2023 • Washington, DC

TUESDAY • MAY 23 REGISTER NOW 63

9:07 Patient Speaker

BASIC • CLINICAL • TRANSLATIONAL
Speaker To Be Announced
SCIENTIFIC SYMPOSIUM 9:12 The Causes and Implication of the Under Recognition of
Cystic Fibrosis as a Genetic Disease in Minority Groups
C6 DISPARITIES IN RESPIRATORY J.L. Taylor-Cousar, MD, MSc, ATSF, Denver, CO
GENOMICS RESEARCH: STRATEGIES TO 9:25 Intersectionality of Sex and Gender in Lung Disease
ADVANCE SCIENCE AND CLINICAL CARE Omics
Assemblies on Allergy, Immunology and Inflammation; D.L. Demeo, MD, Boston, MA
Environmental, Occupational and Population Health; Section on 9:38 Genomic and Social Determinants of Racial Inequality in
Genetics and Genomics Asthma
9:00 a.m. - 10:30 a.m. J.G. Zein, MD, PhD, MBA, Cleveland, OH

Target Audience 9:51 “Omics” of Asthma and Disease Disparities

Everyone in medicine and science has a sphere of influence that could E. Forno, MD, MPH, ATSF, Pittsburgh, PA
contribute to mitigating health disparities -trainees, clinical faculty, 10:04 Ancestral Diversity is Important When Evaluating
research faculty , healthcare staff, research staff, and administration. Respiratory Traits and Disease in Genetic Studies
Objectives V.E. Ortega, MD, PhD, ATSF, Scottsdale, AZ
At the conclusion of this session, the participant will be able to: 10:17 Insights into Ensuring Diversity in Recruitment and
• gain awareness of current race- and sex-specific health inequities in Representation in Science, a Take from the Immediate
complex lung diseases, the importance of addressing Past-Chair of the HDEC
underrepresentation in genomic studies, and implications on the N. Thakur, MD, MPH, San Francisco, CA
development of polygenic risk scores for disease and traits
• awareness of common misconceptions as it relates to minorities and BASIC • CLINICAL • TRANSLATIONAL
Mendelian orphan lung diseases, with a focus on cystic fibrosis, how
this can impair diagnosis, prognosis, and access to precision SCIENTIFIC SYMPOSIUM
modulator therapies, and next best steps forward
• address scientific & clinical issues in genomics as they relate to C7 CANCER IN THOSE WHO HAVE NEVER
health disparities in the context of genetic epidemiology, SMOKED: NEW INSIGHTS FROM BENCH
development of predictive genomic profiles, multi-omics approaches, TO BEDSIDE
gene-by-environment interactions, & clinical translation
Assemblies on Thoracic Oncology; Environmental, Occupational
Advances in genomic technologies have primarily applied to European and Population Health
descent whites with one-to-two percent of African descent minorities
and Hispanics included in genetic studies of disease. These 9:00 a.m. - 10:30 a.m.
underrepresented groups experience a disproportionate burden of Target Audience
respiratory disease and have an underappreciated risk for orphan Those with clinical interest in lung cancer. Those with research
diseases traditionally considered to be white-only, such as cystic interests in non-tobacco risks for lung cancer.
fibrosis. In addition, a minority of genomic studies address differences Objectives
of respiratory disease risk and severity specific to sex. This workshop At the conclusion of this session, the participant will be able to:
will address scientifically and clinically relevant issues in genomics as
they relate to health disparities from the context of genetic • describe new findings on the genetic and epidemiologic
epidemiology, the development of predictive genomic profiles, underpinnings of cancer in those with no tobacco history
multi-omics approaches, gene-by-environment interactions, and clinical • define new strategies for early detection of cancer in those with no
translation. tobacco smoking history
Chairing: A. Souquette, PhD, Memphis, TN • better counsel patients about risk factors for lung cancer beyond
V.E. Ortega, MD, PhD, ATSF, Scottsdale, AZ tobacco smoking
J. Pantaleón García, BS, MD, Houston, TX Lung cancer is a common cause of cancer mortality even in those who
D.L. Demeo, MD, Boston, MA have never used tobacco. Taken alone, lung cancer in those who have
9:00 Introduction never smoked (LCNS) is the seventh leading cause of cancer death in
A. Souquette, PhD, Memphis, TN the United States. This seminar will explore how LCNS differs
epidemiologically and molecularly from lung cancer associated with

ATS 2023 • Washington, DC

64 REGISTER NOW TUESDAY • MAY 23

tobacco use. Speakers will unique risk factors, strategies to identify MDR-TB/pre-XDR-TB (and their contacts) based on recent WHO
those at risk, and novel treatment approaches. guidelines, ATS/IDSA guidelines, and recent clinical trials data

Chairing: E. Ostrin, MD, PhD, Houston, TX This session will review recent translational and clinical data, including
Q. Lan, MD, PhD, MPH, Bethesda, MD recent clinical trials results, to provide state of the art clinical
J.J. Tsay, MD, MSc, New York, NY perspective of new developments in prevention strategies, diagnostics
and management of M. avium complex (MAC) and M. abscessus
9:00 Genomic Risks Behind Lung Adenocarcinoma in Those complex (MAbsC) lung disease, as well as of latent, incipient and
Who Have Never Smoked subclinical TB infections, and multidrug-resistant TB in various groups
Q. Lan, MD, PhD, MPH, Bethesda, MD of patients and settings.
9:18 Calculating Risk for Lung Cancer in Those Who Have
Chairing: P. Escalante, MD, MSc, Rochester, MN
Never Smoked
S.H. Kasperbauer, MD, Denver, CO
M.C. Tammemagi, PhD, DVM, MSc, St. Catharines, Canada
A. Cattamanchi, MD, San Francisco, CA
9:36 The TALENT Trial: Lung Cancer Screening in a
9:00 MAC Pulmonary Disease: Evolving Concepts and Best
Population with Very Low Rates of Tobacco Use
Individualized Management
P.-C. Yang, MD, Taipei, Taiwan
C.L. Daley, MD, Denver, CO
9:54 Air Pollution and Lung Cancer
9:20 M. Abscessus Complex Pulmonary Disease: Novel
J. Schiller, MD, Vienna, VA
Treatment Interventions and Individualized Approach
10:12 New Directions in Treating Lung Cancer in Those Who M.P. Dalcolmo, MD, PhD, Rio De Janeiro, Brazil
Have Never Smoked
9:40 Diagnostics and Therapeutic Interventions in Latent,
E. Shum, MD, New York, NY
Incipient, and Subclinical TB Infections
P. Escalante, MD, MSc, Rochester, MN
CLINICAL • TRANSLATIONAL 10:00 TB and MDR-TB: Evolving Concepts and Recent
Guidelines-Based Therapies
SCIENTIFIC SYMPOSIUM C.A. Haley, MD, MPH, Gainesville, FL
10:20 Questions and Answers
C8 NEW CONCEPTS AND UPDATE IN THE
DIAGNOSIS AND MANAGEMENT OF NTM
AND TB INFECTIONS BEHAVIORAL • CLINICAL
Assemblies on Pulmonary Infections and Tuberculosis; Clinical
SCIENTIFIC SYMPOSIUM
Problems
9:00 a.m. - 10:30 a.m. C9 REHABILITATION FOR THE POST-COVID
Target Audience POPULATION
Clinicians caring for patients with non-tuberculous mycobacteria (NTM)
pulmonary disease and tuberculosis (TB), and/or working in the field of Assemblies on Pulmonary Rehabilitation; Behavioral Science and
NTM and/or TB Health Services Research; Critical Care

Objectives 9:00 a.m. - 10:30 a.m.

At the conclusion of this session, the participant will be able to: Target Audience
Clinicians and researchers working in the field of pulmonary
• participants will be able to learn new diagnostic and therapeutic
rehabilitation who have extended or wish to extend their scope to
strategies, for the best management of patients with complex MAC-
include those with COVID-19, and clinicians caring for patients with
and MAbsC-lung disease, including novel and emergent treatment
COVID-19/ long COVID/ post-COVID syndrome
interventions in the United States and abroad
Objectives
• participants will be able to learn new concepts from recent studies to
At the conclusion of this session, the participant will be able to:
optimally diagnose and manage latent, incipient, and subclinical TB
infection in special settings in TB endemic areas and non-endemic • define the rationale for COVID-rehabilitation in terms of ongoing
areas patient symptoms
• participants will be able to learn new concepts from recent studies to • better understanding of the evidence underpinning rehabilitation in
optimally diagnose and manage patients with TB and the post-COVID population and other treatment approaches
available in order to better advise patients on treatment options

ATS 2023 • Washington, DC

TUESDAY • MAY 23 REGISTER NOW 65

• utilize the most appropriate outcome measures in this field • describe efforts to target sleep deficiency and control of breathing
with therapeutic interventions to promote long-term healthy recovery
Attendees can expect to learn about the rationale and evidence
among patients with OUD.
underpinning the inclusion of patients recovering from COVID-19 in
pulmonary rehabilitation (PR). This sessions will also debate if PR is the • outline an actionable research agenda to evaluate the basic
best intervention for this population or if other forms of rehabilitation/ mechanisms of the relationship between sleep deficiency and OUD
other treatments are better placed. and the potential for behavioral, pharmacologic, and positive airway
pressure treatments to improve OUD treatment outcomes.
Chairing: R.A. Evans, MBChB, FRCP, PhD, Leicester, United Kingdom
F. Franssen, MD, PhD, Horn, Netherlands This session will highlight the bidirectional mechanisms between opioid
use disorder (OUD) and sleep deficiency. It will discuss how targeting
9:00 Rationale for Rehabilitation in the Post-COVID-19 sleep deficiency and control of breathing with therapeutic interventions
Population (Long COVID Symptoms) can promote long-term, healthy recovery among patients in OUD
M. Beauchamp, PT, PhD, Hamilton, Canada treatment. Current knowledge on the effects of opioids on sleep
9:15 Evidence for Post-COVID Exercise-Based Rehabilitation architecture, sleep-disordered breathing, sleep apnea endotypes,
Programs ventilatory control, and and clinical practice are highlighted. Finally, an
S.J. Singh, PhD, Leicester, United Kingdom actionable research agenda is provided to evaluate the basic
mechanisms of the relationship between sleep deficiency and OUD and
9:30 Evidence for Fatigue Management in Long COVID
the potential for behavioral, pharmacologic, and positive airway
T. Chalder, PhD, London, United Kingdom
pressure treatments targeting sleep deficiency to improve OUD
9:45 Core Outcome Set for Long COVID outcomes.
D.M. Needham, MD, PhD, Baltimore, MD
Chairing: J.E. Orr, MD, La Jolla, CA
10:00 Argument 1:Patients Recovering from COVID Should Be T. Kendzerska, MD, PhD, Ottawa, Canada
Integrated into Existing Pulmonary Rehabilitation
Services 9:00 Current Knowledge on the Effects of Opioids on Sleep
R. Gloeckl, PhD, Schoenau am Koenigssee, Germany Quality, Sleep Architecture, Sleep-Disordered Breathing,
Sleep Apnea Endotypes
10:10 Argument 2: There Is a Better Alternative to Integrating D.J. Eckert, PhD, Bedford Park, Australia
Patients with Long COVID into Pulmonary Rehabilitation
D. Wade, MD, Oxford, United Kingdom 9:15 Sleep Deficiency Across the Trajectory of OUD:
Neuro-Biologic, Neuro-Psychiatric, and Social-Ecologic
10:20 Discussion Session Mechanisms
H.K. Yaggi, MD, New Haven, CT
BEHAVIORAL • CLINICAL • TRANSLATIONAL 9:30 Targeting Insomnia in OUD: CBTi and Leveraging the
Orexin System
SCIENTIFIC SYMPOSIUM K. Sharkey, MD, PhD, Providence, RI
9:45 PAP Therapies for Sleep-Disordered Breathing OUD
C10 OPIOID USE DISORDER, SLEEP S. Chowdhuri, MD, MS, ATSF, Detroit, MI
DEFICIENCY, AND VENTILATORY
10:00 Novel Pharmacologic Treatments Targeting Control of
CONTROL: BIDIRECTIONAL
Breathing in Opioid Use: Intranasal Leptin, Ampakines,
MECHANISMS AND THERAPEUTIC and Other Potential Targets
TARGETS V.Y. Polotsky, MD, PhD, Baltimore, MD
Assembly on Sleep and Respiratory Neurobiology 10:15 Sleep Deficiency as a Core Feature of OUD and
9:00 a.m. - 10:30 a.m. Recovery: A Research Agenda
A. Laposky, PhD, Bethesda, MD
Target Audience
Sleep providers, patients with sleep deficiency, opioid use disorder,
Those who take care of patients on opioids, those interested in sleep
phenotypes and control of breathing
Objectives
At the conclusion of this session, the participant will be able to:
• at the end of this session, the participants will have an improved
understanding of the bidirectional mechanisms between opioid use
disorder (OUD) and sleep deficiency.

ATS 2023 • Washington, DC

66 REGISTER NOW TUESDAY • MAY 23

9:25 It’s Reality for Our Patients: Challenges/Barriers Related

BEHAVIORAL • CLINICAL • TRANSLATIONAL
to CMS Regulations and DME Companies
SCIENTIFIC SYMPOSIUM J.A. Krishnan, MD, PhD, ATSF, Chicago, IL
9:40 ATS Means Family and Family Means Nobody Gets Left
C11 ADVANCING CLINICAL ISSUES TO ATS Behind: ATS Responses to Oxygen issues
AND CAPITOL HILL: THE OXYGEN S.S. Jacobs, RN, MS, Stanford, CA
THERAPY EXEMPLAR 9:50 To Capitol Hill and Beyond: ATS Government Relations
Assemblies on Clinical Problems; Environmental, Occupational and Your Advocacy on Capitol Hill
and Population Health; Nursing; Pediatrics; Pulmonary G. Ewart, MHS, Washington, DC
Rehabilitation; International Health Committee; Health Policy 10:00 Access, Recall and Care, Oh My!: The Next Frontier in
Committee Advocacy
9:00 a.m. - 10:30 a.m. H. Schotland, MD, ATSF, New York, NY

Target Audience 10:15 Questions and Answers

All ATS Members (This session is beneficial for all members as it S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN
provides a framework for taking a clinical issue, addressing it through
ATS clinical, research and health policy groups, then engaging
members in advocating for legislative changes. BASIC • CLINICAL • TRANSLATIONAL
Objectives SCIENTIFIC SYMPOSIUM
At the conclusion of this session, the participant will be able to:
• describe two challenges or barriers to patients’ oxygen therapy as C12 IMMUNOLOGY IN CONTEXT:
related to CMS regulations and/or DME Companies. MECHANISMS AND BIOMARKERS THAT
• incorporate approaches from ATS Clinical Oxygen Guidelines to DETERMINE VIRAL DISEASE SEVERITY
address patients’ oxygen therapy concerns. Assemblies on Allergy, Immunology and Inflammation;
• describe two strategies ATS members can use to effectively Pediatrics; Pulmonary Infections and Tuberculosis; Respiratory
advocate for legislation related to oxygen therapy. Cell and Molecular Biology; Section of Genetics and Genomics
Do your patients face difficulty in getting adequate access to 9:00 a.m. - 10:30 a.m.
supplemental oxygen? This session will cover novel oxygen delivery Target Audience
systems for outpatient use and upcoming innovations in oxygen Adult and pediatric pulmonologists, critical care providers,
delivery. A particular focus will include current barriers to oxygen immunologists, cell biologists
delivery, regulatory limitations which impair access to adequate oxygen,
Objectives
and ATS advocacy needed towards legislative change. ATS’s
At the conclusion of this session, the participant will be able to:
involvement in advancing this clinical issue to health policy change will
be addressed. Finally, the session covers the next frontier in access to • better understand and incorporate current and novel biomarkers for
home respiratory support, highlighting patients’ and providers’ respiratory infection correlates of protection or severity, including
challenges after the recent recall of non-invasive ventilation devices and SARS-CoV-2, into current practice
advocating for those issues. • gain knowledge of novel techniques for tracking pathogen-host
Chairing: N.A. Kolaitis, MD, MS, San Francisco, CA interactions over the course of infection, including single cell
S.S. Jacobs, RN, MS, Stanford, CA approaches and cell-free analyses
• discuss comprehensive cohort study design that includes molecular,
9:00 Introduction of the Session
N.A. Kolaitis, MD, MS, San Francisco, CA genetic, environmental, and epidemiological variables as
components of immune modeling for host pathogenesis
9:02 Setting the Tone: Capturing the Patient’s Perspective 1
N.A. Kolaitis, MD, MS, San Francisco, CA Findings presented will highlight novel correlates of severity and
protection during respiratory illness, including SARS-CoV-2 infection,
9:04 Setting the Tone: Capturing the Patient’s Perspective 2 that could be useful as biomarkers for viral illness outcome. The session
J.M. Rommes, PhD, West Des Moines, IA will explore new aspects of the host pathogen interface that could be
9:10 Listening to the Demands for Improvements: harnessed as a clinical tool and lead to host-targeted therapeutics.
Innovations in Oxygen Delivery What biomarkers can be used to determine individuals at higher risk of
D. Hayes, MD, MS, MEd, ATSF, Cincinnati, OH severe illness outcome from respiratory viral infection?

ATS 2023 • Washington, DC

TUESDAY • MAY 23 REGISTER NOW 67

Chairing: A. Rogers, MD, MPH, ATSF, Stanford, CA Technology is increasingly being used in medical education to
T. Flerlage, MD, Memphis, TN supplement the delivery of learning resources. Gamification is defined
E.K. Allen, PhD, Memphis, TN as the use of game design elements in non-game contexts. Studies
have shown that gamification may improve learning outcomes in health
9:00 Immunology in Context
professionals, especially when employing game attributes that improve
E.K. Allen, PhD, Memphis, TN
learning behaviors and attitudes towards learning. Our session will
9:05 Host-Microbiome Interactions in Early in Life - Key to present the evidence behind the use of gamification in medical
Respiratory Infections? education for learners in Pulmonary and Critical Care Medicine. We will
Speaker To Be Announced illustrate strategies for gamifying traditional didactic approaches to
9:20 Q&A learning by using gamification methods within our session. Lastly, we
will explore challenges behind the implementation of gamification as
9:25 SARS-CoV-2 Repeat Infections and Breakthroughs: well as the strategies to overcome them.
Correlates of Immunity and Determinants of Severity
A. Gordon, PhD, Ann Arbor, MI Faculty: N. Sawal, MD, Rochester, MN
9:40 Q&A E.R. Camac, DO, Lexington, KY
J.B. Richards, MD, MA, ATSF, FACP, Cambridge, MA
9:45 Severe Respiratory Viral Infection Results in Persistent S.M. Kassutto, MD, Philadelphia, PA
Immune Activation of Lung Fibroblasts Associated with
Prolonged Respiratory Distress
D.F. Boyd, PhD, Santa Cruz, CA
10:00 Q&A
10:05 Profiling the Mucosal TCR Repertoire Landscape During
Severe Pneumonia
L. Morales-Nebreda, MD, Chicago, IL
10:20 Q&A

MEDICAL EDUCATION SEMINAR

ME103 GAME ON!: GAMIFICATION OF MEDICAL

EDUCATION IN PCCM
Assembly on Behavioral Science and Health Services Research
10:15 a.m. - 11:15 a.m.
Target Audience
The intended target audience is clinician educators with experience or
interest in medical education for all levels of learners. Although this
session will cover the utility of gamification in education, no
prerequisites are required.
Objectives
At the conclusion of this session, the participant will be able to:
• review the available literature for the benefits of using gamified
training platforms for medical education (both preclinical and clinical)
and training.
• identify available platforms suitable for the purpose of gamification
with links to multimedia content.
• outline the challenges in the implementation of gamification and the
strategies available to counteract them.

ATS 2023 • Washington, DC

68 REGISTER NOW TUESDAY • MAY 23

CLINICAL
PEDIATRIC CLINICAL CORE CURRICULUM

PCC2 PEDIATRIC CLINICAL CORE CURRICULUM

Education Committee
12:00 p.m. - 1:00 p.m.
Target Audience
Clinicians who are engaged in maintenance of certification activities
Objectives
At the conclusion of this session, the participant will be able to:
• describe diagnosis and management of central and obstructive
Tuesday Mid-day, May 23 sleep disorders in infants
• identify best practices for management and treatment of pulmonary
hypertension in infants
11:30 a.m. - 1:00 p.m. • describe best practices and standards of care for management of
bronchopulmonary dysplasia in the neonatal intensive care unit and
PLENARY SESSION the post NICU period
W Chairing: J. Gross, MD, PhD, Denver, CO
C. Okorie, MD, Paulo Alto, CA
The Plenary Session will feature a keynote address by Timothy Caulfield, M. McCown, MD, Bethesda, MD
professor of Health Law and Science Policy and best-selling author.
12:00 Obstructive Sleep Disorders in Infants
Timothy Caulfield is a Canada Research Chair in Health Law and Policy, a M. Bedoya, MD, Nashville, TN
Professor in the Faculty of Law and the School of Public Health, and
12:25 Central Sleep Disorders in Infants
Research Director of the Health Law Institute at the University of Alberta. His
M. Maloney, MD, FAAP, Salt Lake City, UT?
interdisciplinary research on topics like stem cells, genetics, research ethics,
the public representations of science, and public health policy has allowed 12:50 Questions and Answers
him to publish over 350 academic articles. He has won numerous academic,
science communication, and writing awards, and is a Fellow of the Royal
Society of Canada and the Canadian Academy of Health Sciences.
He contributes frequently to the popular press and is the author of two
national bestsellers: The Cure for Everything: Untangling the Twisted
Messages about Health, Fitness and Happiness (Penguin 2012) and Is
Gwyneth Paltrow Wrong About Everything?: When Celebrity Culture and
Science Clash (Penguin 2015). His most recent book is Relax, Dammit!: A
User's Guide to the Age of Anxiety (Penguin Random House, 2020) (US Title:
Your Day, Your Way).
Professor Caulfield is also the co-founder of the science engagement
initiative #ScienceUpFirst and the host and co-producer of the award-winning
documentary TV show, A User's Guide to Cheating Death, which has been
shown in over 60 countries, including streaming on Netflix in North America.
The Plenary Session also will include the ratification of the 2023-2024 slate of
officers as well as remarks from outgoing president Greg Downey, MD,
ATSF, and incoming president M. Patricia Rivera, MD, ATSF.
In addition, three Respiratory Health Awards will be presented, including:
• Outstanding Educator Award
• Research Innovation & Translation Award

ATS 2023 • Washington, DC

TUESDAY • MAY 23 REGISTER NOW 69

• learn ECHO’s design to support developmental origins of health and

RESEARCH INTEGRITY IN MEDICAL EDUCATION: disease research.
LESSONS FROM THE TUSKEGEE EXPERIMENT • learn how ECHO data has supported innovative epidemiologic studies
12:00 p.m-1:00 p.m. of the origins of asthma and early onset of health disparities.

TARGET AUDIENCE: Anyone with clinical, research, or • learn the breadth and depth of available ECHO data from diverse
administrative responsibilities. This session is of particular participantsacross the nation spanning decades of data collection and
interest to trainees and individuals that oversee or participate in how to access ECHO data from DASH for airways research.
clinical and/or medical education and research. The NIH-supported Environmental Influences on Child Health Outcomes
Objectives (ECHO) program supports multiple synergistic, longitudinal cohort studies
At the conclusion of this session, the participant will be able to: across the U.S. to investigate how early environmental
exposures—including physical, chemical, social, behavioral, biological,
• recognize the historical lessons from the Tuskegee Syphilis
natural, and built environments—affect genetic susceptibility, child health
Study and how they apply to modern scientific investigation
and development. The multiple cohorts share protocol-specified data
practice
elements from ~100,000 participants and ~50,000 children, including
• examine their own research participation to explore areas of bioassay data analyzed by the NIH Human Health Exposure Analysis
potential unethical practice Resource (HHEAR). A de-identified near anonymized data set is now
• criticize unethical practice in clinical and research settings
available as a national resource for research. This session will focus on
how the ECHO data repository can support child health research
This interactive session and facilitated panel discussion is a particularly relevant to the development of airway diseases and health.
follow up to the ATS webinar on Research Integrity in Medical
Education: Lessons from the Tuskegee Experiment. Prior Chairing: C.J. Blaisdell, MD, North Bethesda, MD
attendance is not required. Together we will review the C.L.M. Joseph, PhD, Detroit, MI
important lessons learned from the unethical practices of the 12:00 ECHO as a National Resource for Lung Research: What
Tuskegee Experiments and discuss how we can combat Have We Learned?
systematic racism collectively. We will discuss the risk of M. Gillman, MD, SM, North Bethesda, MD
vulnerable populations both in research participants and
investigators, the role that junior trainees play as both research 12:15 What is in ECHO’s Controlled Access Public Use Data
participants and as future investigators, and the need for good Set, Now Available in the NICHD Data and Specimen Hub
leadership and mentorship to avoid future tragedies as (DASH)?
experienced in Tuskegee. D. Catellier, PhD, Research Triangle, NC
12:30 How Can Researchers Use ECHO’s Controlled Access
Public Use Data Set in DASH?
R. Rosen, PhD, Bethesda, MD
ENVIRONMENTAL INFLUENCES ON 12:45 Panel Discussion
CHILD HEALTH OUTCOMES (ECHO)/NIH C.J. Blaisdell, MD, North Bethesda, MD

OUTSIDE ORGANIZATION SESSION

DIVISION OF LUNG DISEASES, NHLBI/DLD
L15 NIH ENVIRONMENTAL INFLUENCES ON
CHILD HEALTH OUTCOMES (ECHO): OUTSIDE ORGANIZATION SESSION
NATIONAL LONGITUDINAL RESOURCE
FOR CHILD LUNG HEALTH L16 IMPACT OF SEX AND GENDER ON
RESEARCHERS AUTOIMMUNE LUNG DISEASE

2:00 p.m. - 1:00 p.m. 12:00 p.m. - 1:00 p.m.

Target Audience Target Audience

Providers of maternal and child health; Providers of lung health; Basic scientists, physician-scientists, and healthcare providers with
Researchers of Developmental Origins of Health and Development, research interests related to the influence of sex and gender on
Pediatric Pulmonologists; Environmental researchers and physicians autoimmune-associated lung diseases.

Objectives Objectives
At the conclusion of this session, the participant will be able to: At the conclusion of this session, the participant will be able to:

ATS 2023 • Washington, DC

70 REGISTER NOW TUESDAY • MAY 23

• create awareness, interest, and increase knowledge of the influence This workshop provides a multidisciplinary perspective on how applied
of sex and gender on autoimmune lung disease research. knowledge of environmental health exposure can be used to support the
achievement of respiratory health equality. Attendees will receive updates
• learn about innovative methods to eliminate gaps in the design,
on new trends in radon, asthma, Legionnaires’ disease, wildfires, volatile
conduct, and analysis of sex and gender-related aspects of
organic compounds (VOC) exposure in homes, respiratory health quality
autoimmune lung disease research
improvement initiatives, and patient education for communities with greater
• clinical Phenotyping of autoimmune ILD and diagnose, predict and vulnerability to harmful environmental exposures and lower access to
improve clinical outcomes by re-purposing existing drugs resources. Presenters will highlight how the interaction of social
This session will highlight recent research advances involving the role of determinants contributes to disparities in care quality and health outcomes,
sex and gender in a number of autoimmune-related lung diseases, such as respiratory health using the Vital Conditions Framework, a
including systemic sclerosis-associated interstitial lung disease nationally recognized health equity framework.
(SSc-ILD), rheumatoid arthritis-associated ILD (RA-ILD), systemic lupus
Chairing: A. Perkins, BPH, Atlanta, GA
erythematosus (SLE) pneumonitis/pleuritis, and interstitial pneumonia
with autoimmune features (IPAF). 12:00 Introduction of the Division of Environmental Health
Science and Practice’s Vital Conditions Health Equity
Chairing: L.J. Vuga, MD, MPH, PhD, Bethesda, MD Plan
M.E. Lachowicz-Scroggins, PhD, Bethesda, MD A. Perkins, PhD, Atlanta, GA
12:00 Influence of Sex/Gender on Scleroderma-Associated ILD 12:10 Adverse Health Impacts Associated with Wildland Fire
E. Volkmann, MD, MSci, Los Angeles, CA Smoke Exposure.
12:15 Sex/Gender Differences in Lung Inflammation and A. Vaidyanathan, PhD, Atlanta, GA
Rheumatoid Arthritis 12:20 Trends in Risk for Legionnaires’ Disease Based on
J.A. Sparks, MD, Boston, United States Access to Economic Resources
12:30 Role of B Cells Pulmonary Fibrosis Resulting from N. Clemmons, MPH, Atlanta, GA
STING Gain-of-Function Autoinflammation 12:30 Radon: Reducing a Lung Cancer Risk Factor by
A. Marshak-Rothstein, PhD, Worcester, United States Protecting Communities and Buildings
12:45 The Influence of Sex/Gender on Treatment Effect in A. Salame-alfie, PhD, Atlanta, GA
Interstitial Pneumonia with Autoimmune Features 12:40 Exploring Asthma Health Care Utilization Data to Reduce
A.O. Adegunsoye, MD, MS, Chicago, IL the Elevated Risk During the Pandemic
O. Idubor, MD, Atlanta, GA

NATIONAL CENTER FOR ENVIRONMENTAL HEALTH/CDC 12:50 Volatile Organic Compounds (VOCs) in Low-Income
Housing in a Multi-Site Study
OUTSIDE ORGANIZATION SESSION G. Chew, ScD, Atlanta, GA

L17 ENVIRONMENTAL HEALTH EQUITY

VETERANS HEALTH ADMINISTRATION (VA)
UNDER THE RUBRIC OF VITAL
CONDITIONS OUTSIDE ORGANIZATION SESSION
12:00 p.m. - 1:00 p.m.
Target Audience
L18 VA’S APPROACH TO POST-DEPLOYMENT
Clinicians who seek to understand how environmental health equity affects RESPIRATORY HEALTH: RESEARCH,
a patient’s risk to exposures that result in adverse respiratory health. CLINICAL CARE AND EDUCATION
Objectives 12:00 p.m. - 1:00 p.m.
At the conclusion of this session, the participant will be able to: Target Audience
• improve ATS member’s knowledge about environmental conditions Target audience includes: VA and non-VA providers of lung health; VA
related to lung health in vulnerable populations. and non-VA pulmonary researchers; clinicians/scientists interest in
environmental and occupational health; military Veterans and service
• learn new findings about environmental health conditions that can inform members
ATS members about underlying factors (e.g., vital conditions) that may
influence their patients’ risk. Objectives
At the conclusion of this session, the participant will be able to:
• raise awareness about diversity and health equity issues related to
respiratory health.

ATS 2023 • Washington, DC

TUESDAY • MAY 23 REGISTER NOW 71

• define new strategies to manage the care of Veterans with This session will provide an update on the NHLBI Prevention and Early
deployment-related exposures Treatment of Acute Lung Injury (PETAL) clinical trials network. The
session will describe the structure and goals of the PETAL network, an
• describe new findings about VA research on military exposures and
overview of progress in ongoing studies, opportunities for additional
respiratory health.
studies using PETAL data and biospecimens, and results of studies to
• integrate/incorporate new guidelines and requirements from the date.
PACT Act of 2022 into current practice.
Chairing: J.P. Kiley, Ph.D., Bethesda, MD
Respiratory health of U.S. Veterans, in particular adverse effects related
R.G. Brower, MD, Baltimore, MD
to military deployment, is a priority area for the Department of Veterans
Affairs (VA). Major research, clinical, and educational efforts are 12:00 PETAL Overview
underway – many of which impact the ATS membership, both within R.G. Brower, MD, Baltimore, MD
and outside of the VA, who provide care to Veterans and 12:12 Update on the CLOVERS trial
servicemembers and/or conduct research on inhalational exposures. I.S. Douglas, MD, FRCP, Denver, CO
This session will provide updates on ongoing research and clinical
programs, as well as inform all stakeholders on the implications of the 12:24 Update on the ASTER trial
new Congressional Honoring our Promise to Address Comprehensive M.A. Matthay, MD, San Francisco, CA
Toxics Act of 2022 (PACT Act). 12:36 Update on the CORAL Studies
C.T. Hough, MD, MSc, Portland, OR
Chairing: M.J. Falvo, PhD, East Orange, NJ
E. Garshick, MD, West Roxbury, MA 12:48 Accessing PETAL Data, Images, and Specimens
P.D. Blanc, MD, San Francisco, CA I.D. Peltan, MD, MSc, Murray, UT
12:00 Military Occupational and Environmental Exposures
E. Garshick, MD, West Roxbury, MA NIAID SYSTEMS BIOLOGY OF ANTIMICROBIAL
12:12 Best Practices for the Evaluation the Dyspneic Veteran RESISTANCE
A.M. Sotolongo, MD, East Orange, NJ
12:24 The Airborne Hazards and Open Burn Pit Registry OUTSIDE ORGANIZATION SESSION
M.J. Falvo, PhD, East Orange, NJ
L20 SYSTEMS BIOLOGY FOR ACUTE
12:36 Impact of the PACT Act for VA and non-VA Providers
RESPIRATORY INFECTIONS
P. Hastings, DO, Washington, DC
12:50 Summary and Question/Answer Session 12:00 p.m. - 1:00 p.m.
P.D. Blanc, MD, San Francisco, CA Target Audience
Basic and translational researchers interested in a systems biology
approach to lung pathogens and the host response to them.
DIVISION OF LUNG DISEASES, NHLBI/NIH Objectives
OUTSIDE ORGANIZATION SESSION At the conclusion of this session, the participant will be able to:
• apply a systems biology approach to studying clinical infectious
L19 NHLBI PREVENTION AND EARLY disease outcomes
TREATMENT OF ACUTE LUNG INJURY • define strategies to improve ability to model lung immunity
(PETAL) NETWORK • be aware of NIH resources for studies of host immunity and
12:00 p.m. - 1:00 p.m. microbial pathogenesis
Target Audience The NIH/NIAID uses a variety of mechanisms to support research on
Practicing critical care and emergency medicine clinicians and clinical respiratory infections, including influenza, SARS-CoV-2, fungi, and
researchers would benefit from this session antibiotic resistant bacterial pathogens. A systems biology approach to
Objectives these pathogens, resultant host response, and diseases relevant to the
At the conclusion of this session, the participant will be able to: pulmonary and critical care community will be illustrated.

• understand the goals and structure of the PETAL network Chairing: L. Brown, PhD, Rockville, MD
• understand the questions being addressed in PETAL and the 12:00 NAIAD’s Systems Biology Program in Infectious
design/conducts of the studies Diseases
R. Shabman, PhD, Rockville, MD
• learn new findings and results of PETAL studies

ATS 2023 • Washington, DC

72 REGISTER NOW TUESDAY • MAY 23

12:15 Influenza Viral-Host Interactions

A. Garcia-Sastre, PhD, New York, NY MEET THE EXPERT SEMINARS
12:35 Host-Pathogen Relationship in Severe Pneumonia

12:55
R.G. Wunderink, MD, Chicago, IL
Questions and Panel Discussion
L. Brown, PhD, Rockville, MD
R Pre-registration and additional fees required. Attendance is limited.
$100 Member/Non-Members
$70 LMIC Member/LMIC Non-Members
12:00 p.m. - 1:00 p.m.
MTE37 EXERCISE TEST IN NEW ERA: UPDATED QUALITY IN
DIVISION OF LUNG DISEASES, NHLBI/NIH PULMONARY REHABILITATION AFTER COVID-19
A.E. Holland, PT, PhD, Melbourne, Australia
OUTSIDE ORGANIZATION SESSION
MTE38 REFRACTORY SARCOIDOSIS: WHEN AND HOW TO USE
L21 NEW FINDINGS FROM THE TNF-INHIBITORS
SUBPOPULATIONS AND INTERMEDIATE W.E. James, MD, Charleston, SC
OUTCOME MEASURES IN COPD II MTE39 NAVIGATING SOCIAL MEDIA FOR HEALTHCARE
(SPIROMICS II) STUDY PROFESSIONALS
L. Santhosh, MD, MEd, San Francisco, CA
12:00 p.m. - 1:00 p.m. N. Seam, MD, ATSF, FACP, Bethesda, MD
Target Audience C. Gao-Howard, MD, Chicago, IL
Researchers, medical trainees, those with an interest in COPD
MTE40 CYSTIC FIBROSIS: CLINICAL CHALLENGES IN THE ERA
pathogenesis
OF HIGHLY EFFECTIVE MODULATOR THERAPY
Objectives C.M. Bojanowski, MD, MSCR, New Orleans, LA
At the conclusion of this session, the participant will be able to:
MTE41 PLAYING AT AN AWAY FIELD: REAL LIFE LESSONS
• learn about natural history of smokers with respiratory symptoms FOR INTERNATIONAL MEDICAL GRADUATES WHO ARE
• learn about biomarkers of COPD PURSUING CLINICIAN SCIENTIST TRACK
N. Al Nasrallah, MD, Indianapolis, IN
• learn about social determinants influence on respiratory outcomes R.F. Machado, MD, Indianapolis, IN
SPIROMICS II is an NHLBI-sponsored study that supports the T. Lahm, MD, ATSF, Denver, CO
prospective collection and analysis of phenotypic, biomarker, genetic, C.A. Hage, MD, ATSF, Pittsburgh, PA
genomic, and clinical data from subjects with COPD for the purpose of MTE42 SMOKING RELATED INTERSTITIAL LUNG DISEASES
identifying subpopulations and the biological underpinnings of clinical M. Porteous, MD, MSCE, Philadelphia, PA
phenotypes in COPD. Participants in this session will learn about the
progress in SPIROMICS II including results and analyses of data. MTE43 ORGANS-ON-CHIPS FOR THE LUNGS: PAST, CURRENT
AND FUTURE
Chairing: L. Postow, PhD, Bethesda, MD K. Hajipouran Benam, PhD, Pittsburgh, PA
P. Woodruff, MD, MPH, San Francisco, CA MTE44 VIRTUAL PULMONARY REHABILITATION: IDENTIFYING
12:00 Redefining Therapy in Early COPD (RETHINC) KEY STRATEGIES AND CONQUERING THE CHALLENGES
M.K. Han, MD, MS, ATSF, Ann Arbor, MI TO ESTABLISHING A SUCCESSFUL PROGRAM
S.K. Huang, MD, Ann Arbor, MI
12:12 Bronchodilator Responsiveness in Smoked
Tobacco-Exposed Persons with or without COPD MTE45 CENTRAL SLEEP APNEA, PATHOPHYSIOLOGICAL
S. Fortis, MD, Iowa City, IA CLASSIFICATION AND RELATED MANAGEMENT
S. Javaheri, MD, Cincinnati, OH
12:24 Variation in Mendelian Genes and Risk for COPD
V.E. Ortega, MD, PhD, ATSF, Scottsdale, AZ
12:36 Clinical Relevance of Airway Mucin (MUC5AC and
MUC5B) Concentrations in COPD
J. Kim, MD, MS, Charlottesville, VA
12:48 SPIROMICS Review and Summary
P. Woodruff, MD, MPH, San Francisco, CA

ATS 2023 • Washington, DC

TUESDAY • MAY 23 REGISTER NOW 73

CLINICAL
CLINICAL TOPICS IN PULMONARY MEDICINE

C82 BEYOND THE LUNG: ADDRESSING

COMORBIDITIES IN CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
Assembly on Clinical Problems
2:15 p.m. - 3:45 p.m.
Target Audience
Providers of lung health serving patients with COPD, Individuals
involved in clinical or research activities related to COPD
Objectives
Tuesday Afternoon, May 23 At the conclusion of this session, the participant will be able to:
• describe the burden and clinical implications of comorbidities in
patients with COPD
CLINICAL • integrate comorbidity screening into the current management of
COPD patients
ADULT CLINICAL CORE CURRICULUM
• recognize research gaps in the management of COPD comorbidities

CC4 CRITICAL CARE CLINICAL CORE This session will focus on the prevalence, impact, and burden of
CURRICULUM comorbidities in chronic obstructive pulmonary disease, including a
discussion of challenges and opportunities related to comorbidity
Education Committee screening in patients with COPD. This session also includes a more
2:15 p.m. - 3:45 p.m. in-depth discussion of the more common COPD comorbidities, specifically
depression, cardiovascular disease, and muscle dysfunction.
Target Audience
Clinicians who are engaged in maintenance of certification activities Chairing: A. Agusti, MD, Barcelona, Spain
Objectives N. Putcha, BA, MD, Baltimore, MD
At the conclusion of this session, the participant will be able to: J.K. Krishnan, MD, MBA, MSc, New York, NY
• describe updates in the diagnosis and management of bacterial and 2:15 Introduction
viral respiratory infections A. Agusti, MD, Barcelona, Spain
• identify best practices for treating infections in critically ill 2:18 Patient Perspective
immunosuppressed patients Speaker To Be Announced
• describe diagnosis and management of hospital acquired infections 2:23 The Burden and Impact of Comorbidities in COPD
in the intensive care unit M.J. Divo, MD, MPH, Boston, MA
2:37 Anxiety and Depression in COPD: Prevalence, Risk
Chairing: S. Ahmed, MD, Albuquerque, NM
Factors, and Clinical Implications
D. Kelm, MD, Rochester, MN
V. Kim, MD, ATSF, FAASM, Philadelphia, PA
E. Kilb, MD, Charleston, SC
2:51 Cardiovascular Disease in COPD: Burden, Mechanisms,
2:15. Rejecting Infection: Treatment of Patients After
and Implications for Clinical Practice
Transplantation
J.K. Quint, FRCP, MSc, PhD, London, United Kingdom
A. Lawrence, MD, Dallas, TX
3:05 Skeletal Muscle Dysfunction in COPD: Mechanisms and
2:40 HAART-less: Fighting Opportunistic Infections in HIV
Implications
S. Sellers, MD, MSCR, Chapel Hill, NC
H.B. Rossiter, PhD, Torrance, CA
3:05 Gut with the Program: What Every Intensivist Needs to
3:19 Comorbidity Screening in COPD: Challenges and
Know About Abdominal Infections
Opportunities
J. Davis, MD, Ithaca, NY
J. Bon, MD, MS, ATSF, Pittsburgh, PA
3:30 Questions and Answers

ATS 2023 • Washington, DC

74 REGISTER NOW TUESDAY • MAY 23

3:33 Panel Discussion 2:55 PRO: BAL for Lymphocytosis Should be Performed in
N. Putcha, BA, MD, Baltimore, MD Patients with New Onset Fibrotic ILD
T. Kulkarni, MD, MPH, Birmingham, AL
3:05 CON: 3. BAL for Lymphocytosis Should Be Performed in
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
Patients with New Onset Fibrotic ILD
CLINICAL TOPICS IN PULMONARY MEDICINE N. Chaudhuri, MBChB, PhD, Ulster , Ireland
3:15 PRO: IPF is a Disease of the Recent Past
C83 PRO/CON: HOT TOPICS IN INTERSTITIAL G. Raghu, MD, Seattle, WA
LUNG DISEASE 3:25 CON: IPF is a Disease of the Recent Past
Assemblies on Clinical Problems; Behavioral Science and Health J. Behr, MD, Munchen, Germany
Services Research 3:35 Question and Answer
2:15 p.m. - 3:45 p.m.
Target Audience CLINICAL
Clinicians, researchers, trainees and industry stake-holders interested
in interstitial lung disease CRITICAL CARE TRACK
Objectives
At the conclusion of this session, the participant will be able to: C84 CARDIAC ARREST: NEW SCIENCE AND
• analyze and understand IPF clinical trial results and endpoints and how CHANGING GUIDELINES
these affect clinical practice and future research efforts Assembly on Critical Care
• integrate available data on formal testing and treatment of 2:15 p.m. - 3:45 p.m.
gastroesophageal reflux in progressive fibrotic lung disease in to clinical
Target Audience
practice
Clinicians who treat patients experiencing in-hospital or out-of-hospital
• gauge the risks and potential benefits of bronchoalveolar lavage for cardiac arrest or who are interested in the latest evidence and clinical
patients with fibrotic lung disease practice standards on this topic
This session will feature PRO/CON debates on 4 topics in ILD that are Objectives
relevant to cutting edge clinical practice and research. These will include the At the conclusion of this session, the participant will be able to:
utility of bronchoalveolar lavage in fibrotic lung disease, change in FVC over • understand the evidence (or in some cases lack thereof) behind
3 months as a clinical trial endpoint in IPF, formal testing for acid reflux in current cardiac arrest and post-arrest treatment guidelines
progressive pulmonary fibrosis, and whether IPF is an entity of the past.
• gain knowledge about long term outcomes of cardiac arrest and
Chairing: S. Montesi, MD, Boston, MA treatments that may improve these
G. Raghu, MD, Seattle, WA
• learn about cardiac arrest survivorship and the needs of individuals
2:15 PRO: Formal Testing for Abnormal Acid Reflux Should recovering after cardiac arrest
Be Performed in All Patients with IPF to Determine the
Randomized trials in cardiac arrest and post-arrest care have increased
Need for Anti-Reflux Therapy
dramatically in recent years. Critical care personnel are commonly
M.B. Scholand, MD, Salt Lake City, UT
involved in cardiac arrest resuscitation and the ICU care that most
2:25 CON: Formal Testing for Abnormal Acid Reflux Should patients who achieve return of spontaneous circulation require. The
Be Performed in All Patients with IPF to Determine the latest on cardiac arrest management and care of the post-arrest patient
Need for Anti-Reflux Therapy will be discussed, with a focus on topics where new evidence is
Speaker To Be Announced available or where significant controversy remains, and a survivor’s
2:35 PRO: Change in FVC at 3 Months is an Acceptable perspective will be presented.
Primary Endpoint for IPF Clinical Trials Chairing: K.M. Berg, MD, Boston, MA
Speaker To Be Announced R.E. Sell, MD, Seattle, WA
2:45 CON: 2. Change in FVC at 3 Months is an Acceptable A. Moskowitz, MD, Bronx, NY
Primary Endpoint for IPF Clinical Trials 2:15 Medications During Cardiac Arrest: Do They Really Help?
R.G. Jenkins, BM, MD, MRCP(UK), PhD, London, United L.W. Andersen, MD, PhD, Arhus, Denmark
Kingdom
2:35 E-CPR: Is It Ready for the Mainstream?
J. Bartos, MD, PhD, Minneapolis, MN

ATS 2023 • Washington, DC

TUESDAY • MAY 23 REGISTER NOW 75

2:55 Targeted Temperature Management in Confusing Times 2:24 Introduction - Brief Review of DEI in Pediatric
K.M. Berg, MD, Boston, MA Pulmonology Workforce
J. Rama, MD, MEd, Houston, TX
3:10 Addressing Disparities in Cardiac Arrest
S. Perman, MD, Aurora, CO 2:33 Importance of a Diverse Workforce - Addressing Health
Disparities
3:30 A Survivor’s Experience
B.J. Sheares, MD, MS, New Haven, CT
A. Uzendu, MD, Kansas City, MO
2:42 Importance of a Diverse Workforce - Addressing Health
Disparities
BEHAVIORAL • CLINICAL S. Lovinsky-Desir, MD, MS, New York, NY

SCIENTIFIC SYMPOSIUM 2:51 Results of the Needs Assessment Survey - Key Findings
R.T. Cohen, MD, MPH, Boston, MA
C85 A PATH TOWARDS A MORE DIVERSE 3:00 Results of the Needs Assessment Survey - Key Findings
AND INCLUSIVE WORKFORCE M. Udoko, MD, Aurora, CO

Assemblies on Pediatrics; Behavioral Science and Health 3:09 Strategies to Improve Recruitment and Retention of
Services Research URiM Trainees and Faculty
N. Stephenson, MD, Chapel Hill, NC
2:15 p.m. - 3:45 p.m.
3:18 Strategies to Improve Recruitment and Retention of
Target Audience
URiM Trainees and Faculty
Any provider of lung health (both adult and pediatrics); any
E. Forno, MD, MPH, ATSF, Pittsburgh, PA
multidisciplinary team member; trainees; ancillary support staff
3:27 What Can I Do - The Importance of Leadership, Allies
Objectives
and Advocates
At the conclusion of this session, the participant will be able to:
P.E. Moore, MD, ATSF, Nashville, TN
• define the current demographic breakdown of the pediatric
3:36 What Can I Do - The Importance of Leadership, Allies
pulmonology workforce in the United States (trainees and faculty)
and Advocates
and why diversity matters
I. Narang, MD, Toronto, Canada
• present barriers and opportunities for recruitment (student and
resident level), training (fellow and junior faculty level) and career
development (faculty level) of URiM in the field of pediatric BASIC • CLINICAL • TRANSLATIONAL
pulmonology
SCIENTIFIC SYMPOSIUM
• identify strategies and resources that have been or can be used to
improve the recruitment of URiM residents to the field, the
mentorship of trainees and junior faculty, and the career
C86 BEYOND THE TRANSCRIPTOME: HOW
development of URiM faculty in academic centers THE MULTI-“OMIC” UNIVERSE PROVIDES
NOVEL INSIGHTS INTO IPF/ILD
In response to the critical need to improve diversity, equity and inclusion
PATHOGENESIS
(DEI) in academic medicine, the Pediatric Assembly developed a DEI
Advisory Group in Spring 2020 with the overarching goal to increase Assemblies on Respiratory Cell and Molecular Biology; Allergy,
workforce diversity in the pediatric pulmonology community and Immunology and Inflammation; Clinical Problems
ultimately provide a framework for other medical specialties to follow. 2:15 p.m. - 3:45 p.m.
An ATS Pediatric Assembly Project Grant was funded in 2022, “ATS
Workshop on DEI and the Pediatric Pulmonology Workforce,” which Target Audience
included a needs assessment survey administered to the Pediatric Basic scientists, clinicians, translational researchers in pulmonary
Assembly in May 2022 and a virtual workshop. This symposium will fibrosis
present key findings from the survey and workshop. Objectives
At the conclusion of this session, the participant will be able to:
Chairing: T.A. Laguna, MD, MSci, Chicago, IL
R.T. Cohen, MD, MPH, Boston, MA • to understand and recognize how different biologic processes,
N. Stephenson, MD, Chapel Hill, NC including genomic, epigenomic, metabolomic, and microbiome
changes contribute to the development and pathogenesis of IPF/ILD
2:15 Introduction - Brief Review of DEI in Pediatric
Pulmonology Workforce • to learn how some of these diverse layers of biologic data can be
T.A. Laguna, MD, MSci, Chicago, IL integrated to derive new insights into IPF pathogenesis

ATS 2023 • Washington, DC

76 REGISTER NOW TUESDAY • MAY 23

• To identify challenges to integrating -omics data and identify areas pulmonary hypertension, clinicians and researchers needing instruction
for future research need in IPF/ILD in the evaluation and management of pulmonary hypertension
Studies utilizing RNA sequencing and single-cell approaches have Objectives
identified new cell types, genes, and pathways that contribute to the At the conclusion of this session, the participant will be able to:
pathogenesis of lung fibrosis. However, layers of biologic data beyond • describe the strengths and weaknesses of currently employed
the transcriptome, including genomic, epigenomic, proteomic, and outcome measures in pulmonary hypertension clinical trials
metabolomic studies have also enhanced our understanding of fibrotic
mechanisms. Understanding these multi-omic “universes” and how they • describe novel outcome measures that focus on “feels, functions,
interact with the environment and microbiome can help address and survives” and how these may be applied in PH clinical trials
fundamental questions regarding etiology, prognosis, and strategies for • more appropriately interpret and integrate results from clinical trials
personalized treatment. This session will highlight the current state of into clinical practice
knowledge in these other areas and attempt to integrate these data into
Multiple outcome measures are currently employed in the evaluation
a cohesive understanding of IPF pathogenesis.
and management of patients with pulmonary hypertension (PH),
Chairing: S.K. Huang, MD, Ann Arbor, MI creating confusion about which measure is most appropriate. In this
M.N. Ballinger, PhD, ATSF, Columbus, OH session, we will discuss the state of the art approach to outcomes
J. Kropski, MD, Nashville, TN assessment in PH through in-depth analyses of the current and future
measures of therapeutic response.
2:15 Into the Genomics and Epigenomics Universe of IPF
I.V. Yang, BS, PhD, Aurora, CO Chairing: S.C. Mathai, MD, MHS, Baltimore, MD
2:28 “ATAC”-ing IPF: how Understanding Chromatin Biology C.E. Ventetuolo, MD, MSCR, Providence, RI
Sheds Light on Fibrosis 2:15 Patient Speaker
G. Ligresti, PhD, Boston, MA Speaker To Be Announced
2:41 The next frontier: Proteomics of posttranslational 2:20 The Emperor Has No Clothes: Current Outcome
modifications in IPF Measures in PH
O. Eickelberg, MD, ATSF, Pittsburgh, PA S.C. Mathai, MD, MHS, Baltimore, MD
2:54 Importance of Metabolomic Changes in IPF 2:35 Patient Reported Outcomes: The Missing Piece in
Pathogenesis Assessment of PH Outcomes
Speaker To Be Announced H.M. Dubrock, MD, Rochester, MN
3:06 How Pharmacogenomics and Drug Discovery can 2:55 Walking in Circles: Functional Assessment as an
Provide New Insights into ILD Pathogenesis Outcome Measure in PH
Speaker To Be Announced J. Minhas, MD, MS, MBBS, Philadelphia, PA
3:19 Understanding the systemic microbiome in IPF 3:15 Risk Scores and Survival as Outcome Measures in PH
D.N. O’Dwyer, BM BCH, BMedSci, PhD, Ann Arbor, MI S.M. Kawut, MD, MS, ATSF, Philadelphia, PA
3:32 The Multi-Omic Universe: How Do We Integrate These 3:35 Panel Discussion
Datasets to Better Understand and Eventually Cure IPF
N. Kaminski, MD, ATSF, New Haven, CT
BASIC • CLINICAL • TRANSLATIONAL

BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM

SCIENTIFIC SYMPOSIUM C88 BIOLOGICAL IMPACT OF COVID-19

ACROSS THE LIFESPAN
C87 A MEASURED RESPONSE: ASSESSING
TREATMENT OUTCOMES IN PULMONARY Assemblies on Pediatrics; Allergy, Immunology and
Inflammation; Pulmonary Infections and Tuberculosis;
HYPERTENSION
Respiratory Cell and Molecular Biology
Assemblies on Pulmonary Circulation; Behavioral Science and
2:15 p.m. - 3:45 p.m.
Health Services Research; Clinical Problems
Target Audience
2:15 p.m. - 3:45 p.m. Pediatric pulmonologists, adult pulmonologists, and basic and
Target Audience translational researchers
Providers of patients with pulmonary hypertension, researchers in

ATS 2023 • Washington, DC

TUESDAY • MAY 23 REGISTER NOW 77

Objectives Objectives
At the conclusion of this session, the participant will be able to: At the conclusion of this session, the participant will be able to:
• to better understand the role and durability of passive immunity • increase incorporation of SDOH in current clinical and translational
against COVID-19 and other infections in newborns research
• understand immune responses in the airway in in circulation in • increase underrepresented minorities in research and increase
response to acute SARS-CoV-2 infection workforce needed to support patients impacted by SDOH
• to ascertain the clinical phenotype of long COVID-19 in kids and • align SDOH related research proposals with NIH funding priorities
adults and review the latest research on pathogenicity for SDOH related initiatives
Despite very early assumptions, children are not spared from Attendees will learn about cutting edge research on the impact of
COVID-19. However, biological and clinical responses vary SDOH on respiratory health, including patients affected by SDOH in
considerably across the age spectrum. In this session, we will assess clinical trials, reducing workforce gaps that exacerbate the impact of
biologic responses to SARS-CoV-2, which will serve as a foundation for SDOH on outcome, ATS advocacy activities targeting reduction in
comparisons with other common respiratory viruses. We will discuss the SDOH and NIH research priorities directed at mitigating the impact of
passive transfer of maternal antibodies to infants and their clinical SDOH on health outcomes.
protection; airway signals in the upper airway in response to infection in
children as compared to adults; hematologic biomarkers of severe Chairing: F. Afolabi, MD, Dallas, TX
infection in children and adults infected with SARS-CoV-2; and clinical S.C. Sweet, MD, PhD, Saint Louis, MO
and molecular findings in long COVID-19. 2:15 Addressing SDOH Through Research and Workforce
Development: The Time is NOW
Chairing: L. Yonker, MD, Boston, MA S.C. Sweet, MD, PhD, Saint Louis, MO
M.A. Mall, MD, Berlin, Germany 2:20 Cutting Edge Research: The Impact of SDOH on
2:15 Passive Immunity in Neonates Respiratory Disease, Sleep, Critical Illness, and Recovery
A. Edlow, MD, MSc, Boston, MA S. Jain, MD, New Haven, CT

2:35 Airway Responses to SARS-CoV-2 2:35 Addressing Maslow’s Hierarchy: Integrating SDOH in
M.A. Mall, MD, Berlin, Germany Research
T. Winders, MBA, Vienna, VA
2:55 Hematologic Markers of Severe COVID-19 and MISC
O. Badaki-Makun, MD CM, PhD, Baltimore, MD 2:50 The Workforce Meets SDOH
I.L. Riley, MD, MPH, Durham, NC
3:15 Long COVID-19
3:05 Moving the SDOH Needle: Partnering with Patients and
S.A. Mcgrath-Morrow, MD, Philadelphia, PA Other Organizations to Advocate for Policy Change
3:35 Tying it Together E. Sward, BA, MA, Washington, DC
L. Yonker, MD, Boston, MA 3:20 The Next Frontier: NIH Priorities and Resources to Address
SDOH
M. Freemer, MD, MPH, Bethesda, MD
BEHAVIORAL • CLINICAL • TRANSLATIONAL
3:35 Panel Discussion
SCIENTIFIC SYMPOSIUM
TRANSLATIONAL
C89 ACHIEVING HEALTH EQUITY: REDUCING
THE IMPACT OF SDOH THROUGH SCIENTIFIC SYMPOSIUM
RESEARCH AND ADVOCACY
Assemblies on Behavioral Science and Health Services Research; C90 DOUBLE TROUBLE: AIR POLLUTANTS
Nursing; Pediatrics; Sleep and Respiratory Neurobiology; Health AND TUBERCULOSIS
Equity and Diversity Committee; Health Policy Committee;
Assemblies on Environmental, Occupational and Population
International Health Committee
Health; Behavioral Science and Health Services Research;
2:15 p.m. - 3:45 p.m. Pulmonary Infections and Tuberculosis; International Health
Target Audience Committee
Interprofessional healthcare providers including clinicians, health 2:15 p.m. - 3:45 p.m.
system administrators, researchers focused on health care delivery
Target Audience
science
Clinicians in pulmonary, infectious disease, environmental and

ATS 2023 • Washington, DC

78 REGISTER NOW TUESDAY • MAY 23

occupational health fields, as well as PhD scientists, and those working

in global health
Objectives
At the conclusion of this session, the participant will be able to:
• raise awareness about the emerging epidemiologic and mechanistic
evidence that suggests a causal relationship between air pollution
exposures, tuberculosis development and worsened treatment
outcomes
• review the state of the science for air pollution exposure assessment
approaches, technologies and optimal measurement strategies
• explore translation of scientific discovery into actionable health
preventative steps
This session reviews the current epidemiologic and mechanistic
knowledge on associations between exposures to air pollution, tobacco
smoke and risk for tuberculosis, three eminent health challenges of
global importance, and how exposure risks relate to social determinants
of health. Addressing the need for continued research on exposure
dose response relationships as well as for translation of findings into
regulatory policies, the session also discusses pitfalls and state of the
art of exposure assessments as well as the translation of scientific
findings into advocacy for policy change.

Chairing: C.M. North, MD, MPH, Boston, MA

S. Schwander, MD, PhD, Piscataway, NJ
2:15 The Global State of Air Pollution and Tuberculosis: What
Does the Epidemiology Show?
S. Carroll, BSc, Montreal, Canada
2:30 The State of the Art for Characterizing Air Pollution
Exposure Among People at Risk for Tuberculosis
Q. Meng, PhD, Reno, NV
2:45 The Influence of Social Determinants of Health on Air
Pollution Exposure and Tuberculosis Risk - Triple Trouble
in Resource-Limited Settings
L. Atuyambe, PhD, Kampala, Uganda
3:00 Mechanistic Evidence - Air Pollutant Effects on Immune
Responses to Mycobacterium Tuberculosis: Is the Sum
Greater Than the Parts?
S. Sarkar, PhD, Piscataway, NJ
3:15 Vaping and Smoking - the “Other Air Pollutants”
R.N. Van Zyl Smit, MBChB, PhD, ATSF, Cape Town, South
Africa
3:30 So, Air Pollutants Are Making Tuberculosis Worse - Now
What? Activism and Policy Change
N. Mistry, MD, Mumbai, India

2:15 p.m. - 4:15 p.m.

Oral And Poster Presentations Of Scientific
Research And Case Reports. Abstract Sessions
Will Be Published In The Final Program.

ATS 2023 • Washington, DC

WEDNESDAY • MAY 24 REGISTER NOW 79

11:00 a.m. - 12:00 p.m.

MTE53 WHAT ARE THE REASONS FOR THE NEGATIVE
RESULTS OF RCTS IN OSA
S. Javaheri, MD, Cincinnati, OH
MTE54 UNDERSTANDING SEVERE AND
STEROID-REFRACTORY IMMUNE CHECKPOINT
INHIBITOR PNEUMONITIS
K. Ho, MD, Columbus, OH
J.D. Possick, MD, New Haven, CT
MTE55 RUNNING AN EFFECTIVE INTERSTITIAL LUNG DISEASE
MULTIDISCIPLINARY MEETING: REACHING THE GOLD
STANDARD
E. Valenzi, MD, Pittsburgh, PA
C.T. Lee, MD, Chicago, IL
Wednesday Morning, May 24 MTE56 COMPLEX IN VITRO MODELS OF THE LUNG: BRIDGING
THE GAP BETWEEN DISEASE COMPLEXITY AND
THERAPEUTICS
E.T. Osei, PhD, Kelowna, Canada
MEET THE EXPERT SEMINARS J.K. Burgess, BSc, PhD, ATSF, Groningen, Netherlands
M. Koenigshoff, MD, PhD, ATSF, Pittsburgh, PA
R Pre-registration and additional fees required. Attendance is limited.
$100 Member/Non-Members
$70 LMIC Member/LMIC Non-Members.
9:15 a.m. - 10:15 a.m.
MTE57 GO TEAM! APPLYING TEAM SCIENCE PRINCIPLES FOR
EFFECTIVE INTERPROFESSIONAL LEADERSHIP
S. Cotton, BSN, RN, CCRN, San Diego, CA
J.B. Scott, PhD, RRT, RRT-ACCS, Chicago, IL
MTE47 THE POWER OF TWITTER W.C. Mcguire, MD, MPH, La Jolla, CA
Speaker To Be Announced M.M. Lee, MD, ATSF, FCCP, FACP, Los Angeles, CA
MTE48 ADVOCACY IN LUNG HEALTH MTE58 OVERVIEW OF BRONCHIOLAR DISORDERS
N. Solanki, MD, Cleveland, OH D.C. Gomez Manjarres, MD, Gainesville, FL
D.C. Patel, DO, MBA, Gainesville, FL
MTE49 PHENOTYPING SYSTEMIC SCLEROSIS ASSOCIATED
PULMONARY HYPERTENSION MTE59 MOLECULAR DIAGNOSTICS IN SEVERE PNEUMONIA:
R.G. Argula, MBBS, MPH, Charleston, SC THE EVIDENCE AND CASE-BASED DISCUSSION OF
CLINICAL IMPLEMENTATION
MTE50 CONTROVERSIES IN THE MANAGEMENT OF PATIENTS
C. Pickens, MD, Chicago, IL
WITH CCHS: UPDATES IN MANAGEMENT
R. Wunderink, MD, Chicago, IL
I.A. Perez, MD, ATSF, Los Angeles, CA
A.S. Kasi, MD, Atlanta, GA MTE60 EXTRACORPOREAL MEMBRANE OXYGENATION FOR
CARDIAC ARREST: WHEN, WHY, AND HOW
MTE51 FAMILIAL PULMONARY FIBROSIS
J. Tonna, MD, MS, Salt Lake City, UT
D. Zhang, MD, MS, New York, NY
C. Newton, MD, MS, Dallas, TX MTE61 FROM FEATHERS TO ANTIFIBROTICS: EXPOSURES,
DIAGNOSIS, AND TREATMENT IN HYPERSENSITIVITY
MTE52 LEVERAGING BIG DATA TO BRIDGE THE
PNEUMONITIS
KNOWLEDGE-OUTCOME GAPS IN RARE LUNG
B. Flashner, MD, Boston, MA
DISEASE
B. Kaul, MD, San Francisco, CA
H.R. Collard, MD, MS, San Francisco, CA

ATS 2023 • Washington, DC

80 REGISTER NOW WEDNESDAY • MAY 24

patients with pulmonary fibrosis and caregivers of patients with

YEAR IN REVIEW pulmonary fibrosis.
Objectives
D1 CLINICAL YEAR IN REVIEW 4 At the conclusion of this session, the participant will be able to:

8:00 a.m. - 9:30 a.m. • describe the mechanisms of cough and treat cough in patients with
pulmonary fibrosis
Target Audience
Pulmonary, critical care and sleep providers. The program will discuss • to refer patients with pulmonary fibrosis to ongoing clinical trials
general topics of interest to a broad group of providers, inside and • measure cough in a standardized manner
outside of these subspecialties. The program is relevant to not only
clinicians, but also to researchers and administrators This session will focus on the pathobiology, approach to treatment, the
role of cough as a potential biomarker of disease activity/progression
Objectives and current landscape of recent on ongoing research on cough in
At the conclusion of this session, the participant will be able to: patients with pulmonary fibrosis.
• apply new clinical research knowledge to clinical practice.
Chairing: K.R. Flaherty, MD, Ann Arbor, MI
• apply new findings about key conditions in pulmonary, critical care L.H. Lancaster, MD, Nashville, TN
and sleep. K.K. Brown, MD, Denver, CO
• learn new strategies to manage the care of common conditions in 8:00 Understanding the Pathobiology of Cough in Patients
pulmonary, critical care, and sleep. with Pulmonary Fibrosis
Pulmonary, critical care and sleep providers. The program will discuss S.S. Birring, MD, London SE5 9RS, United Kingdom
general topics of interest to a broad group of providers, inside and 8:20 Approach to Patient with Pulmonary Fibrosis and
outside of these subspecialties. The program is relevant to not only Cough, What Can We Learn from the Chronic Cough
clinicians, but also to researchers and administrators. Field?
M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands
Chairing: R.J. Shah, MD, MSCE, San Francisco, CA
J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil 8:40 Cough as a Prognostic Biomarker, Should We Be
S. Auld, MD, MSc, Atlanta, GA Formally Measuring in Clinical Practice?
T.M. Maher, MD, MSc, PhD, FRCP, Los Angeles, CA
8:00 Lung Transplant
S. Agbor, MD, PhD, Bethesda, MD 9:00 Cough in Pulmonary Fibrosis Clinical Trials: Nothing to
Sneeze At
8:23 Medical Education
S.D. Nathan, MD, Falls Church, VA
J.C. Ferreira, MD, PhD, ATSF, Sao Paulo, Brazil
9:20 Wrap up - Q & A with All Faculty and Audience
8:45 Health Disparities
K.K. Brown, MD, Denver, CO
D.C. Ashana, MD, MBA, MS, Durham, NC
9:08 CF/non-CF bronchiectasis
S. Visser, Camperdown, Netherlands CLINICAL • TRANSLATIONAL
CLINICAL TOPICS IN PULMONARY MEDICINE
CLINICAL
D3 IMAGING BIOMARKERS OF DISEASE
CLINICAL TOPICS IN PULMONARY MEDICINE
MODIFICATION IN COPD
D2 COUGH IN PULMONARY FIBROSIS - Assemblies on Clinical Problems; Respiratory Structure and
ANNOYING SYMPTOM OR Function
DRIVER/MARKER OF DISEASE 8:00 a.m. - 9:30 a.m.
PROGRESSION? Target Audience
Assembly on Clinical Problems Providers of lung health, clinical researchers, those designing and/or
conducting clinical trials, those designing and evaluating therapies for
8:00 a.m. - 9:30 a.m. COPD, industry executives, government and granting administrators
Target Audience Objectives
Healthcare providers that care for patients with fibrotic lung diseases, At the conclusion of this session, the participant will be able to:
researchers studying cough in patients with pulmonary fibrosis,

ATS 2023 • Washington, DC

WEDNESDAY • MAY 24 REGISTER NOW 81

• define new applications of quantitative imaging for the management • to summarize the latest research on long-term outcomes after
of COPD in clinical practice critical illness, including describing newly recognized key domains of
• apply quantitative imaging approaches to guide pharmacotherapy
survivorship
and lung volume reduction for individuals with COPD • to examine the evidence for interventions aimed at improving
• incorporate quantitative CT in shared decision making for COPD
long-term outcomes in ICU patients and explore barriers to their
management with patients and families success
• to understand the strengths and limitations of commonly used
Disease progression and outcomes in COPD have been classically
measured by assessing lung function and clinical symptoms. Advanced measures to assess the long-term impact of ICU interventions
quantitative imaging is increasingly used to quantify the features of We aim to provide an update on the latest evidence and persistent
COPD, specifically emphysema, air trapping, and airway abnormality. challenges surrounding the field of improving long-term outcomes in
Attendees of this session will understand how imaging biomarkers are critically ill patients. In recent years, trials aimed at improving long-term
currently related to disease modification framework in COPD related to outcomes have largely been unsuccessful, suggesting that it may be
prevention and treatments, such as: early diagnosis, inhaled therapies, time for a critical re-examination and “reboot” of our current conceptual
surgical and bronchoscopic interventions, and pulmonary rehabilitation. models. In this session, speakers will discuss the current evidence
Furthermore, this session will discuss the advanced methodologies for base, lessons learned, implications for current practice, and crucial next
functional lung imaging in contrast and combination with physiological steps to advance the field forward.
assessment of disease biomarkers.
Chairing: M. Hua, MD, MS, New York, NY
Chairing: S.P. Bhatt, MD, MSPH, Birmingham, AL C.L. Auriemma, MD, Philadelphia, PA
T. Siddharthan, MD, Miami, FL N. Khandelwal, MD, MS, Seattle, WA
8:00 Ventilation Heterogeneity in COPD Patients 8:00 Is It the Forest or the Trees: Prioritizing Short Versus
T. Siddharthan, MD, Miami, FL Long-Term Outcomes After Critical Illness
8:10 Screening and Detection of COPD C.E. Cox, MD, MPH, MHA, Durham, NC
R. Vliegenthart, MD, EBCR, FNASCI, FICIS, Groningen, 8:13 “She Just Needs More Rehab:” When and Why
Netherlands Aggressive Rehabilitation May Not Be Enough
8:30 Heterogeneity of Ventilation in COPD J. Falvey, PhD, DPT, PT, Baltimore, MD
I. Barjaktarevic, MD, PhD, Los Angeles, CA 8:26 Money Matters: Is Financial Hardship a Missing Key
8:50 Imaging for Bronchoscopic Lung Volume Reduction Outcome in Post-Critical Illness Studies?
Valve Targeting N. Khandelwal, MD, MS, Seattle, WA
M.G. Lester, MD, Nashville, TN 8:39 Psychological Outcomes After Critical Illness: Is the Die
9:10 Panel Discussion and Closing Remarks Already Cast?
S.P. Bhatt, MD, MSPH, Birmingham, AL H. Prigerson, PhD, New York, NY
8:52 To Consult or Not to Consult?: Why Palliative Care May
or May Not Change Outcomes in Critically Ill Patients
CLINICAL D.B. White, MD, Pittsburgh, PA

CRITICAL CARE TRACK 9:05 The Glass is Half?: Prognosticating Long-Term

Outcomes
A. Law, MD, MSci, Boston, MA
D4 THE LONG AND WINDING ROAD: THE
FUTURE OF ICU OUTCOMES RESEARCH 9:18 A Bump or a Fork in the Road: the Broader Impact of
Critical Illness
Assemblies on Critical Care; Behavioral Science and Health T.J. Iwashyna, MD, PhD, Baltimore, MD
Services Research
8:00 a.m. - 9:30 a.m.
Target Audience
Early Career Professionals, Clinicians, Interprofessionals, Nurses
Objectives
At the conclusion of this session, the participant will be able to:

ATS 2023 • Washington, DC

82 REGISTER NOW WEDNESDAY • MAY 24

8:40 The Role of Multicomponent Interventions for Chronic

CLINICAL
Respiratory Disease Prevention and Management in
SCIENTIFIC SYMPOSIUM Low- and Middle-Income Countries.
C. Jenkins, MD, Sydney, Australia
D5 REVISITING BEST BUY INTERVENTIONS 9:00 Infections and Lung Development: the Link Between
FOR THE DIAGNOSIS AND MANAGEMENT Communicable and Non-Communicable Lung Disease
OF CHRONIC RESPIRATORY DISEASES IN H. Zar, MD, PhD, ATSF, Cape Town, South Africa
LOW- AND MIDDLE-INCOME COUNTRIES 9:20 Panel Discussion
W. Checkley, MD, PhD, Baltimore, MD
Assemblies on Clinical Problems; International Health Committee
8:00 a.m. - 9:30 a.m.
Target Audience BASIC • CLINICAL • TRANSLATIONAL
Pulmonary medicine researchers, Clinicians in low- and middle-income
countries.
SCIENTIFIC SYMPOSIUM

Objectives
D6 OBESITY-RELATED ASTHMA:
At the conclusion of this session, the participant will be able to:
MECHANISTIC STUDIES BEGIN TO
• review evidence and prioritize key risk factors for chronic respiratory INFORM THERAPEUTICS
diseases across a diverse range of LMICs.
Assemblies on Allergy, Immunology and Inflammation;
• identify chronic disease management strategies with greatest Respiratory Structure and Function
potential impact, feasibility, and sustainability in LMICs, i.e., best buy
interventions. 8:00 a.m. - 9:30 a.m.

• develop a comprehensive framework of best buy interventions that

Target Audience
Health care providers, translational and clinical science researchers,
mitigate risk factors and reduce risk for the development of chronic
trainees, advanced healthcare practitioners
respiratory diseases or aid in
Objectives
Chronic respiratory diseases are a significant but neglected public
At the conclusion of this session, the participant will be able to:
health problem in low- and middle-income countries. Moreover, current
best buy interventions recommended by the World Health Organization • to understand the cellular effects of obesity-mediated complications
are limited: they principally consist of inhaled bronchodilator therapy for on the lung
symptom management and mitigation of household air pollution. Yet • to understand the contribution of obesity-related metabolic
there are opportunities for primary and secondary prevention that could complications and that of therapeutics targeted to these metabolic
help both reduce the development of chronic respiratory diseases and complications to asthma outcomes
improve management. This session aims to identify current unmet
needs for chronic respiratory diseases in low- and middle-income • to understand the contribution of oxidative and nitrosative stress on
countries and identify other potential best buy interventions that can obesity-related asthma and the dietary interventions to ameliorate
improve diagnosis and management of chronic respiratory diseases. these effects
Obesity-related asthma is a well-established distinct asthma phenotype
Chairing: J. Hurst, MD, London, United Kingdom
that is poorly responsive to current asthma therapeutic approaches. The
W. Checkley, MD, PhD, Baltimore, MD
lack of responsiveness to medications highlights the need to identify
O.B. Ozoh, MBBS, ATSF, MSc, Lagos, Nigeria
alternative management strategies. This symposium will discuss
8:00 The Burden of Chronic Respiratory Diseases in Low- breakthrough findings over the past 2-3 years on biologic mechanisms
and Middle-Income Countries and Unmet Needs for their underlying obesity-related asthma that have directly informed
Diagnosis and Management therapeutic approaches distinct from traditional asthma management.
A.S. Buist, MD, MB, BCh, Portland, OR
Chairing: D. Rastogi, MBBS, MS, ATSF, Washington, DC
8:20 An Overview of Best Buy Interventions Recommended F. Holguin, MD, MPH, Aurora, CO
by the World Health Organization for the Diagnosis and
Management of Chronic Respiratory Diseases. 8:00 The Devil Is in the Detail: Exploring the Cellular Effects
S. Rylance, BMedSci, MBBS, PhD, Blantyre, Malawi of Obesity-Mediated Complications on Obesity-Related
Asthma
J.L. Ingram, PhD, ATSF, Durham, NC
8:15 Discussion

ATS 2023 • Washington, DC

WEDNESDAY • MAY 24 REGISTER NOW 83

8:18 Are Immune Perturbations Associated With professional organizations also identify gaps in such advocacy among
Obesity-Related Asthma Ready for Prime Time other health care professionals. This session will describe various
Therapeutics? routes for advocacy, provide training on advocating for public health
D. Rastogi, MBBS, MS, ATSF, Washington, DC issues, address interprofessional advocacy, and share exemplars of
incorporating advocacy activities into teaching and promotion portfolios.
8:33 Discussion
8:36 Is Obesity-Related Asthma a Bystander to Benefit From Chairing: A. Volerman, MD, Chicago, IL
Treatment Strategies for Obesity-Mediated Metabolic V. Balasubramaniam, MD, Madison, WI
Perturbations L.B. Gerald, PhD, MSPH, Tucson, AZ
A.E. Dixon, MA, BM BCH, ATSF, Burlington, VT 8:00 Framework for Advocacy in Medicine
8:51 Discussion L.B. Gerald, PhD, MSPH, Tucson, AZ
8:54 Can Dietary Supplements Be Repurposed to Address the 8:10 Legislative Advocacy: Stock Albuterol in Schools
Contribution of Oxidative Stress to Obesity-Related A. Volerman, MD, Chicago, IL
Asthma 8:22 Regulatory Advocacy: Ozone and Particulate Matter
F. Holguin, MD, MPH, Aurora, CO standards
9:09 Discussion M.B. Rice, MD, MPH, Boston, MA
9:12 The Role of Nitrosative Stress in Obesity-Related 8:34 Advocacy Through the Courts: Clean Air and Climate
Asthma: A New Arena for Therapeutic Development S. Colangelo, JD, Washington, DC
L.G. Que, MD, Durham, NC 8:46 Fostering Advocacy Among Students, Trainees, Faculty,
9:27 Discussion and Clinicians: A 3-Prong Approach
S.J. Crowder, PhD, RN, ATSF, Indianapolis, IN
8:58 Academic Advocacy and Promotion: How to Climb a
CLINICAL
Ladder Not Yet Built
SCIENTIFIC SYMPOSIUM V. Balasubramaniam, MD, Madison, WI
9:10 Question and Answer Panel
D7 WANT TO BE AN ADVOCATE FOR LUNG G. Ewart, MHS, Washington, DC
HEALTH? LEARN FROM SUCCESS!
Assemblies on Pediatrics; Behavioral Science and Health BASIC • TRANSLATIONAL
Services Research; Clinical Problems; Environmental,
Occupational and Population Health; Nursing; Pediatric Advocacy SCIENTIFIC SYMPOSIUM
Subcommittee
8:00 a.m. - 9:30 a.m. D8 UNDER THE MAGNIFYING GLASS: OMICS
AND DEEP PHENOTYPING IN
Target Audience
Pulmonary, critical care, and sleep providers as well as trainees, PULMONARY VASCULAR DISEASES
researchers, and public health professionals Assemblies on Pulmonary Circulation; Respiratory Cell and
Objectives Molecular Biology
At the conclusion of this session, the participant will be able to: 8:00 a.m. - 9:30 a.m.
• identify a framework for approaching advocacy Target Audience
• compare and distinguish the uses of various approaches to Researchers from undergraduate student to postdoc and faculty, and
advocate for issues of importance in the field of lung health PI Medical professionals from undergraduate to faculty

• understand how to leverage advocacy activities as part of teaching

Objectives
and to support a promotion portfolio At the conclusion of this session, the participant will be able to:
• define the novel unbiased and large scale Omics and phenotyping
The American Medical Association endorses advocacy, stating that
physicians must “advocate for the social, economic, educational and methods available to pulmonary vascular researchers
political changes that ameliorate suffering and contribute to human • increase understanding of pulmonary vascular cell phenotype and
well-being.” While physicians are well acquainted with their role as function through Omics, visualization and deep phenotyping
advocates for the individual patient, most have limited knowledge or
• acquire knowledge on how Omics and deep phenotyping can
experience with broad advocacy for public health. The literature and
influence the clinical-translational understanding of patients with

ATS 2023 • Washington, DC

84 REGISTER NOW WEDNESDAY • MAY 24

pulmonary vascular disease and can support precision-targeted physician-scientists, trainees, clinical fellows, junior-senior
therapy investigators, etc.
The last years have seen a remarkable growth in methods that allow Objectives
large scale insight into cell phenotypes, gene and protein changes. At the conclusion of this session, the participant will be able to:
These methods become increasingly common in the field of pulmonary • to learn on the newly and rapidly evolving paradigms about circadian
vascular research and carry great promise not only for a better clock regulation in innate immunity, sleep and pathogenesis of
understanding of the pathophysiology, but also for a phenotyping of chronic lung diseases
subtypes of patients as a prerequisite for precision medicine. The
session will demonstrate to the attendee how these methodologies can • to identify potential clock targets that can modulate cellular functions
be used to receive a holistic view on pulmonary vascular diseases and and molecular pathways essential for lung development and for the
thus lead to a better stratification of patients and a more targeted treatment and management of chronic inflammatory lung diseases
treatment. • to identify novel biomarkers that supports circadian disruption
causal-effect relationships in chronic lung diseases progression;
Chairing: L. Farkas, MD, Columbus, OH Develop novel clock-based targeted therapies that can ameliorate
G. Kwapiszewska, PhD, Graz, Austria pathophysiological phenotypes of chronic lung diseases
S.Y. Chan, MD, PhD, Pittsburgh, PA
This exciting Scientific Symposium explores the role of the circadian
8:00 Single Cell RNAseq Redefines Vascular Cell clock in the development of chronic lung disease. This session is fully
Heterogeneity in the Lung translational, providing a bench-to-bedside view of clock biology, basic
N. Kaminski, MD, ATSF, New Haven, CT mechanisms of circadian clock dysregulation in development of OSA,
8:15 Beyond RNA - Multi-Dimensional -Omics in the COPD, and IPF, and clinical translation drawing on results of
Pulmonary Circulation chronotherapy trials in asthma, showing the role of environmental
S.Y. Chan, MD, PhD, Pittsburgh, PA influences on circadian biology and learning from individuals with sleep
disorders. We have assembled an impressive and diverse group of
8:30 Advancing the Understanding of the Immune Response
speakers from across the globe and this promises to be an exceptional
and Inflammation in the Lung Through Omics
session.
C. Dela Cruz, MD, PhD, ATSF, New Haven, CT
8:45 PVDOMICs - Molecular-Based Phenotyping of Chairing: H. Durrington, PhD, MA, MBChB, Manchester, United
Pulmonary Vascular Diseases Kingdom
A. Hemnes, MD, ATSF, Nashville, TN I.K. Sundar, BSc, MSc, PhD, Kansas City, KS
N.N. Jarjour, MD, ATSF, CPE, Madison, WI
9:00 From Omics to Targeted Treatment Options in
M.P. Knauert, PhD, MD, New Haven, CT
Pulmonary Vascular Disease
M. Rabinovitch, MD, Stanford, CA 8:00 Sleep and Circadian Rhythms: Considerations for
Diagnosis, Monitoring and Treatment
9:15 Panel Discussion
V. Revell, PhD, Guildford, United Kingdom
8:15 Impact of Intermittent Hypoxia on Circadian
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL Dysregulation of Gene Expression and Physiology
D.F. Smith, MD, PhD, Cincinnati, OH
SCIENTIFIC SYMPOSIUM
8:30 Asthma… It’s a Matter of Time!
H. Durrington, PhD, MA, MBChB, Manchester, United
D9 IT’S ABOUT TIME! THE CIRCADIAN Kingdom
CLOCK IN LUNG DISEASE, FROM BENCH
TO BEDSIDE 8:45 Clock in the Lung: How Environmental Cues Tik Tok
I. Rahman, PhD, ATSF, Rochester, NY
Assemblies on Respiratory Structure and Function; Allergy,
9:00 Tik Tok of Pulmonary Fibrosis Using in Vitro and In Vivo
Immunology and Inflammation; Environmental, Occupational and
models
Population Health; Respiratory Cell and Molecular Biology; Sleep
I.K. Sundar, BSc, MSc, PhD, Kansas City, KS
and Respiratory Neurobiology
9:15 Bringing Circadian Biology to Medicine
8:00 a.m. - 9:30 a.m.
J.B. Hogenesch, PhD, Cincinnati, OH
Target Audience
Researchers interested in understanding the molecular mechanisms
that involve the circadian clock in chronic lung diseases, physicians,

ATS 2023 • Washington, DC

WEDNESDAY • MAY 24 REGISTER NOW 85

8:46 Pharmacotherapy in the Older Adult with Chronic Lung

BASIC • BEHAVIORAL • CLINICAL
Disease
SCIENTIFIC SYMPOSIUM A.L. Martirosov, PharmD, Detroit, MI
8:58 Frailty, Falls and Chronic Lung Disease
D10 AN AGE-FRIENDLY FRAMEWORK FOR A.M. Yohannes, PhD, ATSF, Azusa, CA
CARING FOR OLDER ADULTS WITH 9:10 Caring for Chronic Lung Disease Patients in Nursing
CHRONIC LUNG DISEASE Homes
Assemblies on Behavioral Science and Health Services Research; M.F. Griffith, MD, MPH, Aurora, CO
Pulmonary Rehabilitation 9:22 Moderated Q&A by Chairs
8:00 a.m. - 9:30 a.m.
Target Audience BASIC • CLINICAL • TRANSLATIONAL
Pulmonary providers, pharmacists, pulmonary rehabilitation providers,
and health policy makers who care for older adults with chronic lung SCIENTIFIC SYMPOSIUM
diseases
Objectives D11 THE EVOLVING ROLE FOR
At the conclusion of this session, the participant will be able to: IMMUNOTHERAPY IN LUNG CANCER
• define the components of age-friendly healthcare (4Ms) in chronic Assembly on Thoracic Oncology
lung disease
8:00 a.m. - 9:30 a.m.
• apply the 4M framework and understanding of the physiology of
Target Audience
aging to adapt diagnostic testing algorithms and treatment protocols
Clinicians and researchers who care for thoracic oncology patients
for older adults with and without geriatric syndromes
Objectives
• identify geriatrics assessments that should be routinely performed
At the conclusion of this session, the participant will be able to:
by pulmonologists or assessed by these experts prior to making
diagnosis or treatment decisions for chronic lung diseases • understand how immune checkpoint inhibitors are used to treat lung
cancer
Older adults are disproportionately affected by many chronic lung
diseases (e.g. COPD, asthma, bronchiectasis). Developing diagnostic • summarize recent updates in cancer immunotherapy for lung cancer
and treatment strategies for older adults in an age-friendly health • describe management approaches for difficult or refractory
system must consider diagnostic accuracy, likelihood of benefit, and the immune-related adverse events
unique needs of this population. The John A. Hartford Foundation and
the Institute for Healthcare Improvement have outlined a conceptual Our understanding of the role of the immune system in lung cancer has
framework for age-friendly healthcare delivery called the 4Ms – changed dramatically over the past couple decades. Immune
Medication, Mobility, Mentation, and What Matters. The proposed checkpoint inhibitors have revolutionized the treatment of lung cancer,
symposium includes a diverse group of interprofessional and leading to durable responses in a subset of non-small cell lung cancer
international experts in aging who will highlight the impact this patients. However, many patients with lung cancer fail to respond or
framework has on caring for patients with chronic lung disease. develop resistance to immune checkpoint inhibitors, highlighting the
need for novel immunotherapies. Immune checkpoint inhibitors are also
Chairing: M.F. Griffith, MD, MPH, Aurora, CO associated with toxicities that will be managed by pulmonologists and
L.J. Witt, MD, San Francisco, CA intensivists, such as pneumonitis. The speakers, all world-class experts
A.S. Iyer, MD, MSPH, Birmingham, AL in lung immuno-oncology, will provide perspective on this quickly
S. Jain, MD, New Haven, CT evolving field.
8:00 Public Advisory Roundtable Presentation Chairing: S. Shojaee, MD, MPH, Nashville, TN
8:10 Overview of The Age-Friendly Health System (4M) J. Deepak, MD, MBBS, FACP, Baltimore, MD
Framework M. Acunzo, PhD, Richmond, VA
M. Bellantoni, MD, Baltimore, MD 8:00 Introduction
8:22 Biology of Lung Aging S. Shojaee, MD, MPH, Nashville, TN
S. Krick, MD, PhD, Birmingham, AL 8:05 Immune Dynamics During Lung Cancer Development,
8:34 Diagnostic Dilemmas in Chronic Lung Disease for the from Premalignant to Invasive
Older Adult S.M. Dubinett, MD, Los Angeles, CA
J. Hurst, MD, London, United Kingdom

ATS 2023 • Washington, DC

86 REGISTER NOW WEDNESDAY • MAY 24

8:22 Adoptive T Cell Transfer and CAR T Cell Therapy for

Lung Cancer
S.M. Albelda, MD, Philadelphia, PA
8:39 Neoadjuvant Checkpoint Blockade for Lung Cancer
Immunotherapy
P. Forde, MBBCh, Baltimore, MD
8:56 Immune Escape and Contribution of Neutrophils to
Immune Checkpoint Inhibitor Treatment Failures
A.M. Houghton, MD, Seattle, WA
9:13 The Diagnosis and Management of Immune Checkpoint
Inhibitor-Related Pneumonitis
C.R. Sears, MD, ATSF, Indianapolis, IN

CLINICAL Wednesday Mid-day, May 24

ADULT CLINICAL CORE CURRICULUM
DIVISION OF LUNG DISEASES, NHLBI/NIH
CC5 PULMONARY CLINICAL CORE
CURRICULUM OUTSIDE ORGANIZATION SESSION
Education Committee
L22 THE NHLBI LUNG TRANSPLANT
10:00 a.m. - 11:30 a.m.
CONSORTIUM
Target Audience
Clinicians who are engaged in maintenance of certification activities 10:30 a.m. - 11:30 a.m.

Objectives Target Audience

Those with research interests involving the study of lung transplant
At the conclusion of this session, the participant will be able to:
donors or recipients.
• describe updates in the diagnosis and management of mild,
Objectives
moderate, and severe asthma in 2023
At the conclusion of this session, the participant will be able to:
• identify the local and global impact of one's environment on asthma
• learn about the impact of certain clinical practices on, and the value
management
of collecting particular data elements to inform, donor lung utilization
• describe best practices for asthma management in the pregnant and and early post-transplant outcomes in lung transplant recipients.
post-partum woman
• increase awareness among the broader lung transplant research
Chairing: G. Garrison, MD, Burlington, VT community of the availability of the consortium’s resources to
J. Cho, MD, Iowa City, IA support ancillary studies.
10:00 Everyday Asthma: Updates to the Diagnosis, Classification, • be able to more appropriately design and control for clinical
and Management of Mild to Moderate Asthma variables during the conduct of multi-site research studies involving
J. Barry, MD, MPH, San Diego, CA lung transplant donors or recipients.
10:25 Stepping on the Pedal: Approaches to the Management This session will review recent research findings generated by
of Severe and Uncontrolled Asthma investigators within the NHLBI Lung Transplant Consortium, which
L. Eggert, MD, Stanford, CA encompasses a series of observational cohort studies that aim to
understand the impact of site-specific lung transplant selection criteria
10:50 Exasperating Exacerbations: Management of Severe and clinical management strategies on donor lung utilization and/or
Asthma Exacerbations early post-transplant outcomes in recipients.
M.C. McGregor, MD, St. Louis, MO
11:15 Questions and Answers Chairing: M. Craig, PhD, Bethesda, MD
J.D. Christie, MD, MS, ATSF, Philadelphia, PA

ATS 2023 • Washington, DC

WEDNESDAY • MAY 24 REGISTER NOW 87

10:30 The NHLBI Lung Transplant Consortium Data Chairing: S.S. Nadadur, PhD, Research Triangle Park, NC
Coordinating Center B.D. Levy, MD, ATSF, Boston, MA
S.M. Palmer, MD, MHS, Durham, NC 10:30 Introduction
10:42 Clinical and Biological Factors Predicting Lung S.S. Nadadur, PhD, Research Triangle Park, NC
Transplant Textbook Outcomes 10:36 SPM Pathway Responses to Lung Environmental
L.D. Snyder, MD, Durham, NC Challenge
10:54 Peri-operative Factors That Drive Cell-Free B.D. Levy, MD, ATSF, Boston, MA
Hemoglobin-mediated Primary Graft Dysfunction 10:52 Role of Pro-Resolution Macrophages in Chronic Ozone
L.B. Ware, MD, ATSF, Nashville, TN Exposure Pulmonary Effectss
11:06 The Impact of Body Composition on Peri-Operative and D.L. Laskin, PhD, Piscataway, NJ
Patient-Centered Outcomes in Lung Transplantation 11:08 Arachidonic Acid Metabolic Pathways and Resolution
J.P. Singer, MD, MSci, san francisco, CA Versus Progression of the Cardiometabolic Toxicity
11:18 The Clinical and Molecular Impacts of Lung Primary Induced by Particulate Matter.
Graft Dysfunction J.A. Araujo, MD, PhD, Los Angeles, CA
J.F. Mcdyer, MD, Pittsburgh, PA 11:24 Discussion
S.S. Nadadur, PhD, Research Triangle Park, NC
NATIONAL INSTITUTE OF
ENVIRONMENTAL HEALTH SCIENCES, NIH AMERICAN LUNG ASSOCIATION
OUTSIDE ORGANIZATION SESSION AIRWAYS CLINICAL RESEARCH CENTERS
OUTSIDE ORGANIZATION SESSION
L23 INFLAMMATION RESOLUTION
PATHWAYS IN ENVIRONMENTAL L24 STUDY UPDATES FROM THE AMERICAN
PULMONARY HEALTH AND MORBIDITY LUNG ASSOCIATION’S AIRWAY CLINICAL
10:30 a.m. - 11:30 a.m. RESEARCH CENTERS NETWORK
Target Audience 10:30 a.m. - 11:30 a.m.
Clinicians, clinician scientists, basic research scientists, fellows and
Target Audience
residents
Physicians, clinical scientists, nurses, paraprofessionals, educators,
Objectives health care providers
At the conclusion of this session, the participant will be able to:
Objectives
• gain knowledge on how exposure to environmental At the conclusion of this session, the participant will be able to:
agents/chemicals may initiate and exacerbate preexisting • better counsel patients about the approach to management of
inflammatory status asthma in obese patients.
• role of chronic exposure to environmental agents in chronic lung
• describe the use of biomarkers for assessing the progression of
diseases emphysema.
• understanding of emerging and novel pathways involved in
• incorporate home spirometry testing in management of patients with
inflammation resolution lung disease.
The emerging interplay between unresolved inflammation and The purpose of the session is to discuss ongoing research initiatives
environmentally induced perturbations to inflammation resolution within the American Lung Association Airways Clinical Research
suggests exposure and inflammatory activation or exacerbation Centers network.
contributes to chronic lung disease progression. This session will
provide an overview on the current state-of-science on inflammation Chairing: L.J. Smith, MD, Chicago, IL
resolution biology, and how chronic exposure to air pollutants, ozone, R.A. Wise, MD, Baltimore, MD
and fine particulate matter impact these processes. It will also provide
10:30 Introduction
an overview on how NIEHS and other NIH Institutes encourage
L.J. Smith, MD, Chicago, IL
research in this area to support potential therapeutic and interventional
strategies aimed at promoting inflammation resolution to reduce 10:35 Relationship Between Cystic Fibrosis Transmembrane
environmental contributions to pulmonary morbidity and mortality. Conductance Regulator Function, Ventilation

ATS 2023 • Washington, DC

88 REGISTER NOW WEDNESDAY • MAY 24

Heterogeneity, & Airway Obstruction in Young Adults 10:45 High-Dimensional Single-Cell Imaging Maps Distinct
S.S. Krishnan, MD, MPH, Valhalla, NY Inflammatory Cell Subsets to PAH Vasculopathy
S. Ferrian, PhD, Stanford, United States
10:45 TRIM Results Update
C.R. Morris, PhD, Burlington, VT 11:00 Phase I and Phase II Clinical Trial Design and
Implementation in PAH
10:55 Home Spirometry Validation Study
R.T. Zamanian, MD, FCCP, Stanford, CA
E. Sugar, PhD, Baltimore, MD
11:15 Identifying Novel Biomarkers for Elafin and other PAH
11:05 Markers of Lung Degradation and Emphysema: A Pilot
Therapies
Study
A. Sweatt, MD, Stanford, CA
J.M. Wells, MD, MSPH, Birmingham, AL
11:15 Questions
R.A. Wise, MD, Baltimore, MD U.S. FOOD AND DRUG ADMINISTRATION
OUTSIDE ORGANIZATION SESSION
DIVISION OF LUNG DISEASES, NHLBI/NIH
L26 PULMONARY UPDATE FROM THE US
OUTSIDE ORGANIZATION SESSION
FOOD AND DRUG ADMINISTRATION
L25 ELAFIN: FROM TRANSLATIONAL PPG TO 10:30 a.m. - 11:30 a.m.
CLINICAL TRIAL Target Audience
Clinicians in practice, academic researchers, pharmaceutical industry
10:30 a.m. - 11:30 a.m.
representatives, international regulators
Target Audience
Objectives
Clinicians, basic scientists, nurses, technologists and trainees
At the conclusion of this session, the participant will be able to:
interested in pulmonary vascular disease trials
• to provide a better understanding of the regulatory considerations
Objectives
and lessons learned in review of immunomodulators for COVID-19
At the conclusion of this session, the participant will be able to:
• to provide a better understanding of regulatory considerations
• learn about ways to successfully translate preclinical laboratory
regarding potential changes in asthma management and treatment
findings into IND-enabling work for the development of therapeutics
paradigms
to treat PAH
• to provide an overview of recent approval actions, safety issues, and
• learn about Phase I and II clinical trial design for pulmonary arterial
hypertension hot topics which arose over the past year in the pulmonary division
at FDA.
• learn about the importance of biomarker design and inclusion in
clinical studies to monitor disease progression and treatment effects The most recent FDA actions, including recent drug approvals for
pulmonary diseases will be discussed, recent research endeavors,
This session will discuss results derived from an NHLBI-funded safety issues, and other hot topics that we have navigated over the past
Translational Program Project Grant (TPPG) that supported pre-clinical year in the Division of Pulmonology, Allergy, and Critical Care in the
studies of elafin in chronic lung disease of infancy, lung transplant Office of New Drugs at FDA.
rejection, and pulmonary arterial hypertension, and successfully
translated those findings into follow-on IND-enabling safety Chairing: B. Karimi-Shah, MD, Silver Spring, MD
pharmacology and toxicology studies and a subsequent Phase I clinical S. Seymour, MD, Silver Spring, MD
trial of Elafin use in healthy subjects. Plans for a Phase II clinical trial in 10:30 Regulatory Considerations in COVID-19 Development
PAH patients will also be discussed, with a description of relevant Programs: Lessons Learned
biomarkers and planned endpoints. A. Clerman, MD, PhD, Silver Spring, MD
Chairing: L. Xiao, MD, PhD, Bethesda, MD 10:55 FDA Updates: Highlights From Recent Asthma
A. Hemnes, MD, ATSF, Nashville, TN Approvals
10:30 The Role of Elastase and Elafin in PAH and Other E. Boulos, MD, MPhil, Silver Spring, MD
Respiratory Diseases 11:20 Question and Answers
M. Rabinovitch, MD, Stanford, CA B. Karimi-Shah, MD, Silver Spring, United States

ATS 2023 • Washington, DC

WEDNESDAY • MAY 24 REGISTER NOW 89

NATIONAL INSTITUTE OF DIVISION OF LUNG DISEASES, NHLBI/NIH

ALLERGY AND INFECTIOUS DISEASES, NIH OUTSIDE ORGANIZATION SESSION
OUTSIDE ORGANIZATION SESSION
L28 COPDGENE: ADVANCES IN COPD
L27 AIRWAY OMICS FOR DISEASE HETEROGENEITY AND PROGRESSION
ENDOTYPING AND MANAGEMENT 10:30 a.m. - 11:30 a.m.
10:30 a.m. - 11:30 a.m. Target Audience
Target Audience Researchers, medical trainees, those with an interest in COPD
Clinical researchers and clinicians pathogenesis

Objectives Objectives
At the conclusion of this session, the participant will be able to: At the conclusion of this session, the participant will be able to:
• learn about aging and mortality in the COPDGene study
• describe new findings relating nasal airway transcriptomic
signatures with disease outcomes in data obtained as part of a • learn about COPD progression in the COPD study
randomized placebo-controlled trial of mepolizumab in urban
• learn about reclassification of COPD in the COPDGene study
children with exacerbation prone asthma.
Chronic obstructive pulmonary disease (COPD), the fourth leading
• describe the lower airway immune response in patients with severe
cause of death in the United States in 2019, is a heterologous
COVID-19, compare transcriptomic signatures from upper and lower
syndrome. The COPDGene study has created the largest cohort of
airways in these patients, and identify airway immune signatures
well-characterized current and former smokers for respiratory disease
associated with disease severity
research. The primary goals of COPDGene are: 1) to identify new
• describe approaches to integrate nasal transcriptomic and genetic loci that influence the development of COPD and COPD-related
microbiome data in infants with respiratory bronchiolitis to identify phenotypes and 2) to reclassify COPD into subtypes that can ultimately
endotypes associated with asthma development. be used to develop effective therapies. In this session, presenters will
This session will describe results from 3 NIAID-funded programs that discuss new results from the COPDGene study, including new ways to
utilize omics data collected from the upper and/or lower airway to define diagnose the disease, deep learning approaches to imaging data,
disease endotypes, to potentially inform personalized medicine genetics, epigenetics, transcriptomics, proteomics, and an integrative
approaches to disease prognosis and/or management. Omics approach.

Chairing: P.M. Becker, MD, Bethesda, MD Chairing: L. Postow, PhD, Bethesda, MD

J.D. Crapo, MD, Denver, CO
10:30 Using Airway Transcriptomics to Identify Pathways
Associated with Exacerbation and Responsiveness to 10:30 Progression of COPD by Chest CT
Mepolizumab Therapy in Children S. Ash, MD, Boston, United States
M.C. Altman, MD, MPhil, Seattle, WA 10:42 Mortality in COPDGene
10:50 Integrated Analysis of Airway Immune Responses in W.W. Labaki, MD, MS, Ann Arbor, MI
Severe COVID-19: Results from the IMPACC Cohort 10:54 Cognitive Decline and Aging
R.R. Montgomery, PhD, New Haven, CT K.F. Hoth, PhD, Iowa City, IA
11:10 Integrated Omics Investigation into the Mechanisms 11:06 Metabolomics and COPD Progression
Linking Severe Bronchiolitis During Infancy and the S. Godbole, PhD, Denver, United States
Development of Asthma
11:18 Reclassifying COPD
K. Hasegawa, MD, MPH, PhD, Boston, MA
G.L. Kinney, MPH, PhD, Aurora, CO

ATS 2023 • Washington, DC

90 REGISTER NOW WEDNESDAY • MAY 24

CLINICAL
PEDIATRIC CLINICAL CORE CURRICULUM

PCC3 PEDIATRIC CLINICAL CORE CURRICULUM

Education Committee
11:00 a.m. - 12:00 p.m.
Target Audience:
Clinicians who are engaged in maintenance of certification activities
Objectives
At the conclusion of this session, the participant will be able to:
• describe diagnosis and management of central and obstructive
sleep disorders in infants
Wednesday Afternoon, May 24
• identify best practices for management and treatment of pulmonary
hypertension in infants
• describe best practices and standards of care for management of
bronchopulmonary dysplasia in the neonatal intensive care unit and CLINICAL
the post NICU period
ADULT CLINICAL CORE CURRICULUM
Chairing: J. Gross, MD, PhD, Denver, CO
C. Okorie, MD, Paulo Alto, CA CC6 PULMONARY CLINICAL CORE
M. McCown, MD, Bethesda, MD
CURRICULUM
11:00. Interstitial Lung Disease in Infants
Education Committee
M. Selleck, MD, Los Angeles, CA
12:00 p.m. - 1:30 p.m.
11:25 Pulmonary Hypertension in Infants
D. Bush, MD, NYC, NY Target Audience
Clinicians who are engaged in maintenance of certification activities
11:50 Questions and Answers
Objectives
At the conclusion of this session, the participant will be able to:
• describe updates in the diagnosis and management of mild,
moderate, and severe asthma in 2023
• identify the local and global impact of one's environment on asthma
management
• describe best practices for asthma management in the pregnant and
post-partum woman

Chairing: G. Garrison, MD, Burlington, VT

J. Cho, MD, Iowa City, IA
12:00 Asthma Where We Live and Work: The Impact of
Environmental Change on Asthma Control
N. Nassikas, MD, Cambridge, MA
12:25 Inequities in Asthma Care: Addressing Social Determinants of
Health and Disparities in Asthma Management
A.Rusk, MD, Rochester, MN
12:50 An ICS for Two: Treating Asthma in the Prenatal and
Perinatal Settings
E. Batchelor, MD, Med, Phoenix, AZ
1:15 Questions and Answers

ATS 2023 • Washington, DC

WEDNESDAY • MAY 24 REGISTER NOW 91

12:36 Epidemiologic Evidence for Metformin in COPD

BASIC • CLINICAL • TRANSLATIONAL
T.D. Wu, MD, MHS, Houston, TX
CLINICAL TOPICS IN PULMONARY MEDICINE 12:45 Antiplatelet Therapy in COPD
A. Fawzy, MD, MPH, Baltimore, MD
D82 REPURPOSING EXISTING MEDICATIONS 12:54 Clinical Trial Considerations
FOR TREATMENT OF COPD F.J. Martinez, MD, MS, New York, NY
Assemblies on Clinical Problems; Respiratory Cell and Molecular 1:03 Panel Discussion
Biology
1:26 Concluding Remarks
12:00 p.m. - 1:30 p.m. I.M. Adcock, PhD, London, United Kingdom
Target Audience
Providers who care for patients with COPD and individuals interested
in COPD research CLINICAL
Objectives CLINICAL TOPICS IN PULMONARY MEDICINE
At the conclusion of this session, the participant will be able to:
• describe findings from experimental and observational studies D83 ESTABLISHING A PARADIGM FOR
supporting the potential efficacy of angiotensin receptor blockers, MULTIDISCIPLINARY CARE IN
metformin, and antiplatelet therapy in COPD SARCOIDOSIS
• understand the reason for discrepancies between Assemblies on Clinical Problems; Environmental, Occupational
experimental/observational studies and clinical trial results in COPD and Population Health
• evaluate emerging research that investigates repurposing existing 12:00 p.m. - 1:30 p.m.
medications for the treatment of COPD
Target Audience
Researchers have struggled to identify effective systemic Healthcare providers and trainees from across disciplines that care for
pharmacologic therapies for COPD. Current COPD management patients with sarcoidosis or other chronic/systemic conditions.
consists of inhaled bronchodilators with few add on therapies for certain
Objectives
patient populations. Recently, researchers have focused on whether
At the conclusion of this session, the participant will be able to:
systemic medications commonly prescribed for non-respiratory
indications may be effective in the treatment of COPD. In this session • understand our current systems of practice, how they limit access and
we discuss the scientific and clinical evidence for repurposing the specific concerns patient with sarcoidosis have
angiotensin receptor blockers (ARBs), metformin, and antiplatelet • learn about ways to improve multidisciplinary care and access to care
therapy as disease-modifying agents in COPD. We will also review the
disconnect between murine models and human observational studies • discuss ways to improve our structure/practices/systems to reduce
compared to clinical trial results for statins and beta-blockers. A panel disparities
discussion will follow. Sarcoidosis is an inflammatory multi-organ disease with a wide variety of
clinical manifestations that requires a team approach to address the
Chairing: I.M. Adcock, PhD, London, United Kingdom
needs of patients. Oftentimes patients lack the resources to navigate the
S. Christenson, MD, MS, San Francisco, CA
complex health care systems. The challenges are exacerbated by the fact
C.L. Pistenmaa, MD, MS, Boston, MA
that sarcoidosis disproportionately impacts Black patients and these
A. Fawzy, MD, MPH, Baltimore, MD
patients are also impacted by entrenched institutional biases in medicine.
12:00 Introduction This session will propose to improve our current models of care to meet
M.T. Dransfield, MD, Birmingham, AL the needs of the patients, and will propose the concept of “primary
12:09 Murine Models to Study ARB in Emphysema sarcoidosis specialist” as an alternative to current models of care.
E.R. Neptune, MD, ATSF, Baltimore, MD Chairing: D.C. Patel, DO, MBA, Gainesville, FL
12:18 Current Evidence for ARBs and Angiotensin II Pathway O.N. Obi, MD, MPH, MSc, Greenville, NC
in COPD 12:00 My Experience with Getting a Diagnosis and Treatment
V. Tejwani, MD, Cleveland, OH for Sarcoidosis
12:27 Mechanisms of Metformin in COPD Speaker To Be Announced
F. Polverino, MD, PhD, Houston, TX 12:08 The State of Sarcoidosis Care
D.C. Patel, DO, MBA, Gainesville, FL

ATS 2023 • Washington, DC

92 REGISTER NOW WEDNESDAY • MAY 24

12:12 The “Primary Sarcoidosis Specialist” 12:15 It’s Written in the Genes: Understanding the
P.H.S. Sporn, MD, ATSF, FCCP, Chicago, IL Susceptibilities to Critical Illness
T.K. Jones, MD, MPH, MSCE, Philadelphia, PA
12:22 The Burden of Sarcoidosis on Patients
Speaker To Be Announced 12:30 Polygenic Risk Scores in Critical Care: A Tale of Two
Post-Operative Complications
12:31 Non-Organ Related Manifestations of Sarcoidosis
L. Bastarache, MS, Nashville, TN
V. Kahlmann, MD, Rotterdam, Netherlands
12:45 Phenotypes in ICU Acquired Weakness
12:41 Social Determinants and How They Impact Sarcoidosis
C.C. Dos Santos, MD, Toronto, Canada
Care
Y. Cozier, DSc, MPH, Boston, MA 1:00 Phenotypes Over Clinical Syndromes: A More Logical
Lumping Paradigm
12:50 Measuring Outcomes to Improve Care in Sarcoidosis
P. Sinha, MB BCh, PhD, ST LOUIS, MO
M. Sharp, MD, MHS, Baltimore, MD
1:15 Clinical Trials and Treatment Effects: Don’t be Average,
1:00 Discussions
C. Bonham, MD, Charlottesville, VA Be an Individual
M.M. Churpek, MD, MPH, PhD, ATSF, Madison, WI

BASIC • CLINICAL • TRANSLATIONAL

BASIC • CLINICAL • TRANSLATIONAL
CRITICAL CARE TRACK
SCIENTIFIC SYMPOSIUM
D84 FROM GENES TO CLINICAL TRIALS:
D85 EARLY LIFE ENVIRONMENTAL
STATE-OF-THE-ART APPROACHES TO
EXPOSURES, EPIGENETICS, AND
HETEROGENEITY IN THE ICU
ASTHMA DEVELOPMENT
Assemblies on Critical Care; Clinical Problems; Respiratory
Assemblies on Pediatrics; Allergy, Immunology and
Structure and Function
Inflammation; Environmental, Occupational and Population
12:00 p.m. - 1:30 p.m. Health; Respiratory Cell and Molecular Biology
Target Audience 12:00 p.m. - 1:30 p.m.
Clinicians (RN, NP, MD) who care for critically ill patients and
researches who wish to improve the rigor with which they understand Target Audience
clinical trial data. Researchers in asthma/allergy, genetics, epigenetics, virology, and
bioinformatics, as well as clinicians/nurses/RTs/advanced practice
Objectives providers who treat asthma
At the conclusion of this session, the participant will be able to:
Objectives
• describe novel approaches to phenotyping in acute critical care At the conclusion of this session, the participant will be able to:
syndromes
• understand the potential and limitations of genetics, epigenetics, and
• describe new findings concerning the complexity of critical care integrated omics approaches in examining asthma pathogenesis
syndromes
• gain an understanding of the link between early-life exposures and
• define new strategies to manage the care of ARDS and septic shock asthma development
Heterogeneity is increasingly recognized as a central challenge in • understand the integrated role of environmental exposures and
critical care research. Sub-phenotyping and endotyping efforts designed multi-omics in incident asthma
to reduce heterogeneity in clinical trial populations and individualize
treatment protocols are central to efforts to improve outcomes. In this Growing evidence suggests that early-life environmental exposures
session we discuss both established and novel techniques for (e.g., airway infection, nutrition, air pollution) contribute to the risk of
phenotyping critically ill patients with the aim of familiarizing clinicians, developing asthma in childhood and beyond. During early-life
development, environmental exposures interact with both the
clinical researchers and basic researchers with the latest in the field.
expression and function of human genetic/epigenetic factors and lead to
Chairing: C.C. Hardin, MD, PhD, ATSF, Boston, MA differential disease risks. This session will highlight examples of recent
P. Sinha, MB BCh, PhD, ST LOUIS, MO studies from the NIH-supported Environmental Influences on Child
T.K. Jones, MD, MPH, MSCE, Philadelphia, PA Health Outcomes (ECHO) Program that offer deeper insights into the
integrated roles of early-life environmental exposures, genetics, and
12:00 Untangling Complexity in Critical Illness
C.C. Hardin, MD, PhD, ATSF, Boston, MA

ATS 2023 • Washington, DC

WEDNESDAY • MAY 24 REGISTER NOW 93

epigenetics in incident asthma and the development of primary As the COVID-19 pandemic continues, researchers have observed the
prevention strategies for asthma providers. possible links and relationships between diseases and the environment.
The One Health concept represents a holistic approach that
Chairing: C.J. Blaisdell, MD, MEd, North Bethesda, MD encompasses the interactions between all living beings with their
K. Hasegawa, MD, MPH, PhD, Boston, MA environments. These interactions are crucial to recognize this
12:00 DNA Methylation Signatures of Early Life Exposures and interconnectedness, which provides insight into where interventions can
Genetic Variation as Mediators of Asthma and Allergies be implemented to mitigate disease risk and enhance preparedness
in Childhood efforts on emerging concerns. This session will focus on how living
C. Ober, PhD, Chicago, IL beings interact with the ecosystem that may lead to adverse impact on
human health. Leading scientists will discuss the scale of the problem,
12:21 Vitamin C Supplementation to Maternal Smokers During
evidence, vulnerability, and policy development.
Pregnancy: Stable Effects on Offspring Wheeze and
Buccal DNA Methylation Through 5 Years of Age Chairing: M. Akpinar-Elci, MD, MPH, ATSF, Reno, NV
L. Shorey-Kendrick, PhD, BA, Beaverton, OR H. Chapman, MD, PhD, Washington, DC
12:42 Viral Bronchiolitis, Nasal Airway MicroRNA, and Risk for M. Rice, MD, MPH, Boston, MA
Developing Asthma S. Singh, MD, PhD, New York, NY
Z. Zhu, ScD, Boston, MA 12:00 Overview of One Health, Using Innovative Data
1:03 Integrative Metabolomics and the Early Life Origins of H. Chapman, MD, PhD, Washington, DC
Asthma 12:10 Environmental Pulmonary Pathology from a One Health
R.S. Kelly, MPH, PhD, Boston, MA Perspective
1:24 Patient Speaker J. Harkema, DVM, PhD, DACVP, ATSF, East Lansing, MI
Speaker To Be Announced 12:24 A One Health Approach to Addressing Vector-borne and
Zoonotic Diseases
C. Beard, PhD, Fort Collins, CO
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
12:38 Climate Change Through the Lens of a One Health
SCIENTIFIC SYMPOSIUM Approach
M. Akpinar-Elci, MD, MPH, ATSF, Reno, NV
D86 HUMANS, ANIMALS, THE ENVIRONMENT: 12:48 Health Impacts of Air Pollution; the One Health Concept
WHY IS THE ONE HEALTH APPROACH H. Bayram, MD, PhD, ATSF, Istanbul, Turkey
NEEDED FOR EMERGING HEALTH ISSUES? 1:02 Pneumonia, TB, Health Disparities, and One Health
Assemblies on Environmental, Occupational and Population A. Videla, MD, Pilar, Argentina
Health; Allergy, Immunology and Inflammation; Behavioral 1:16 One Health Collaboration
Science and Health Services Research; Nursing; Pulmonary B. Dunham, DVM, PhD, Washington,, DC
Infections and Tuberculosis
12:00 p.m. - 1:30 p.m.
CLINICAL • TRANSLATIONAL
Target Audience
Scientists, clinicians (pulmonology, cardiology, pediatrics, SCIENTIFIC SYMPOSIUM
gerontology), public health/global health practitioners, and trainees
interested in environmental impacts on health
D87 THE UN HIGH LEVEL MEETING ON TB
Objectives 2023: A CHANCE TO BEAT THIS
At the conclusion of this session, the participant will be able to: PARTICULAR PANDEMIC
• explain how the One Health approach can promote multidisciplinary
Assemblies on Pulmonary Infections and Tuberculosis;
collaborations across scientific disciplines International Health Committee
• analyze at least two examples where clinicians and researchers can
12:00 p.m. - 1:30 p.m.
participate in research, policy or advocacy
Target Audience
• discuss and encourage ATS members and others to influence policy Clinicians, Public health researchers, Policy Makers, Patients,
makers through One Health approach when they are responding to Administrators, Research sponsors
emerging health challenges
Objectives
At the conclusion of this session, the participant will be able to:

ATS 2023 • Washington, DC

94 REGISTER NOW WEDNESDAY • MAY 24

• Better understand that improving global health is everyone’s • recognize disease specific metabolic changes in lungs cell and
business and involves reducing health disparities describe how metabolic pathways may potentially be targeted for
treatment
• To appreciate the long-term consequences of TB disease and so
improve detection and its management Cellular metabolism is the fundamental step of bioenergetic process.
• How to enable people with TB’s voice to be heard
Growing evidence demonstrates the importance of cellular metabolism
in disease pathogenesis beyond energy production. In this session, we
The second UN General Assembly High Level Meeting on tuberculosis will provide key knowledge about major cellular metabolic pathways and
(TB) is due to take place in September 2023. If we are to eliminate TB, present recent discoveries and future perspectives on how these
we must engage our political leaders. This symposium will discuss pathways regulate the pathogenesis of pulmonary diseases, such as
priorities from the perspective of TB survivors, academics and COPD, pulmonary hypertension, interstitial lung diseases and lung
clinicians. What are our policy demands? Where do we anticipate cancer and how they may be targeted to alter disease progression. This
sticking points? How do we ensure our voices are heard? session brings together experts who are among the pioneers to explore
the new paradigm of cellular metabolic dysregulation as a key
Chairing: D.M. Lewinsohn, MD, PhD, ATSF, Portland, OR
manifestation of pulmonary diseases.
D. Garcia, MA, Austin, TX
12:00 Living with TB Chairing: G.M. Mutlu, MD, ATSF, Chicago, IL
K. O’Brien, BA, Rumson, NJ S.C. Erzurum, MD, Cleveland, OH
G. Liu, MD, PhD, Birmingham, AL
12:22 Beyond Cure - Living With the Long-Term Effects of TB
Disease 12:00 Metabolic Changes in Immune Cells in COPD
J. Potter, PhD, London, United Kingdom S.M. Cloonan, PhD, New York City, NY

12:45 The United Nations High-Level Meeting - the Last 12:18 Amino Acid Metabolism in Pulmonary Fibrosis
Chance for the Sustainable Development Goal on TB? R.B. Hamanaka, PhD, Chicago, IL
M. Oliver, BA, Cambridge, United Kingdom 12:36 Metabolism in Pulmonary Hypertension
1:08 Turning Policy into Practice to Make a Difference to S.C. Erzurum, MD, Cleveland, OH
People with TB 12:54 Lipid Metabolism in Lung Diseases
P. Vera Bejarano, BA, Asuncion, Paraguay R. Summer, MD, Philadelphia, PA
1:12 Macrophage Metabolism in ARDS
BASIC • TRANSLATIONAL W.J. Janssen, MD, Denver, CO

SCIENTIFIC SYMPOSIUM
BASIC • CLINICAL • TRANSLATIONAL
D88 BEYOND BIOENERGETICS: CELLULAR SCIENTIFIC SYMPOSIUM
METABOLISM IN LUNG HEALTH AND
DISEASE D89 OSA-ASSOCIATED INFLAMMATION AND
Assemblies on Respiratory Cell and Molecular Biology; Critical COMORBIDITIES: CAUSES AND
Care; Pulmonary Circulation; Pulmonary Infections and CONSEQUENCES
Tuberculosis; Respiratory Structure and Function; Thoracic
Assemblies on Sleep and Respiratory Neurobiology; Allergy,
Oncology
Immunology and Inflammation
12:00 p.m. - 1:30 p.m.
12:00 p.m. - 1:30 p.m.
Target Audience
Basic and translational researchers, and clinicians who are interested Target Audience
in the mechanisms behind lung diseases Pulmonary critical care and sleep medicine practitioners (physicians,
psychologists, nurse-practitioners) and researchers interested in the
Objectives interactions between obstructive sleep apnea (OSA), inflammation,
At the conclusion of this session, the participant will be able to: and comorbid chronic disease.
• describe metabolic changes that occur in various cell populations in Objectives
lung diseases and lung cancer At the conclusion of this session, the participant will be able to:
• describe the role of mitochondria as signaling organelles in lung • describe the interplay of both biologic (genetic) and epidemiologic
cancer associations between OSA, chronic systemic inflammation and

ATS 2023 • Washington, DC

WEDNESDAY • MAY 24 REGISTER NOW 95

comorbid disease.this will improve medical knowledge and

practice-based learning and improvement
• understand the contribution of OSA in chronic comorbid diseases,
including asthma, interstitial lung disease, cardiovascular disease,
and HIV. This will improve medical knowledge, practice-based
learning and improvement, and evidence-based practice
• identify research goals for precision health and personalized
medicine in patients with OSA and co-morbid chronic inflammatory
disease. This will improve medical knowledge
This session will focus on the interplay between OSA-associated
inflammation and chronic comorbidities. The session will begin by
detailing both epidemiologic and genetic associations between OSA
and inflammatory biomarkers, which are key mediators in the
downstream cardiopulmonary consequences in OSA. Particular focus
will be given to the contribution of OSA-associated inflammation in the
acceleration of chronic comorbid diseases, including asthma, interstitial
lung disease, cardiovascular disease, and HIV. The session will
conclude with a discussion/Q&A that will explore future research areas
for this important field.

Chairing: V. Kundel, MD, New York, NY

P.V. Borker, MD, Pittsburgh, PA
B.E. Cade, PhD, Boston, MA
12:00 Welcome and Introduction of Speakers
V. Kundel, MD, New York, NY
12:05 Sleep Apnea, Biomarkers of Vascular Injury and
Inflammation
S. Jelic, MD, New York, NY
12:20 Role of Epigenetic Regulation in Sleep Apnea
R. Cortese, PhD, Columbia, MO
12:35 Epidemiological and Genetic Associations Between
Sleep-Disordered Breathing and Inflammatory Traits
B.E. Cade, PhD, Boston, MA
12:50 Investigating the Impact of Sleep Health on
HIV-Associated Inflammation
P.V. Borker, MD, Pittsburgh, PA
1:05 OSA and Chronic Lung Disease
M. Teodorescu, MD, MS, Madison, WI
1:20 Question and Answer/Panel Discussion

12:00 p.m. - 2:00 p.m.

Oral And Poster Presentations Of Scientific
Research And Case Reports. Abstract Sessions
Will Be Published In The Final Program.

ATS 2023 • Washington, DC

 2023
conference.thoracic.org